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1.1 Introduction
Economic evaluation has been defined as `the comparative analysis of alternative courses 
of action in terms of both their costs and consequences’ [1]. In an economic evaluation in 
healthcare, two or more interventions are compared in terms of costs and health outcomes. 
This results in estimates of the incremental health effects and the incremental costs. If one 
intervention leads to higher costs as well as more health benefits, an incremental cost-
effectiveness ratio (ICER) can be calculated. This ratio expresses the cost per additional 
unit of health gain. An economic evaluation can play a role in policy makers’ decisions on 
whether the health benefits of an intervention are worth the costs.
The scientific field of economic evaluation in healthcare has gained prominence since 
the 1980s. The number of publications has increased enormously [2] and the methodology 
has become more sophisticated [3]. The role of results of economic evaluations in policy 
decisions has increased markedly [4] – especially in the United Kingdom, but also in con-
tinental European countries, such as the Netherlands, although important barriers still 
hamper their use in decision-making [3,4].
Many economic evaluations are based on or conducted in combination with medical 
studies, in particular phase III randomised controlled trials, also in COPD [5]. These trials 
are set up to demonstrate the effectiveness of a specific new intervention compared to a 
conventional treatment or to placebo. However, an economic evaluation is more than a 
medical study with costs as an additional outcome measure. It is more complicated than 
combining the effectiveness results from a trial with the invoices from physicians, hospitals 
and pharmacies. Economic evaluations are often characterized by challenges that do not 
occur in purely clinical trials. A number of these challenges are central to this thesis.
Firstly, in many cases costs cannot be observed directly. They are generally different from 
payments or tariffs. There is a consensus that, from a societal point of view as well as from a 
healthcare perspective, the relevant costs of a resource are the opportunity costs: the value 
of the forgone benefits because the resource cannot be applied for the next best alternative 
purpose [1]. This means that all relevant resources that are used in and after the intervention 
should be identified and valued separately. Payments do not always reflect all resources at 
proper societal values, especially when insurance payments are involved or when tariffs 
apply to a combination of resources and actions (e.g. diagnosis-treatment combination), 
possibly averaged across a heterogeneous patient population.
When the benefits of treatment stretch into the future, costs that are incurred in later 
times must be included in the analysis as well. When a societal perspective is taken, all 
costs must be taken into account, whoever bears them. This may imply that informal care is 
valued, even if it is not paid.
Secondly, the objective of many, although not all, clinical trials are to find statistical 
proof that one intervention is superior to another one. In an economic evaluation the size of 
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the treatment effect is essential, not merely its existence. If the effect is estimated in an RCT 
that was designed to establish superiority, the estimated size may not be generalizable to the 
full patient population for whom the intervention is relevant. RCTs often include relatively 
homogenous, precisely selected groups of patients, who may not be completely representa-
tive of the patients who will later be treated in real life. In order to achieve external validity, 
an observational study can be conducted on patients in real life. However, this study design 
lacks the benefit of randomisation, which is aimed at balancing treatment groups in terms 
of prognostic characteristics. Adjustment for possible differences between treatment groups 
is required.
Thirdly, the size of the treatment effect must be estimated in terms of natural units of 
health in order to be useful in an economic evaluation. Possible outcome measures include 
absolute differences, risk differences and risk ratios. However, the results of medical and 
epidemiological studies are often expressed in hazard ratios – in time-to-event analyses – or 
odds ratios – for binary count data. These ratios are sufficient when merely the existence of 
a treatment effect is investigated, but they are purely statistical measures without a clear 
intuitive interpretation and, more importantly, not directly transferable to the size of the 
relevant treatment effect. They cannot be used in economic evaluations, in which outcome 
measures such as survival time and numbers of successes and failures are required instead.
Fourthly, in order to make the results of economic evaluations comparable across in-
terventions and diseases, health gains must be expressed in a common outcome measure. 
Health-related quality-adjusted life years (QALYs) encompass both survival time and qual-
ity of life, which enables them to reflect changes in morbidity as well as mortality. In general, 
they are calculated by multiplying time spent in a certain health state with quality weights. 
The scale of the QALY weights included are anchored by the health states perfect health 
(weight=1) and death (weight=0). Weights for other health states may be below 0 but not 
higher than 1. A year spent in perfect health equals 1 QALY.
The papers in this thesis address these challenges. The thesis consists of two parts. The 
calculation of treatment costs is a major issue in this part, which is dedicated to the GO 
AHEAD study (Assessment of GOing Home under Early Assisted Discharge). This multi-
centre randomised controlled trial, examined several aspects of an early assisted discharge 
program for patients who were hospitalized for a COPD exacerbation in the Netherlands.
The second part is centered on the remaining three methodological issues mentioned 
above: natural units of health gain, quality-of-life measurement and observational studies.
1.2 Part I. Hospital-at-home after a COPD exacerbation
COPD is a chronic disease that is currently ranked the fourth cause of death globally, and 
the sixth in high income countries [6]. The World Health Organization has estimated that 
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worldwide 64 million people suffer from the disease [7]. A Dutch study found a prevalence 
of 11.6% in the population of 55 years and older [8], which would mean that 567,000 people 
had the disease by the end of 2011. Many of these cases are undiagnosed [9,10].
Due to an aging population and late effects of smoking, the prevalence is expected to 
rise in the coming decades [11]. COPD is characterised by airflow limitation which is not 
fully reversible. The symptoms, which include sputum production, cough and dyspnoea, are 
chronic and progressive over time [12]. The disease cannot be cured, but it can be treated to 
limit symptoms, prevent exacerbations and improve quality of life.
An acute exacerbation of COPD is a sudden, temporary deterioration of symptoms. 
Depending on the severity, exacerbations strongly affect the health-related quality of life of 
patients [13,14]. They lead to faster lung function decline [15] and a higher risk of mortality 
[16].
Most exacerbations can be treated with medication. However, in many cases, patients 
are admitted to the hospital. Indeed, exacerbations are the main cause of hospitalisation for 
COPD. The average annual frequencies have been estimated to vary from 0.11 for patients 
with mild COPD (GOLD stage I, as defined by airflow obstruction [12] and 0.16 for moderate 
disease (GOLD II), to 0.22 and 0.28 for severe and very severe COPD (GOLD III and IV) [17]. 
Nevertheless, the extent to which patients are prone to exacerbations varies substantially 
within GOLD stages [18].
With a mean length of stay in the hospital of 8.5 to 10 days [16,19], the large number of 
hospital admissions for exacerbations among COPD patients results in a high pressure on 
scarce hospital beds and high healthcare costs. Across several countries, hospitalisations 
have been shown to be a main driver for costs of COPD treatment [20-26]. In the Nether-
lands, they were estimated to account for 27% of all costs, including for account for 18 to 
50% of total healthcare expenditure for COPD, including the costs of homecare and nursing 
homes [27]. Only medication accounted for a larger share of expenditures.
Several studies have shown that some patients with an exacerbation, who would oth-
erwise be admitted to the hospital, can be treated at home safely after examination in the 
emergency department or a short hospital admission [28-32]. This is called hospital-at-home. 
Hospital-at-home aims to avoid admission, or reduce length of stay (early assisted discharge 
schemes). While no differences were found in the number of readmissions, mortality and 
disease-specific quality of life between hospital-at-home and usual hospital care [28-32], 
the results on costs and cost-effectiveness have been mixed. While some studies found cost 
savings [33-36], others observed increased costs [37], or yielded inconclusive results [32,38].
Hence, treating COPD exacerbations at home has the potential to reduce costs. To what 
extent it does so in the Dutch setting, remains to be demonstrated. Apart from the exact 
description of the intervention, the health economic impact of a therapy depends heavily on 
national and local treatment patterns, healthcare delivery structures, funding and reimburse-
ment systems, absolute and relative differences in unit costs of resource use and drug prices.
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There is a risk that cost savings are overestimated in hospital-at-home studies [39]. Firstly, 
the transfer of part of the patient care to unpaid, informal caregivers, does not mean that it is 
costless. Secondly, inpatient hospital days are not a homogenous commodity. They consist 
of many actions and provisions by nurses, physicians, laboratory personnel, administrative 
staff and others. The combination of resource that is contained in an inpatient day, may 
vary per patient, as well as across diseases and interventions. Crucially for hospital-at-home 
studies, treatment intensity may decrease over the course of an admission. This makes it 
likely that the savings from a reduction of one inpatient day are likely to be lower than the 
average daily cost [1,39].
Aim and research questions part 1
The objective of the first part of the thesis was to perform a full economic evaluation of the 
GO AHEAD trial of early assisted discharge of COPD patients after an exacerbation and to 
investigate treatment preferences of patients and informal caregivers.
The following research questions were formulated to achieve this aim:
• What evidence on cost savings for hospital-at-home services is currently available and 
what is its quality?
• What is the effectiveness, cost-effectiveness and cost-utility of early assisted discharge 
after a COPD exacerbation in the Netherlands from a healthcare perspective and a 
societal perspective?
• How can an early assisted discharge program for COPD patients be designed in order to 
optimize its acceptability to patients and informal caregivers?
1.3 Part II. Methodological issues
The second part of this thesis is devoted to the three remaining methodological issues that 
were mentioned at the beginning of this chapter: natural units of health gain, quality-of-life 
measurement and observational studies.
Natural outcome measures and quality-of-life
Medical interventions are aimed at improving quality of life, prolonging life, or at the 
combination of both. In the first case, if the effects of treatments are to be completely ap-
preciated, health-related quality-of-life gains must be determined in order to calculate the 
gain in QALYs. Among the most widely used instruments to measure these is the EQ-5D 
[40]. It has been validated and applied in the stable phase of COPD [41] as well as in severe 
exacerbations of the disease, which require hospital admission [13,42]. It has been criticized 
for not being sensitive enough to changes in health status of COPD patients. However, it has 
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been shown to be able to distinguish between different GOLD stages of airflow obstruction 
[43]. This thesis contains an evaluation of the EQ-5D to detect the recovery from a moderate 
COPD exacerbation, which is defined as requiring antibiotic or systemic steroid therapy but 
no hospital admission [44]. It results in the tentative estimation of the health loss due to a 
moderate exacerbation.
When the prolonging of life is concerned, economic evaluations require an estimate of 
the difference in survival time. However, in time-to-event (or survival) analyses, the treat-
ment effect is often expressed in a hazard ratio: the time-dependent probability of instantly 
experiencing the event of interest for subjects in one treatment group, as a proportion of 
this probability in the reference group. Parametric survival models can be used to estimate 
projected mean time-to-event [45], but their outcomes may suffer from non-collapsibility 
and from bias due to censoring [46-49]. Earlier studies have often confused these two phe-
nomena, but it is essential that they are distinguished and addressed properly.
Bias in observational studies: potential solutions
Randomised controlled trials (RCTs) have long been viewed as the gold standard for esti-
mating treatment effects of healthcare interventions. In ideal randomised experiments (i.e. 
large sample size, perfectly randomised, no loss to follow up, full adherence to assigned 
treatment and no measurement error) internal validity is assured. Association is causation: 
association measures can be directly interpreted as effect measures.
However, patients enrolled in clinical trials may not be representative of the population 
to which the therapy will eventually be applied. Treatment effectiveness and healthcare re-
source use in daily practice may be different from those in clinical trials. This is increasingly 
recognized by researchers, policy makers and decision makers responsible for pricing and 
reimbursement of healthcare interventions. Evaluations in ‘real world’ daily practice can 
provide policymakers with results that are more relevant and applicable.
As an alternative to RCTs, the use of observational data allows investigators to estimate 
the (cost)-effectiveness of treatment in day-to-day practice. Yet this approach has its own 
challenges. In daily clinical practice treatments are not randomly assigned. Treatments are 
assigned based on patient prognosis, preferences, regional or institutional conventions, 
time or other factors. Consequently, the prognosis of patients receiving a treatment will 
often differ systematically from that of patients not receiving a treatment. In other words, 
treatment assignment and prognostic factors may be associated. If this confounding is not 
removed or reduced, the treatment effect will be either underestimated or overestimated.
In COPD, the disease severity stage is a crucial factor for which adjustment is required. 
The most widely used severity classification is the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) classification [12]. It is based on airflow obstruction, which is 
associated with mortality [50], exacerbations [51,52], healthcare utilization and costs [53]. 
An association with quality of life exists as well, although this is less strong [54]. Because 
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it is increasingly recognized that COPD is not only a lung disease but a multi-dimensional 
disease with many systemic, extra-pulmonary effects, composite measures of COPD severity 
have been proposed, but almost all of these are still partly based on the forced expiratory 
volume in 1 second as a percentage of the predicted value (FEV
1
-%predicted) [55-59].
However, measurements of airflow obstruction and information on disease severity 
are not routinely included in the databases and registries that are available for retrospec-
tive observational studies. It appears obvious that COPD severity is related to healthcare 
resource use and demographic data (such as age, sex and smoking status). However, this 
association must be quite strong if resource use is to be used as proxy for disease severity. It 
is not clear that this is the case and that an algorithm can be derived that strongly links the 
severity of COPD as classified by GOLD to variables that are commonly available in routine 
databases.
Another issue in observational studies is the technique that is applied in order to adjust 
for observed prognostic factors. Traditionally, regression methods have been used for this 
purpose. More recently, methods based on propensity scores have become increasingly 
popular. They are aimed at removing the association between treatment and prognostic fac-
tors and to create a RCT-like design. The propensity score is defined as a subject’s probability 
of receiving a specific treatment assignment, based on certain observed characteristics of 
that subject. This score, which is usually derived from on a logit or probit regression model, 
can be used in several ways to address confounding. Methods include matching, weighting 
and stratification on the propensity score and regression adjustment with the propensity 
score as a covariate [60].
Examples of the application of propensity-score methods in cost-effectiveness analyses 
are still scarce and their relative performance in this context has not been investigated. 
More knowledge about the value of these methods in cost-effectiveness analyses would be 
useful. One of the reasons is that cost data have different properties than data on clinical 
effectiveness. More importantly, health economic studies examine two outcomes simulta-
neously, incremental costs and incremental effects, and combine them into incremental 
cost-effectiveness ratios (ICERs).
Aim and research questions part 2
The objective of the second part of this thesis is to contribute to methodological advance-
ment in the field of health economics and economic evaluations, in particular with regard to 
observational studies and the estimation of health outcomes.
The following research questions are posed:
• Can the EQ-5D be used to measure changes in health-related quality of life during the 
recovery from a moderate COPD exacerbation?
• Is it possible to adjust for COPD severity in database studies by using variables that are 
routinely available, when no spirometry data have been recorded?
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• How should propensity-score based adjustment methods be applied in observational 
cost-effectiveness studies?
• What is the impact of non-collapsibility and censoring bias on hazard ratios and pre-
dicted mean survival in Weibull models?
1.4 Outline of this thesis
This thesis is structure as followed. The next four chapters deal with hospital-at-home and 
the GO AHEAD trial. Chapter 2 presents the results of a systematic review of cost studies of 
hospital-at-home for several diseases and interventions. The focus is on the quality of the cost 
calculations. Chapter 3 contains the backgrounds and the study protocol of the GO AHEAD 
trial. In chapter 4, the incremental effectiveness, costs and cost-effectiveness of the program 
are evaluated. The preferences of patients and informal caregivers for different characteristics 
of aspects of hospital-at-home are investigated in a discrete choice experiment in chapter 5.
The next five chapters focus on a number of methodological issues in economic evalua-
tions. In chapter 6, the usefulness of the EQ-5D questionnaire for measuring health-related 
quality of life during moderate COPD exacerbations is determined. In chapter 7, the con-
cepts of non-collapsibility, confounding and omitted-variable bias are disentangled and 
demonstrated in the context of mean predicted survival in parametric proportional hazard 
survival models. Chapter 8 compares the validity and accuracy of the results of several 
propensity-score-based statistical techniques in survival models for observational studies in 
a simulation study. In chapter 9 the reliability of these methods in the context of economic 
evaluations is investigated. The focus of chapter 10 is whether the severity of COPD can be 
derived from databases by relying on other patient characteristics and healthcare resource 
use. Finally, chapter 11 is the general discussion.
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2A systematic review of hospital-at-home care
Cost savings are overestimated
Background The concept of hospital-at-home means that home treatment is provided to 
patients who would otherwise have been treated in the hospital. Admissions may be short-
ened (early assisted discharge, EAD) or avoided. This may lead to lower costs, but savings 
are overestimated if relevant costs are not taken into account appropriately, or if average or 
generic prices per inpatient day are assumed. The objective of this study was to assess the 
quality of cost analyses of hospital-at-home studies for acute conditions published from 
1996 through 2011 and to present an overview of evidence.
Methods The Medline and NHS HEED databases were searched. Cost calculations were 
considered incorrect if they failed to meet four criteria. Costs per inpatient hospital day had 
to be disease-specific. The decreasing intensity of care over the course of an admission had 
to be reflected in costs of inpatient days. In studies from the societal perspective, informal 
care costs had to be included. Violating any of these three criteria leads to overestimation 
of savings. Finally, follow-up had to be at least one month in order to capture relevant 
downstream costs.
Results Most studies found cost differences in favour of hospital-at-home; the range var-
ied from a saving of €3020 to a cost increase of €1835 per patient. Five out of 29 studies met 
all criteria. The most frequent problems were the use of average costs per inpatient hospital 
day and too short follow-up. Informal care costs were wrongly ignored in one study.
Conclusion Many cost savings were probably overestimated.
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2.1 Introduction
The concept of hospital-at-home means that home treatment is provided to patients 
who would otherwise have been treated in the hospital. The hospital admission may be 
avoided completely (admission avoidance, AA) or shortened by early assisted discharge 
(EAD). Hospital-at-home can be attractive from different points of view. Patients may pre-
fer home treatment to staying in the hospital, they may have a smaller risk of nosocomial 
infection, beds in the hospital may be used more efficiently and the total costs of care may 
be lower.
However, there is a risk that cost savings are overestimated in cost(-effectiveness) studies 
[1]. Firstly, part of the care of patients is transferred to relatives, friends, neighbours and other 
informal caregivers, even if patients receive formal professional care at home. The fact that 
care is delivered outside of the health care system, or even that it is unpaid, does not mean 
that no costs are involved. From a societal perspective, these informal care costs should not 
be ignored, as is stated in many international guidelines for economic evaluation studies, 
which recommend all costs to be included, whoever bears them [2,3]. Secondly, since the 
reduction of hospital days is the principal driver of potential cost savings, the calculation of 
the costs per hospital day is crucial. Not all hospital days are the same. The intensity of care 
may be different across diseases and interventions. Standard or reference costs per day may 
not be sufficiently representative for the use in a particular study [4]. Furthermore, since 
treatment intensity may decrease over the course of an admission, the savings from a reduc-
tion of one inpatient day are likely to be lower than the average daily cost [1,3]. This is likely 
to have a larger influence on the cost estimates in early discharge studies than in admission 
avoidance studies.
Three systematic reviews of hospital-at-home studies which paid attention to costs have 
been published in recent years. A Cochrane review of early assisted discharge that included 
12 randomised controlled trials concluded that there is no ‘compelling evidence’ that 
hospital-at-home produces cost savings [5]. A second Cochrane review of admission avoid-
ance found, after reviewing five randomised trials, that ‘in most instances’ estimated costs 
were lower in the admission avoidance scheme than in conventional hospital treatment 
[6,7]. A third review of hospital-at-home for exacerbations of chronic obstructive pulmonary 
disease (COPD) observed that ‘substantial’ savings had been found in four studies and did 
not mention any studies indicating cost increases [8]. However, these reviews discussed 
only a selection of all cost studies of hospital-at-home. They included only randomised 
controlled trials which mainly focused on the effectiveness of the intervention. Costs and 
costing methodology were not discussed extensively.
The current systematic review aimed to cast a wider net in order to comprise all papers 
on the costs of hospital-at-home for acute conditions published from 1996 to the end of 
2011. Cost-minimization studies and cost-consequence studies were included as well as full 
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economic evaluations. Modelling studies, observational studies and pragmatic trials were 
reviewed as well as randomised controlled trials.
The first objective was an assessment of the quality of the cost analyses of the hospital-
at-home studies, with an emphasis on the method of calculating the costs of hospital days, 
and the inclusion of the costs of readmissions and the costs of informal care. The second 
objective was to present an overview of currently available evidence on cost savings of 
hospital-at-home services. Finally, we investigated what proportions of patients were eli-
gible for the various hospital-at-home programs.
2.2 Methods
Data sources
We searched MEDLINE and NHS HEED for studies published between January 1st 1996 and 
December 31st 2011 using predefined search strategies. Search terms for MEDLINE were 
(1) cost, costs or cost-effectiveness and (2) hospital-at-home, early (supported/assisted) 
discharge, home hospitalization/hospitalization, in-home healthcare or hospital in the 
home. Search terms for additional studies in NHS HEED were ‘hospital-at-home’ or ‘early 
discharge’ or ‘early assisted discharge’ or ‘early supported discharge’. Systematic reviews 
were checked for additional studies.
Study selection
Two reviewers independently selected studies for inclusion or exclusion. A preliminary 
selection was made based on titles and abstracts. In case of initial disagreements, studies 
were included or excluded based on consensus. A second selection round took place after 
retrieving the full papers. Early discharge programs as well as hospital avoidance programs 
were selected.
To be considered for inclusion, studies had to comply with the following criteria:
• a comparison between treatment at home and conventional inpatient hospital treat-
ment
• conventional hospital treatment had to include at least a one-night stay and more nights 
than the alternative;
• treatment of an acute condition or acute worsening of a chronic disease with a planned 
treatment period lasting 14 days maximum (rehabilitation programs were excluded);
• costs had to be reported in monetary terms;
• patients in the hospital-at-home scheme had to receive formal care at home, in the form 
of visits by nurses, paramedics and/or physicians;
• interventions involving children, child birth and mental healthcare were not included;
• papers had to have been written in English.
24 Chapter 2
Assessment of quality
The methodological quality of each study was assessed by two reviewers using the Quality of 
Health Economic Studies instrument (QHES). This method uses the answers to 16 questions 
to express the overall quality of each study in one score on a 0 to 100 scale, with a higher 
score indicating a better quality [9]. Each study was independently assessed by two review-
ers. Since the QHES contains questions on both empirical health economic studies and 
economic modelling as well as on both costs and health outcomes, not all questions are ap-
plicable to each study. After the two reviewers had reached consensus on the applicability of 
the questions, the final score was calculated as the average of the two reviewers’ total scores, 
expressed as a percentage of the potential maximum score on the applicable questions.
In addition to the overall quality assessment, a more in-depth examination of the cost 
analysis of each study was performed. The first focal point was the reduction of hospital 
costs in early discharge studies: were all hospital days assumed to be equally costly (average 
costing) or were the avoided days analysed separately (marginal costing). The second point 
was the use of disease-specific or general hospital costs. Thirdly, the time horizon of the cost 
analysis was recorded. The fourth issue was the inclusion of costs of informal care.
The QHES contains a question on the correctness and clarity of the cost calculations. 
No points were awarded for this question when an early discharge study used average costs 
of hospital days instead of marginal costs. Also, no points were granted when generic costs 
were applied instead of disease-specific costs in early assisted discharge as well as admis-
sion avoidance studies. Other reasons for assigning zero points included a time horizon of 
less than one month, the use of tariffs instead of opportunity costs, except when the payer 
perspective was taken, and a lack of explanation, which made the assessment of the cost 
estimate impossible. For observational studies, the calculations were not considered correct 
if no adjustment was made for possible differences in baseline characteristics. The exclusion 
of informal care cost did not automatically lead to a lower QHES score, since the cost esti-
mate could still be valid in the health care or payer perspectives. Studies were not excluded 
from further analysis based on the QHES score.
Data extraction
The study characteristics and outcomes of interest were the diagnosis group, intervention, 
country, study perspective, the estimated costs of each treatment, the cost difference, the 
length of hospital stay for each group, the duration of home care, the total duration of care in 
the hospital followed by the home care, and the proportion of patients who were recruited in 
the study. We distinguished three study perspectives. A perspective was labelled “societal” 
when all costs were taken into account, whoever bore them. These included costs within the 
healthcare sector and outside of it, such as productivity losses, travel costs and, potentially, 
informal care costs. Resource use had to be valued in terms of opportunity costs, not tariffs, 
charges, or payments to healthcare providers, because they may not reflect the real costs 
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in terms of the value of resources used. A perspective was labelled “healthcare” when only 
costs within the healthcare sector were taken into account and resource use was valued by 
the same method as in the societal perspective. Under the payer perspective, all costs were 
expressed as tariffs, charges, or payments by an insurer or other payer.
In order to facilitate comparisons, all cost savings and cost increases were converted 
into euros. This was done by using purchasing power parities (PPP) for the average price 
level of the Eurozone in the year to which the study applied [10]. That means that costs that 
were already presented in euros were adjusted to the Eurozone-wide PPP. No adjustment for 
inflation was made.
2.3 Results
Search results
The search resulted in a total of 423 potentially eligible papers. After inspection of the 
abstracts, 63 remained. Examination of the full text led to the exclusion of 32 additional 
papers. Two studies were presented in two papers, which were counted as one. The reasons 
for excluding initially selected articles are presented in table 2.1. All studies on stroke were 
excluded because they included a rehabilitation period that exceeded 14 days.
Table 2.1 Search results.
First selection round (after reading abstracts)
Source Search 
result
Ex-
cluded
Com-
parison 
not 
right
No 
formal 
care at 
home
No cost 
analysis
Paedi-
atrics/ 
obstet-
rics
Long-
term 
care
Mental 
health
Lan-
guage
Review Study 
protocol
Double 
report
Re-
main-
ing
Pubmed 397 341 208 195 186 44 1 2 25 36 3 0 56
NHS Heed 44 42 21 30 12 5 3 0 0 10 0 0 2
Reviews 43 35 10 4 25 1 1 0 1 0 0 0 8
Total 484 418 239 229 223 50 5 0 26 46 3 0 66
Second selection round (after reading full texts)
Pubmed 29 8 3 5 3 13 0 0 0 0 2 25
NHS Heed 1 1 1 0 0 0 0 0 0 0 0 1
Reviews 5 0 0 0 1 4 0 0 0 0 0 3
Total 35 8 4 5 4 16 0 0 0 0 2 29
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Of the 29 studies that were finally included, 27 covered a single intervention or diagnosis: 5 
addressed COPD exacerbations [11-15], 3 joint replacement [16-19]1, 2 breast cancer [20,21], 
2 coronary bypass surgery [22,23], 2 (elective) surgery [24-26]2, 7 hospital-at-home in general 
for acute diseases in elderly patients [27-33], 2 congestive heart failure [34,35] and 4 other 
diseases (pneumonia [36], cystic fibrosis [37], diabetes [38], deep venous thrombosis [39].
Two studies included multiple, diagnosis groups for which the results were presented 
separately: COPD, hip and knee replacement, hysterectomy and elderly in general [40]; and 
COPD, pneumonia, congestive heart failure and cellulitis [41].
The majority was conducted in two countries: England (9) and Australia (6). The United 
States and Spain each were the focus of three studies and there were two papers from New 
Zealand. The other papers came from Italy, Sweden, Iceland, Hong Kong, Canada and the 
Netherlands.
Assessment of methodological quality
Design
The results of the quality assessment are presented in table 2.2. Most studies, 20 out of 29, 
were randomised controlled trials.
Three studies were designed as sequential controlled trials. The papers of Frick et al. and 
Leff et al. are based on the same trial [27,41]. Frick et al. performed analyses per diagnosis, 
Leff et al. calculated costs for the entire sample. These three trials prospectively followed 
control group patients before the introduction of a hospital-at-home program and recruited 
the intervention group afterwards. Hardy et al. and Evans et al. used historical controls 
[21,33] and Campbell used a self-selected control group [30], which means that patients 
could choose whether they were treated at home or in the hospital. The control group of 
Hensher consisted of a small number of patients who were medically eligible for hospital-
at-home but who lived outside the scheme’s catchment area [17].
Eligibility criteria were the same for both groups in all non-randomised controlled tri-
als. None of them applied a form of regression analysis or matching in order to adjust for 
possible differences between the baseline characteristics when the cost differences were 
calculated. Some studies did mention that the characteristics were ‘similar’ [33] or ‘not sta-
tistically significantly’ different [25]. However, this does not mean that possible confounding 
was addressed. Frick et al. did perform regression adjustment in order to present efficient 
p-values, though not for point estimates for cost differences.
Two studies did not include an actual control group. Ting et al. applied the average cost 
per inpatient hospital day on the treatment duration of the intervention group in order to es-
timate the costs for the hospital treatment in similar patients [39]. Fleming et al. mentioned 
1. The papers by Jester et al. report on the same study. They were counted as one.
2. The papers by Caplan et al. and Board et al. report on the same study. They were counted as one.
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that they estimated the relative costs of the intervention group compared with a ‘representa-
tive sample’ of routine treatment patients. No more details were presented [24].
Study perspective
Most studies, 20, were performed from the healthcare perspective. Sigurdsson et al. and 
Bonnema et al. adopted a societal perspective [16,20] and five studies explicitly took a payer 
perspective [12,13,27,36,41]. For the studies by Penque et al. and Wong et al., the perspective 
could not be determined [23,38].
Generic or disease-specific inpatient hospital costs
Almost all studies, 24, used disease-specific costs per inpatient hospital day. Mendoza et al. 
and Wong et al. applied generic costs [35,38]. The papers by Booth et al., Penque et al. and 
Patel et al. did not make clear what kind of inpatient hospital costs they used [22,23,34].
Average or marginal inpatient hospital costs
The large majority, 20 studies, used average costs per hospital day. For the early-assisted-
discharge studies, for which we considered using marginal costs as essential for a correct 
cost calculation, the number was 12 out of 19. For two of this studies, however, the tariff per 
day was justified by their payer perspective [12,13]. For one EAD study, three AA studies 
and one combined program, it is not clear whether average of marginal costs per inpatient 
hospital day were used.
Opportunity costs or tariffs
In 5 studies that took the societal or healthcare perspective, tariffs instead of (or in addition 
to) opportunity costs were used for important costs categories [14,21,34,35,38]. All studies 
that took the payer perspective used tariffs for the appropriate cost categories.
Informal care
Only Bonnema et al. included the costs of informal care in their calculations [20]. The other 
study a societal perspective, Sigurdsson et al., did not do this.
Correct cost calculation
Based on the criteria set out in the Methods section and the results in the preceding subsec-
tions, the cost calculations of 7 studies were considered correct [11-13,25,26,28,31,40].
Time horizon
For 14 studies, the follow-up period was not sufficiently long to capture all relevant costs. 
They only recorded costs for the initial treatment episode. Of the 7 studies with a correct cost 
calculation, 5 also had an appropriate follow-up period [12,13,28,31,42].
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QHES scores
The average QHES score was 65. Six studies scored less than 50 out of the potential 100 
points [19,21,24,33,36,39]. The highest score was achieved by Shepperd et al., 91 [40]. The 
lowest score, 22, was for Ting et al. [39].
Estimated cost differences
All estimates of the cost differences between hospital-at-home and conventional hospital 
treatment are presented in figure 2.1. Most (sub)studies, 19 out of 29, found cost savings. 
The largest savings were estimated by Sigurdsson et al. for early assisted discharge after hip 
replacement in Iceland: €3020. On the other extreme, Harris et al. found cost increases of 
€1835 for a combined early assisted discharge and admission avoidance scheme for elderly 
patients in New Zealand.
COPD exacerbation
Results for the treatment of COPD exacerbations are presented in table 2.3. The cost cal-
culations in three studies, by Shepperd et al., Hernandez et al. and Puig-Junoy et al. were 
considered correct in our quality assessment.
Shepperd et al. is the only COPD study on a pure early-assisted-discharge scheme and 
the only study that found significantly higher costs for the hospital-at-home group [40]. The 
difference between the medians is €1603. Although no explanation for this result is given 
in the paper, it appears to be caused by the high number of days of readmissions to the 
hospital in hospital-at-home group compared to the usual care group (median 5 vs. 0). The 
total length of stay for the initial treatment is similar in both groups.
The studies by Hernandez and Puig-Junoy are based on different analyses of the same 
data sample of a mixed AA and EAD scheme in Spain, which explains why their estimated 
savings for hospital-at-home are very similar (€931 and €969). In addition to calculating 
mean costs per patient, Puig-Junoy estimated the expected cost per patient for different 
levels of disease severity through a regression model [12,13].The savings for patients with 
average characteristics, slight, moderate and severe COPD were €774, €548, €927 and €1698, 
respectively.
The remaining four studies investigated an admission avoidance program. Nicholson et 
al., again in a small sample, observed significant cost savings of €1204 per patient in Aus-
tralia [14]. Since no details were given on length of stay, it is unclear what drove the savings.
Aimonino Ricauda et al. found non-significant savings of €172 per patient in Italy [11]. 
Costs per day of treatment were lower for the hospital-at-home group, but this advantage 
was largely but not entirely offset by the longer duration of care in this group. Furthermore, 
the control group experienced more readmissions, which were not included in the cost 
analysis since the time horizon of this analysis was limited to the first acute episode. Finally, 
11.7% of the patients in the control group received a short period of care in a long-term 
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care facility, whereas all hospital-at-home patients stayed at home. These costs were also 
excluded from the cost analysis.
The largest cost savings were found by Frick et al. for the USA [41]. However, part of this 
difference might be explained by residual confounding resulting from the observational 
study design. It is conceivable that patients in the hospital-at-home group were less severely 
ill than patients in the control group. This is consistent with the shorter duration of care, with 
less variation, in the hospital-at-home group.
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Figure 2.1: Summary of incremental cost estimates of early assisted discharge or admission avoidance versus regular hospital care.
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Skwarska et al. found savings of €1163 per patient in England [15]. The uncertainty of 
hospital costs was addressed in a sensitivity analysis in which the assumed costs per in-
patient hospital day were halved. This reduced the cost difference to €19 per patient. The 
reason for performing this sensitivity analysis is the authors’ notion that average bed day 
costs overestimate the value of potential savings because fixed costs continue if beds are 
not occupied. However, in the longer run these resources can be expected to be put to use. 
Nevertheless, base-case cost savings may have been overestimated because of the use of 
average costs per hospital day.
Pneumonia
The cost calculations of neither study of the costs in hospital-at-home for pneumonia were 
considered correct in the quality assessment. Richards et al. found a saving of €232 per 
patient in a New Zealand admission avoidance scheme (see table 2.3) [36]. No patient-level 
costing was performed, and the statistical significance of this difference was not tested. The 
Table 2.3. Estimated costs savings: COPD, pneumonia, cystic fibrosis, congestive heart failure
First author Type Year Country Costs, 
hospital-
at-home
Costs, usual 
hospital 
treatment
Amount saved 
(original 
currency)
Amount 
saved (in 
PPP euros)a
Statisticsb Propor-
tion re-
cruited
COPD
Shepperd EAD 1998 England £2380c £1248c -£1132c -1603 0.01 nr
Nicholson AA 2001 Australia A$745 A$2543 A$1798 1204 <0.01 15%
Aimonino Ricauda AA 2008 Italy $1176 $1391 $215 172 0.38 34%
Frick AA 2009 USA $4928 $7274 $2346 2035 <0.05 nr
Skwarska AA 2000 Scotland £877 £1753 £876 1199 nr 26%
Hernandez Both 2003 Spain 1255 2034 € 778 931 0.003 39%
Puig-Junoy Both 2007 Spain 1154 1964 € 810 969 €418-€1169 39%
1154 1801 € 647 774 €217-€959 na
Pneumonia
Richards AA 2005 New Zealand NZ$158 NZ$1556 NZ$398 232 nr 27%
Frick AA 2009 USA $6072 $7686 $1614 1400 not sign. nr
Cystic fibrosis
Wolter EAD 1997 Australia AS$2476 AS$ 5028 AS$ 2552 1247 nr nr
Congestive heart failure
Mendoza, initial treatm. AA 2009 Spain €2541 €4502 €1961 2216 <0.001 nr
Mendoza, follow-up €3425 €4619 €1194 1350 0.83 na
Frick AA 2009 USA $3959 $7232 $3273 2839 <0.001 nr
Patel, initial treatment Both 2008 Sweden €586 €3277 €2691 2287 nr 13%
Patel, including follow-up €2680 €5150 €2470 2100 0.08 13%
a A negative amount means a cost increase ; b 95% confidence interval or p-value; c Medians
Abbreviation: nr, not reported.
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American study by Frick et al. found savings of €1400 per patient, which were not statistically 
significant [41].
Congestive heart failure
All three studies – the cost calculations of which were not considered correct in the quality 
assessment – found significant cost savings for hospital-a-home, ranging from €2100 to €3566 
(see table 2.3). For the Spanish admission avoidance study by Mendoza et al., the cost differ-
ence was statistically significant during the initial treatment but not during the follow-up [35].
Although Patel et al. combined admission avoidance and early assisted discharge, their 
Swedish hospital-at-home program was not more costly (€2287 during the admission phase) 
than the admission avoidance programs in the other studies (€2216 for the admission phase 
in Spain and $2839 with 8 weeks of follow-up in the United States) [34,41]. The duration of 
care is much longer in the study by Mendoza et al.
Joint replacement
The calculations of costs of joint replacement by Shepperd et al. were considered correct 
in the quality assessment. They found a small and insignificant increase for early assisted 
discharge for both hip (€135) and knee replacement (€122) in England (see table 2.4). [40]. 
Hospital-at-home patients received more days of care than hospital patients.
The two English schemes for early discharge after hip replacement that were investigated 
by Hensher et al. were thought to bring about significant cost increases as well: €1009 and 
€1081, respectively [17]. Treatment duration was longer than for usual hospital care, while 
costs per day were equally high or only slightly lower in the hospital-at-home group.
According to the Iceland study by Sigurdsson et al., early assisted discharge after hip 
replacement led to substantial and significant savings: €3020 from the societal perspective, 
€2257 from the healthcare perspective [16]. Half of the cost savings from the healthcare per-
spective were due to the days that patients in the usual care group spent in a convalescent 
home after leaving the hospital. Furthermore, no patient in the hospital-at-home group had 
to be readmitted, whereas there were readmissions in the usual care group.
Jester et al. found savings of €905 for the hip and knee replacement in England, but no 
significance testing was performed [19].
Breast cancer surgery
The cost calculations of neither study of the costs in hospital-at-home for breast cancer 
surgery were considered correct in the quality assessment. In the Canadian study by Evans 
et al., calculations were made separately for patients with mastectomy and lumpectomy 
(see table 2.4). Compared to usual hospital care, net savings for lumpectomy patients who 
avoided hospital admission were estimated to be €2067. Savings due to inpatient days 
avoided were offset partly by higher costs for surgery and counselling [21].
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The estimated savings for mastectomy patients were €1945. For this patient group, a risk 
of readmission was assumed, whereas this was disregarded for mastectomy patients. No 
significance testing was performed.
Both patient groups were combined in an early assisted discharge program investigated 
by Bonnema et al. [20], who found significant savings of €1050 due to hospital-at-home care 
for breast cancer surgery in the Netherlands. This might be an overestimation because the 
inpatient days that were substituted for care at home, were less costly than the average costs 
that were used in this study.
Table 2.4 Estimated cost savings: surgery
First author Type Year Country Costs, 
hospital-
at-home
Costs, 
usual 
hospital 
treatment
Amount 
saved 
(original 
currency)
Amount 
saved 
(in PPP 
euros)a
Statisticsb Proportion 
recruited
Hip replacement
Sigurdsson EAD 2008 Iceland $8550 $11,952 $3402 3020 nr nr
$5720 $8263 $2543 2257 nr nr
Hensher EAD 1996 England £2780 £2012 -£768 -1081 <0.05 nr
Hensher EAD 1996 England £2023 £1306 -£717 -1009 <0.05 nr
Shepperd EAD 1998 England £911 £816 -£96 -135 0.59 20%
Knee replacement
Shepperd EAD 1998 England £1462 £1375 -£86 -122 0.55 25%
Knee or hip replacement
Jester EAD 2003 England £2332 £2984 £652 905 nr nr
Lumpectomy
Evans AA 2000 Canada C$6050 C$8836 C$2786 2067 nr nr
Mastectomy
Evans EAD 2000 Canada 3424 6046 $2622 1945 nr nr
Lumpectomy or mastectomy
Bonnema EAD 1998 Netherlands $3062 $4382 $1320 1050 0.0007 nr
Coronary bypass surgery
Booth EAD 2004 England £6127 £6381 £254 346 -€474 - €1252 nr
Penque EAD 1999 USA $17,749 $17,480 -$269 -239 nr nr
Cholystectomy
Caplan/Board EAD 1998/2000 Australia A$2887 A$3282 A$265 182 nr nr
Fleming AA 2000 Australia A$3145 A$4129 A$984 668 nr 56%
Herrhnioraphy
Caplan/Board EAD 1998/2000 Australia A$2082 A$2321 A$239 164 nr nr
Hysterectomy
Shepperd EAD 1998 England £772 £679 -£93 -131 <0.01 35%
a A negative amount means a cost increase; b 95% confidence interval or p-value.
Abbreviation: nr, not reported.
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Coronary bypass surgery
The cost calculations in both studies of hospital-at-home after coronary bypass surgery were 
considered incorrect in the quality assessment.
Penque et al. found that an early assisted discharge program for coronary bypass surgery 
in Minnesota, United States, was €239 per patient more expensive than regular treatment (see 
table 2.4) [23]. This difference was not tested statistically. However, the authors argue that 
patients in both trial arms were discharged earlier than ‘usual’. Therefore, they also compared 
the costs in the hospital-at-home group with an ‘average’ of costs for patients undergoing this 
form of surgery, for which no source was given. This difference was said to be significant and 
in favour of hospital-at-home. It is not clear whether a comparison of patients in the trial with 
the average patient was justified. In the English study by Booth et al. the total healthcare costs 
per patient in the three months after surgery were €346 lower in the hospital-at-home group 
than in the usual hospital care group [22]. This difference was not statistically significant. 
It was caused almost entirely by the higher costs of readmissions in the usual hospital care 
group. The costs during the initial episode were almost the same in both groups.
Elective surgery
The calculations of costs of hysterectomy by Shepperd et al. were considered correct in the 
quality assessment [40]. The calculations in the other studies of elective surgery were not. 
Shepperd et al. investigated early assisted discharge after hysterectomy in England and 
found significantly higher costs for the hospital-at-home group. The cost difference was €131 
per patient (see table 2.4). Total treatment duration was longer for hospital-at-home care 
than for usual care.
Two papers reported on one study on assisted discharge after herniorrhaphy or cholys-
tectomy in Australia and are discussed together [25,26]. They found that per-patient costs 
were €164 and €182 lower than usual hospital care, respectively. However, part of these 
differences is due to the fact that patients in the usual care group spent more time in the 
hospital before the operation.
According to Fleming et al. avoiding hospital admission for cholystectomy in England 
led to costs savings of €668 per patient. These savings were achieved by reducing the length 
of stay with merely one day. However, hospital-at-home patients recovered in a day-surgery 
unit, which was less expensive than the recovery room of the main theatre suite [24].
Acute diseases in elderly patients
For three of the studies of hospital-at-home for elderly patients, the cost calculations were 
considered correct in the quality assessment [28,31,40].
In a pure admission avoidance scheme, Jones found statistically insignificant savings of 
€291 per patient when the intention-to-treat principle was applied (see table 2.5). Patients 
who refused to be treated at home, were still counted as hospital-at-home patients anyway. 
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When these patients were left out, the savings were larger (€1505 per patient) and statisti-
cally significant.
Board et al. reported significant savings of €1270 per patient for an Australian admission 
avoidance program [27,31]. In the English study by Shepperd et al., the costs were €448 per 
patient higher than for usual hospital care in England, but this difference was not statisti-
cally significant [40]. Duration of treatment was longer in the hospital-at-home group.
Three of the other studies reported savings for hospital-at-home. The largest savings 
were calculated by Campbell et al. in a program for early assisted discharge and admission 
avoidance in an English hospital (€2562 per patient) [30]. The difference was statistically 
significant.
Two other English studies found savings as well, but they did not provide statistical test-
ing results. Coast et al. reported that early assisted discharge was less costly than regular 
hospital treatment, a difference of €1119 per patient [29]. Hardy et al. found savings for a mix 
of assisted discharge and admission avoidance: €1063 [33].
The study by Leff et al. was based on the same data as the study by Frick et al., in which 
treatments for different diseases were assessed separately. The estimated cost savings for 
admission avoidance were €2081 and were statistically significant [27].
Harris et al. found a significant cost increase for hospital-at-home: €1835 per patient 
in New Zealand [32]. In the latter study, the duration of treatment in the hospital-at-home 
group was much longer than the length of stay in the regular hospital care group. The authors 
note that the program was terminated shortly after the study was completed.
Different interventions
The cost calculations in the studies for the remaining interventions were not considered 
correct in the quality assessment. Wolter et al. examined the costs of an early discharge 
hospital-at-home program for patients with an infective exacerbation of cystic fibrosis in 
Australia [37]. In case of a recurrent episode, patients alternated treatment arms. A possible 
effect of the first treatment on later exacerbations was not taken into account. They found 
a healthcare cost difference of €1247 in favour of hospital-at-home, which was not tested 
statistically (table 2.5).
Wong et al. investigated early assisted discharge for patients with diabetes type I or II 
who were admitted to achieve glycaemic control in Hong Kong (table 2.5) [38]. Treatment 
at home consisted of telephone calls by nurses to monitor glycaemic levels until these were 
stable. If necessary, patients were asked to return to the clinic. The costs for these returns 
were not included in the analysis. The authors found that the costs in the hospital-at-home 
program – after the first days of admission to the hospital – were less than 3% of the costs in 
the regular hospital care group, saving €1647 per patient.
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Ting et al. assessed cost savings of early assisted discharge for patients with lower-limb 
deep venous thrombosis in Australia [39]. The estimated cost savings per patient were €838 
(table 2.5). No significance testing was performed.
Frick et al. estimated the mean savings, when avoiding admission of cellulitis patients 
in the US, at €2675 per patient (table 2.5) [41]. This difference was statistically significant.
Proportion of recruited patients
The authors of 15 of the selected (sub)studies presented the proportion of patients that 
underwent the intervention and who were recruited in the study. For COPD exacerbations, 
proportions varied from 14.9% [14] to 38.8% [12,13] of all patients hospitalized for a COPD 
exacerbation. In acute care for elderly patients, 25.2% to 50.1% was considered eligible. The 
lowest number, 13.0% was found in the study by Patel et al. [34]. Fleming et al. recruited the 
highest proportion of admitted patients, 56% [24].
Table 2.5. Estimated cost savings: elderly patients, other diseases.
First author Type Year Country Costs, 
hospital-
at-home
Costs, usual 
hospital 
treatment
Amount 
saved 
(original 
currency)
Amount 
saved 
(in PPP 
euros)a
Statisticsb Proportion
recruited
Acute care for elderly patients
Coast EAD 1998 England £2545 £3336 £791 1119 nr nr
Leff AA 2005 USA $5081 $7480 $2399 2081 <0.001 25%
Board AA 2000 Australia AS$1764 A$3775 A$2011 1381 <0.001 nr
Jones AA 1999 England £3671 £3877 £206 291 0.647 nr
£3697c £4761c £1064c 1505c 0.025 nr
Campbell Both 2001 England £2864 £4748 £1884 2562 <0.001 42.2%, 50.1%d
Harris Both 2005 New Zealand NZ$6524 NZ$3525 -NZ$2999 -1835 <0.0001 nr
Shepperd Both 1998 England £1705 £1388 -£317 -448 0.09 nr
Hardy EAD 2001 England nr nr £782 1063 nr nr
Diabetes
Wong EAD 2005 Hong Kong HK$322 HK$12,210 HK$11,888 1647 <0.001 nr
Deep venous thrombosis
Ting EAD 1998 Australia AS$2613 AS$3852 AS$1239 838 nr nr
Cellulitis
Frick AA 2009 USA $4927 $8011 $3084 2675 not sign. nr
a A negative amount means a cost increase; b 95% confidence interval or p-value; c Excluding patients who refused their assigned treatment ; 
d Admission avoidance and early assisted discharge, respectively.
Abbreviations: PPP, purchasing power parity; nr, not reported.
A systematic review of hospital-at-home care 39
2
2.4 Discussion
This systematic review provided an overview and quality assessment of all cost- studies 
of hospital-at-home programs published between 1996 and 2011. Cost calculations were 
considered correct only if they met a number of explicit criteria. Firstly, the unit costs of 
inpatient hospital days had to be disease-specific. Secondly, in studies of early discharge 
programs, these unit costs were also required to take into account that the intensity of care 
might decrease in the course of an admission. Thirdly, in studies that took the societal per-
spective, the costs of informal care had to be included. Fourthly, the time horizon had to 
be at least one month after admission in order to capture costs and effects after the initial 
treatment episode. This particularly includes the costs of re-admissions in patients that were 
discharged early or the costs of hospital admissions in patients that were part of an admis-
sion avoidance program.
Only 5 out of 29 studies, containing 10 out of 43 sub studies, met all criteria and had 
a sufficiently clear explanation of their methodology [12,13,28,31,40]. The most frequent 
problem was the use of average costs per inpatient hospital day, which was problematic 
in at least 10 studies of early discharge schemes [17-22,29,32,37-39]. This is unclear for one 
study [23].
Generic instead of disease-specific inpatient costs were applied in at least two studies 
[35,38], while this was unclear for three others [22,23,34]. Informal care costs were left out of 
one study that stated to adopt a societal perspective [16].
The follow-up period was considered too short in 13 studies to include all relevant 
down-stream costs of the hospital-at-home program, in particular costs of (re-) admissions 
[11,14,17-19,23-26,33,36-39]. In one study, the explicit criteria were met but insufficient in-
formation on the calculation of costs was presented [15]. None of the observational studies 
adjusted for possible baseline differences between the treatment groups. [21,24,27,30,33,41].
Violating any of first three explicit criteria leads to an overestimation of the savings (or 
underestimation of the cost increases) from a hospital-at-home program compared to regu-
lar hospital care. The last days in the hospital tend to be the less costly since patients require 
less care than the average over the regular admission period [1,3]. Exchanging these days for 
care at home leaves the more expensive hospital days in place. Generic, non-disease-specific 
costs per inpatient hospital day are based on the average patient across several conditions 
and diseases. Patients who are eligible for hospital-at-home are likely to need less care than 
this average patient. Even if disease-specific costs are used, when they are not tailored to the 
specific target group of the hospital-at-home program, they may lead to overestimation of the 
costs of inpatient hospital days, and of the cost savings, because the severely ill patients are 
usually excluded from the program. Finally, when the costs of informal care are not included 
in the analyses, part of the care for the patient in a hospital-at-home program wrongly appears 
to bear no opportunity costs. Violation of the criterion on the time horizon does not have to 
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lead to overestimation of the savings. It only does so when the need for re-hospitalization 
or other forms of care is higher in the hospital-at-home group than in the usual care group.
This leads to the conclusion that, while most studies found that hospital-at-home was 
cost-saving, these savings were probably overestimated. Savings may not disappear after 
adjusted calculations, but they will be considerably smaller.
In some cases, however, hospital-at-home led to cost increases [17,23,25,26,32,33,40]. 
There were two reasons for these results. In many studies, the treatment period was not 
fixed and patients in the regular hospital care group were discharged from hospital earlier 
than patients in the hospital-at-home group stopped home care. The threshold for adding 
another day to the treatment period appeared to have been lower in hospital-at-home. In 
these studies, the lower costs per day were offset by a higher number of days in treatment. 
The second reason is that patients in the hospital-at-home group sometimes had more 
readmissions.
There was a correlation between the criteria for unbiased calculation of cost savings and 
the QHES score. The three studies that met our criteria for a correct cost calculation scored 
very high on the QHES score, while studies with low QHES scores also scored badly on our 
criteria, especially the time horizon. At the same time, some studies with biased estimates 
still achieved high QHES scores. Since violation of our criteria led to an overestimation of 
cost savings, better designed studies were less likely to find large savings. This difference 
was enhanced by the fact that Shepperd et al. found cost increases for hospital-at-home for 
several diseases.
One more issue with the cost estimates of inpatient hospital days requires discussion. In 
all papers, as in other cost-effectiveness studies, they were treated as fixed unit costs. How-
ever, an inpatient hospital day is a complex combination of staff time, hotel costs, equipment, 
medication, overhead costs. This combination is different for each patient, which means that 
uncertainty surrounding the mean of the cost estimate should be taken into account. This 
would require patient-level data on each separate inpatient hospital day, the collection of 
which would not be feasible in most studies. Instead, the uncertainty could be acknowl-
edged by performing sensitivity analyses with different costs per hospital admission.
We did not perform a meta-analysis, which would involve pooling results from different 
studies in order to combine evidence by statistical methods. The question whether hospital-
at-home in general is cost-saving may not be very meaningful. Hospital-at-home is not 
one uniform treatment. It is an umbrella term which covers a great deal of combinations of 
treatment characteristics. Treatment patterns, health systems, the organisation that delivers 
the homecare (hospital or a separate organisation), price levels, price differentials differ 
across jurisdictions, time and hospital-at-home programs. Costs and cost savings depend 
on the exact specifications of the program. Furthermore, many of the selected paper did not 
contain the information that is required to perform a meta-analysis.
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The answer to the question on the effectiveness and costs of these programs always 
depends on who is treated. Hospital-at-home treatments are probably acceptable to pa-
tients and care providers only if their health outcomes are at least equivalent to those of 
regular hospital admissions. Patients who are most at risk of needing intensive treatment at 
home – where it may be more expensive as well as less effective or more hazardous than in 
the hospital – may not be included in the program. Different assessments of the suitability 
of patients may be made in different programs. The proportions of eligible patients in the 
selected studies were quite low, probably because physicians wanted to avoid risks.
As in any review, the risk of publication bias must be acknowledged. It is conceivable 
that negative results of hospital-at-home schemes were not published. Indeed, the expecta-
tion of savings was the rationale for the implementation of many programs. The hospital-at-
home scheme reported by Harris et al. was terminated after the study ended with negative 
conclusions [32].
This review discussed more studies than earlier reviews [5-8]. We aimed at including 
observational studies as well as randomised controlled trials. Even if RCTs are considered 
the gold standard in obtaining evidence on the efficacy of treatments, well-executed studies 
in daily practice – which cannot always be randomised – are useful.
If the value of the current review is not in combining all available evidence in one 
conclusion about the costs of hospital-at-home, it is in identifying the problems in existing 
studies and in presenting an overview of the evidence per disease area. The results of most of 
the studies should at best be regarded as the upper limit of potential cost benefits: especially 
the savings due to the reduction of inpatient hospital days are overestimated.
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3Effectiveness and cost-effectiveness of early assisted 
discharge for Chronic Obstructive 
Pulmonary Disease exacerbations
The design of a randomised controlled trial
Background Exacerbations are the main cause for hospitalization of Chronic Obstructive 
Pulmonary Disease (COPD) patients. Hospitalisations result in a high pressure on hospital 
beds and high health care costs. Because of the increasing prevalence of COPD this will 
only become worse. Hospital-at-home is one of the alternatives that has been proved to be 
a safe alternative for hospitalisation in COPD. Most schemes are early assisted discharge 
schemes with specialised respiratory nurses providing care at home. Whether this type of 
service is cost-effective depends on the setting in which it is delivered and the way in which 
it is organised.
Methods GO AHEAD (Assessment Of Going Home under Early Assisted Discharge) is a 
3-months, randomised controlled, multi-centre clinical trial. Patients admitted to hospital 
for a COPD exacerbation are either discharged on the fourth day of admission and further 
treated at home, or receive usual inpatient hospital care. Home treatment is supervised by 
general nurses. Primary outcome is the effectiveness and cost effectiveness of an early as-
sisted discharge intervention in comparison with usual inpatient hospital care for patients 
hospitalised with a COPD exacerbation. Secondary outcomes include effects on quality 
of life, primary informal caregiver burden and patient and primary caregiver satisfaction. 
Additionally, a discrete choice experiment is performed to provide insight in patient and 
informal caregiver preferences for different treatment characteristics. Measurements are 
performed on the first day of admission and 3 days, 7 days, 1 month and 3 months thereaf-
ter. Ethical approval has been obtained and the study has been registered.
Conclusion This article describes the study protocol of the GO AHEAD study. Early 
assisted discharge could be an effective and cost-effective method to reduce length of hos-
pital stay in the Netherlands which is beneficial for patients and society. If effectiveness and 
cost-effectiveness can be proven, implementation in the Dutch health care system should 
be considered.
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3.1 Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that is currently ranked 
as fourth major cause of death globally [1]. Due to an aging population and late effects of 
smoking, the prevalence of COPD will increase in the following 20 years [2]. Projections 
for the year 2030 indicate that COPD will be third major cause of death, as a result of the 
projected increase of tobacco use, especially among women and low-and middle income 
countries [1]. COPD is characterised by an airflow limitation which is not fully reversible. 
Symptoms include sputum production, cough and dyspnoea. These symptoms are chronic 
and progressive over time [3].
Acute exacerbations of COPD can be defined as ‘an event in the natural course of the 
disease characterized by a change in a patients’ baseline dyspnoea, cough and/ or sputum 
production that is beyond the day-to-day variations, is acute in onset, and may warrant a 
change in regular medication in a patient with underlying COPD’ [3]. The exacerbation fre-
quency is dependent on several factors including disease severity and number of exacerba-
tions in the previous year [4,5]. Although most exacerbations are treated in the community 
[5], exacerbations are the main cause for hospitalisations in COPD patients [5,6]. Studies 
have shown that exacerbations and hospital admissions negatively influence patient out-
comes, by increasing lung function decline [5,6], decreasing quality of life [7,8], increasing 
mortality [9] and increasing readmission risk [8,10].
With a mean length of stay in the hospital of 9 days [6,11] the large number of hospital 
admissions for exacerbations among COPD patients result in a high pressure on scarce 
hospital beds and high health care costs, accounting for up to 70% of total expenses for 
COPD [12,13]. Even without intervention, hospital costs will rise as a result of the increasing 
prevalence of COPD, especially among women. To reduce health care costs, alternatives 
for hospital treatment have been developed. One alternative that has gained popularity in 
the last 15 years are hospital-at-home schemes [14,15]. These schemes aim at reducing the 
pressure on hospital beds and overall health care costs without negatively influencing the 
patient outcomes and increase patient satisfaction[16] [16].
Hospital-at-home and early assisted discharge
Hospital-at-home is defined as ‘a service that provides active treatment by health care 
professionals in the patient’s home for a condition that otherwise would require acute in-
patient care, and always for a limited time period’ [17]. Hospital-at-home is also known as 
‘home hospitalisation’ or ‘hospital in the home’. Depending on the target population of the 
scheme and the type of care provided, schemes vary in organisational structure and may 
involve different professionals [17]. Hospital-at-home schemes can be divided in admis-
sion avoidance schemes, (early) assisted or supported discharge schemes and combined 
schemes. Depending on who bears the financial and management responsibilities, the 
Effectiveness and cost-effectiveness of early assisted discharge for COPD exacerbations 47
3
schemes can further be divided in community resourced or hospital resourced. Community 
resourced schemes commonly built on the existing infrastructure for care provision in the 
community, whereas hospital resourced schemes work on an outreach basis and home care 
is provided by hospital staff.
Hospital-at-home for COPD exacerbations
Hospital-at-home schemes for the treatment of COPD exacerbations specifically, have been 
studied in several randomised controlled trials [18-24] and various nonrandomised studies 
including observational studies [25-30] and studies with retrospective analysis [31]. Studies 
were performed in the United Kingdom [19,20,23-28], Ireland [29], Australia [22], Italy [18] 
and Spain [21,30]. These studies showed that approximately 25% of all patients with an acute 
exacerbation of COPD can be treated at home safely with no negative effects on their health 
outcomes and with great patient satisfaction [16]. These results triggered the wide imple-
mentation of hospital-at-home schemes for COPD exacerbations in the United Kingdom 
over the last 10 years [14,15]. In 2007, the British Thoracic Society developed the Hospital-at-
Home in Chronic Obstructive Pulmonary Disease guideline providing a framework for the 
development and adjustment of hospital-at-home schemes [32].
Most hospital-at-home schemes active in the United Kingdom are assisted discharge 
schemes, with specialised respiratory nurses providing home care on an outpatient basis 
[14,15]. However, it remains unknown whether this is the most effective model for hospital-
at-home care. The use of generic community district nurses or telephone monitoring might 
be an option that increases the capacity of the hospital-at-home schemes for COPD exacer-
bation. Supported by their positive results, Davison et al. [27] suggest that the use of generic 
community nurses in hospital-at-home schemes should be studied more intensively.
Hospital-at-home for COPD exacerbations initially requiring hospital admission has 
also been the subject of several cost or cost-effectiveness studies [18,21,22,24,33-35]. Statis-
tically significant and substantial cost savings were found in Australia (€1200 per episode) 
[22], Spain (€800) [21,34] and the United States (€1700) [33]. No significant cost savings were 
found for England and Italy [18,35]. (Amounts were converted to euros, using exchange 
rates of March 2010.) All studies were performed from a health care or payer perspective, 
meaning that they recorded only costs in the health care sector and not included costs of 
informal care. Although treating COPD exacerbations at home has the potential to reduce 
costs, whether and the extent to which it does so in the Netherlands is unknown. Apart from 
the exact organisation of the hospital-at-home scheme, its health economic impact depends 
heavily on national and local treatment patterns, health care delivery structures, funding 
and reimbursement systems, absolute and relative differences in unit costs of resource use 
and drug prices. The limited transferability of cost-effectiveness results to other settings 
stresses the need for setting-specific cost-effectiveness studies.
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This contribution presents the design of the GO AHEAD trial (GO AHEAD is an acronym 
for Assessment Of Going Home under Early Assisted Discharge). In this Randomised Con-
trolled Trial (RCT) patients admitted to the hospital for an exacerbation of their COPD are 
discharged early and monitored at home by nurses.
Research questions
Our primary research question is: “What is the effectiveness and cost-effectiveness of an early 
assisted discharge intervention compared to hospital care as usual for patients hospitalised 
with an exacerbation of their COPD.” The primary measure of effectiveness will expressed by 
the change in health status, measured by the change in Clinical COPD Questionnaire (CCQ)
[36] scores between randomisation and day 7, while costs include COPD-related health 
care costs, patients’ and informal caregivers’ out-of-pocket costs and patients’ and informal 
caregivers’ costs of production loss.
The following secondary research questions will be addressed:
1) What is the long-term effectiveness of early assisted discharge compared to hospital 
care as usual?
2) What is the difference in treatment failures between the early assisted discharge scheme 
and usual care in hospital? Treatment failure in the intervention group is defined as 
readmission before day 7 or death before day 7. In the control group treatment failure 
is defined as death before day 7 or clinical deterioration leading to prolongation of 
hospital stay after day 7.
3) What is the effect of early assisted discharge on readmission rates after discharge from 
hospital or the early assisted discharge scheme, in comparison with usual care in hos-
pital?
4) What is the effect of early assisted discharge on mortality after discharge from hospital 
or early assisted discharge scheme, in comparison with usual care in hospital?
5) What is the effect of early assisted discharge on patients quality of life in comparison 
with usual care in hospital?
6) What is the effect of early assisted discharge on primary informal caregiver burden in 
comparison with usual care in hospital?
7) How is patient and primary informal caregiver satisfaction with the early assisted dis-
charge scheme compared with usual care in hospital?
Additionally a discrete choice experiment (DCE) is performed in order to provide more 
insight in patient and primary informal caregiver preferences for different treatment char-
acteristics.
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3.2 Methods
Design, recruitment and outcome measures
The GO AHEAD study is a randomised controlled, multi-centre trial comparing two man-
agement strategies for patients admitted to the hospital for a COPD exacerbation. The 
intervention strategy is early assisted discharge, which implies that patients are discharged 
early from hospital with a package of home care. Recovery is monitored while patients are 
further treated at home. This management strategy is compared to usual hospital care, 
where patients remain hospitalised and are monitored in hospital. The total length of the ac-
tive, supervised treatment phase for both groups is planned to be seven days. The follow up 
period of the trial is three months. Figure 3.1 gives a complete overview of the study design. 
Main focus of the study is not only to perform an effect evaluation, but also a cost evaluation 
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Figure 3.1 Trial design.
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and a discrete choice experiment. This trial was approved by the Medical Ethics Committee 
of the Catharina-hospital Eindhoven, the Netherlands and this approval was reconfirmed by 
the Medical Ethics Committees of the other participating hospitals.
Setting and recruitment
Patients admitted to one of the participating hospitals because of an exacerbation of their 
COPD, through either the emergency department or after an unscheduled outpatient visit to 
the pulmonologist, are screened for eligibility. Patients are assessed for eligibility at two time 
points. On day one, the pulmonologist and research nurse screen the patient for eligibility 
according to the inclusion and exclusion criteria listed in table 3.1.
On day 1 patients are considered eligible for potential early discharge if they meet the 
following inclusion criteria: aged 40 or over, competent, diagnosed with at least COPD 
GOLD stage 1 (post-bronchodilator FEV1/FVC < 70%[3] ) and a smoking history of mini-
mally 10 pack years (PY), hospitalised with a moderate to severe exacerbation and finally, 
completed informed consent on day three of admission. Patients are excluded if they meet 
any of the following exclusion criteria: major uncontrolled comorbidity, mental disability, 
active alcohol- or drug abuse, inability to understand the program, living outside the region 
of the participating home care organisation, indication for admission to the intensive care 
unit or non-invasive ventilation and insufficient availability of informal care at home.
On day 1, all patients considered eligible for potential early discharge are invited to par-
ticipate in the controlled clinical trial in which they either continue their hospital admission 
or are discharged early to home care. These patients are informed that, if they fulfil the in- 
and exclusion criteria and are still willing to participate on day 3, they will be randomised on 
Table 3.1 Inclusion and exclusion criteria
Inclusion criteria
Age 40 years and over
Competent
Diagnosed with at least COPD GOLD I and 10 Pack Years or grounded susceptibility for COPD
Hospitalised with COPD exacerbation
Completed informed consent on day 3 of admission
Exclusion criteria
Major uncontrolled comorbidity
Mental disability
Active alcohol abuse and/or drug abuse
Inability to understand the program
Living outside care region of the home care organisation
Indication for admission to intensive care unit or non-invasive ventilation
Insufficient availability of informal care at home
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day 3 and discharged on day 4. For patients admitted before 12:00 pm, the day of admission 
is considered as day 1, otherwise, the following day is considered as day 1.
Patients must have signed the informed consent form before randomisation on day 3, 
which means they have three days to decide whether they want to participate in the trial 
or not. This procedure is possible because the treatment in the first three days is not differ-
ent from that of patients not participating in the trial. Data collected before the third day of 
admission will be destroyed if the patient does not give informed consent on that day. This 
procedure has been approved by the ethics committee.
Patients who refuse to participate in the trial are invited to participate only in the discrete 
choice experiment study without participating in the RCT. These patients are contacted by 
telephone one month after admission and asked to give informed consent for this part of the 
study. This informed consent form is different from the form that is used in the RCT.
Randomisation procedure
On the third day of admission clinical stability is assessed in order to determine whether 
patients can be randomised. This design for randomisation is adapted from the Spanish 
study performed by Diaz et al. [37] although the criteria for clinical stability were adapted 
to represent the current practice in the participating hospitals and because of the difference 
in treatment package patients receive at home. Patients need to meet the following criteria 
to be randomised: (1) acceptable general health defined as decrease of physical complaints, 
non-dependence on therapies that cannot be given at home and being able to visit the 
toilet independently; (2) normal or moderately increased blood sugar levels, defined as ≤ 15 
mmol/L or ≥ 15 mmol/L while the patient is capable to regulate blood sugars independently 
at home; and respiratory complaints of dyspnoea, wheezing and rhonchi must have de-
creased in comparison with day one of admission. A special symptoms scoring list adapted 
from the one used by Ojoo et al.[23] is used for this. This scoring chart scores the major 
exacerbation symptoms such as dyspnoea, coughing, mucus production and colour and 
oedema. By scoring these symptoms daily, improvement or deterioration in comparison 
with the previous days becomes more visual and supports the pulmonologist when applying 
the randomisation criteria to the patient.
Randomisation is performed on a 1:1 scale using a computer-generated randomisation 
list that is placed in sealed envelopes containing the allocation sequence of the two treat-
ment groups. Randomisation is performed per participating location of the hospitals. We 
chose this procedure to ensure all participating hospitals have a similar proportion of 
patients in the intervention group and patients in the control group and that the burden 
for each participating home care organisations is similar. Furthermore, a block size of 6 is 
applied to create equal numbers in both groups.
The treatment protocol for the following four days is started after randomisation and for 
the intervention group the process of discharge planning is started.
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Treatment protocol day 1-3 and day 4-7
The treatment protocol during the seven days of supervised treatment can be divided in the 
treatment before randomisation and the treatment after randomisation.
During the first three days of the treatment all patients receive usual care. The pharmaco-
logical part of this treatment consists of systemic corticosteroids (10 days in total, first 3 days 
50 mg of oral or intravenous prednisolone or other corticosteroid with an equivalent dose, 
following 7 days of 30 mg oral prednisolone or other corticosteroid with an equivalent dose), 
nebulised bronchodilators (ipratropium 500 μg/salbutamol 2.5 mg, 4-6 times per day), sub 
cutaneous thrombosis prophylaxis, stomach protection – because of the high dosage of cor-
ticosteroids – and, if necessary, oxygen therapy. Antibiotics are prescribed if patients meet 
any of the following criteria: increase of the amount of mucus, mucus purulence or CRP > 
50 for which no other cause can be determined. First choice of antibiotics is co-amoxiclav. 
However, if previous mucus cultures show sensitivity for different antibiotics, or patients are 
allergic, different antibiotics can be prescribed. Antibiotics are prescribed for at least 7 days.
Non-pharmacologic usual care consists of physiotherapy for all patients and dietary 
advice upon indication [38]. The physiotherapist instructs the patient in breathing and 
coughing techniques and reactivation. A standardised (additional) written instruction was 
developed ensuring identical instruction in the participating hospitals. Dietary advice is 
indicated in case of a Body Mass Index ≤ 21 or 10% unintended weight loss in the six months 
prior to admission [38].
After randomisation systemic corticosteroids are continued and patients start with 
pressure metered dose inhaled medication via spacer (at least an β
2
-antagonist or anti-
cholinergic with inhaled gluco-corticosteroid). Patients receive inhalation instruction on 
the day before starting with these inhalations. Patients already using nebulised inhalation 
medication prior to admission, may continue this after randomisation.
The physiotherapist instructs patients to follow the written instructions at home and 
dietary consultation is continued as in usual care and at the dietician’s judgement.
On the fourth day of admission the intervention group is transferred home and under-
goes the early assisted discharge intervention. The control group remains hospitalised and 
receives usual care in hospital.
In both groups, patient recovery progress is monitored daily using the translated and 
adapted exacerbation symptom scoring chart.
Early assisted discharge intervention
Patients randomised into the early assisted discharge group are transferred home on day 
four of admission. The previously described treatment is continued at home and supervised 
by nurses. These nurses have daily contact with the patient for four consecutive days. Main 
objective of the supervision of the home treatment is the observation of the patient’s re-
covery and providing counselling and reassurance to the patient and the primary informal 
Effectiveness and cost-effectiveness of early assisted discharge for COPD exacerbations 53
3
caregiver. The nurses also address medication compliance and inhalation techniques, 
provide support in applying breathing- and coughing techniques and, if applicable, provide 
support in adhering to dietary advices. If necessary patients, can be supported in their daily 
life activities (e.g. washing and dressing) by the home care organisation. During the four 
days of home treatment, the emphasis lies on the recovery of the exacerbation. Secondary 
objectives like disease management and smoking cessation are addressed during the first 
follow up moment one month after randomisation.
General practitioners are informed about patients’ participation in the trial but are not 
directly involved in these patients’ home care. In cases of deterioration of the patient, the 
patient is discussed with the treating hospital pulmonologist and if necessary the patient is 
readmitted to the hospital. Patients can contact the hospital 24 hours a day, 7 days a week 
with questions or in case of an emergency.
Follow-up visits
For both treatment groups two follow up visits at the outpatient clinic are scheduled at one 
month and three months after randomisation. During these visits patients are seen by their 
own pulmonologist and a respiratory nurse. The visits to the pulmonologist are as in usual 
care, the visits to the respiratory nurse have a twofold purpose. Firstly, these visits focus on 
the different aspects of disease management. It is at the discretion of the respiratory nurse 
which aspects need to be addressed in each specific patient. Secondly, these visits are used 
to collect, dispense and administer the questionnaires and cost diaries. Additional visits can 
be planned at discretion of the pulmonologist (e.g. for additional testing) but do not fall 
under the study protocol. At the three month follow up visit lung function testing and a six 
minute walking distance test are performed as well.
Data collection
Data are collected on five time points: on the first day of admission (T0), on the third day 
of admission (randomisation, T1), at the end of the supervised treatment (day 7, T2) and 
one month (T3) and three months after randomisation (T4). We use self-administered 
questionnaires and cost diaries to obtain data. The questionnaires are administered when 
supervision is available. Cost diaries are supplied at two time points (T2 and T3) for the 
upcoming period, collected at the end of each follow up period and if necessary completed 
under supervision.
Effect evaluation
Table 3.2 provides an overview of the measures of the effect evaluation and the economic 
evaluation, and at which time point the measurements are performed.
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Table 3.2 Overview of measurements per time point
Measurement T0 T1 T2 T3 T4
Demographic characteristics x
Smoking x
Body Mass Index x
Living situation x
Comorbidity x
Coping style (UCL) x
Medical treatment prior to admission x
Exacerbation severity x
Indication for admission x
Clinical COPD Questionnaire (CCQ) x x x x
EuroQol 5D (EQ-5D) x x x
Satisfaction
 patient satisfaction x x
 primary caregiver satisfaction x x
Caregiver Strain Index x x
Treatment Failures x
Readmissions x
Mortality x
Cost diary x (IG) x x
Discrete Choice Experiment x
Lung function testing x
6 Minute Walking Distance x
Abbreviations: T0 = baseline; T1 = randomisation; T2 = end of treatment; T3 = follow -up 1; T4 = follow-up 2; IG = intervention group only.
Primary outcome measures
Primary outcome measure in this study is the effectiveness of early assisted discharge com-
pared to usual care expressed by the change on the Clinical COPD Questionnaire (CCQ) 
[36] between the third day of admission (T1) and the last day of supervised treatment (T2 = 
day 7). The CCQ is a disease specific, ten-item questionnaire that calculates an overall score 
and three domain scores: symptoms, functional state and emotional state. All items are 
scored on a seven point scale with 0 representing the best possible score and 6 representing 
the worst possible score [36]. In this study the version with a 24-hour recall period is used, 
reflecting the health status of the past 24 hours. The CCQ is responsive to change [36] and 
a study in patients admitted to the hospital with an acute exacerbation of COPD, indicated 
that the minimal clinical important difference (MCID) of the CCQ is 0.4 [39].
Secondary outcome measures
Main secondary outcome measurement of the study is the cost-effectiveness. This will be 
discussed in the economic evaluation section. The following other secondary measure-
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ments will be performed. These correspond with the secondary research questions from the 
last paragraph of the introduction section:
1. Long-term effectiveness, measured with the CCQ change over the time points from day 
1 to the end of the follow-up period (T4).
2. Number of treatment failures.
3. Number of readmissions to hospital and time to readmission during the three months 
follow-up period.
4. Mortality and time to death during the three months follow-up.
5. Generic health related quality of life, measured with the EuroQol (EQ-5D) 5D [40]. The 
EQ-5D will also be used to calculate quality adjusted life year (QALYs), discussed in the 
economic evaluation section.
6. Effects on primary informal caregiver burden measured by the Caregiver Strain Index 
[41].
7. Patient and primary informal caregiver satisfaction with the program. We use a trans-
lated version of the satisfaction questionnaire used by Ojoo et al.[23] and extended it 
with additional questions.
Patient characteristics
Patients are characterised using the following variables: demographic factors (age, gender, 
socioeconomic status measured through level of education and income), smoking, Body 
Mass Index, living situation, comorbidity measured with the Charlson Comorbidity Index 
(CCI) [42], Coping Style measured with the Utrecht Coping List [43], medical treatment at 
home prior to the admission, severity of the exacerbation, indication for admission and fi-
nally severity of the disease are measured as well. In addition, severity of COPD is measured 
three months after admission at the end of the follow up period by performing lung function 
testing and a six minute walking test.
Economic evaluation
In accordance with the broad international consensus that economic evaluations should be 
conducted from a societal perspective [44] this cost-effectiveness analysis will include all 
costs, irrespective of who actually bears them.
All direct health care and non-health care costs as well as the costs of productivity losses of 
patient and caregiver within the three months after randomisation will be taken into account.
The following types of resource use will be recorded to calculate direct health care 
costs: number and length of hospital admissions and readmissions, total amount of time of 
community nursing care (distinguished by nurse grade), number of visits to the emergency 
department, number of contacts with pulmonologist, other specialist physicians, general 
practitioner, respiratory nurse, dietician, physiotherapist, and social worker, number of 
ambulance rides and medication use. These will be recorded in cost diaries and obtained 
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from hospital records. Costs of organisational arrangements of the early discharge scheme 
will also be included.
Direct non-health care costs primarily include paid and unpaid household help, includ-
ing the time spent by the primary informal caregiver.
Indirect costs are costs of productivity losses. We record the days a patient is absent from 
paid work. We also ask informal caregivers to record the number of days off work due to 
caring for the patient. Costs are calculated by multiplying the volume of resource use (such 
as hospital days, physician visits, time spent by formal and informal caregivers) by a price 
per unit that includes total, not marginal costs.
In addition to the societal perspective, we will calculate the costs from the financial hos-
pital perspective, the financial perspective of the organisation providing the home care and 
the perspective of the health care sector. This includes costs covered by the hospital budget, 
the budget of the homecare organisation and the health care sectors budget, respectively.
The principal health outcome measures in the economic evaluation are the number of 
patients with a clinically relevant improvement in CCQ between day of randomisation and 
day 7, and between day of randomisation and month 3, the change in CCQ score between 
day of randomisation and day 7 and day of randomisation and month 3, the number of QA-
LYs randomisation and the end of the three-month follow-up period. The latter is calculated 
using the Dutch EQ-5D tariff [45].
Health outcomes will be related to cost outcomes. If one of the treatment options is more 
effective but also more costly, results will be presented as an incremental cost-effectiveness 
analysis: the additional cost per additional unit of health gain, which is calculated as the 
difference in mean costs between early discharge and usual inpatient hospital care divided 
by the in mean health effects.
Data analysis
Data analysis will be performed according to the intention to treat principle. Data from 
patients who die, quit participation or are otherwise lost to follow up will be included in the 
analysis up until the point of drop out. Missing observations will be imputed or weighted 
appropriately. All primary and secondary outcome measurements will be analysed using 
analysis of covariance. In order to control for dependency between the repeated measure-
ments within one patient, and for the dependency between patients from the same hospital, 
multilevel analyses will be performed as well. We set the significance level at α = 0.05.
Primary outcome measure
The changes on the primary outcome measurement, the CCQ, will be analysed with in a 
repeated measures model. The dependent variable is the change in CCQ score from baseline 
(T1) to the end of the supervised treatment (T2) and to the end of follow-up (T4). Baseline 
CCQ score (T1) and centre of treatment are considered as covariates. Age, gender and 
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severity of the disease will also be included in the model as covariates. If necessary, other 
covariates will be included in the model.
Secondary outcomes measurements
All time-to-event outcomes (i.e. time to readmission and time to death) will be analysed 
using Kaplan-Meier curves and Cox proportional hazards regression model. Event rates (i.e. 
treatment failures, readmission rates and mortality rates) will be analysed using an appro-
priate model for count data (e.g. poisson regression or binomial regression).
Differences in outcomes defined as the mean change from baseline (e.g. long-term 
effectiveness, primary informal caregiver burden, patient- and primary informal caregiver 
satisfaction and quality of life) will be analysed using repeated measures model..
Patient- and caregiver preference for place of treatment will be analysed using a logistic 
regression model.
Cost-effectiveness
In order to derive the total utility experienced over the course of the investigation, the num-
ber of QALYs per patient will be calculated as the area under the utility curve.
Uncertainty around the estimates of costs and health outcomes will be addressed by 
bootstrapping the data with bias correction and acceleration (BCa) [46]. The 95% confidence 
interval around the difference in mean costs and health outcomes will be determined by 
taking the 2.5th percentile and the 97.5th percentile of these bootstrap replications. The 
bootstrap replicates will be plotted in cost-effectiveness planes (CE-planes). A CE-plane is 
an x-y-diagram with the x-axis representing the difference in health outcome between the 
treatment and usual care group and the y-axis representing the difference in costs. By plot-
ting all bootstrap replicates in this diagram the uncertainty around the point estimates of the 
ICERs will be displayed [47]. The information from the CE-planes will be summarised into 
cost-effectiveness acceptability curves, which represent the likelihood that early assisted 
discharge is the most cost-effective option at different values of the maximum acceptable 
willingness to pay (WTP) for a health outcome [48].
Sample size calculation
Primary outcome is the change in the CCQ score between baseline (day 3 of admission) and 
the end of the supervised treatment (day 7).
Before the start of the study, a preliminary sample size calculation for an independent 
samples t-test was performed based on the results of a pilot study, where the average CCQ 
decreased from 3.8 on the day of admission to 2.6 by the end of the supervised treatment The 
standard deviation of that change was 1.04. With a MCID of 0.4, the required Cohen’s effect 
size d would be 0.385 [99]. For a risk of a type-I error of 5% (α = 0.05) and a risk of a type-II 
error 20% (1-b = 0.80), the required sample size was 214.
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However, primary outcome measure in this study is the change in the CCQ score from 
the third day of admission and the end of the supervised treatment (day 7), which is likely 
to have a stronger correlation with the baseline score. Therefore, a new sample size calcula-
tion for ANCOVA was performed after 85 patients had been treated, without breaking the 
randomisation code. Taking into account the correlation between the baseline score and 
the change (ρ = 0.288), as well as the standard deviations measured in the trial (0.988 for the 
intervention group and 0.922 for the control group), the required effect size f is 0.22 and the 
sample size is 165.
3.3 Discrete Choice Experiment
Background
As part of the GO AHEAD trial we perform a discrete choice experiment (DCE) to explore the 
preferences of patients and their informal caregivers for different treatment arrangements. 
The DCE provides quantitative information on the relative importance of the characteristics 
of the hospital treatment and the early assisted discharge scheme and the rate at which 
patients are willing to trade between them.
A DCE is a type of conjoint analysis used to determine individual preferences. In this 
study it involves presenting respondents with a series of choices between an early assisted 
discharge scenario and a usual hospital care scenario. Each scenario is described in terms 
of several characteristics, which are called attributes.
DCEs originate from mathematical psychology and have been most widely applied in 
market research to determine consumer preferences for goods and services and investigate 
the relative importance of the characteristics of these goods and services [49,50].
Design
A review of literature and conversations with patients and pulmonologists have lead to the 
selection of seven attributes with two or three levels each for the home treatment options, 
while the hospital option is kept constant and is not described by attributes. The attributes 
for the home treatments are: type of nurse (generic or respiratory), number of home visits 
(1, 2 or 3 per day), copayment (€0, €50 or €100), risk of readmission to hospital within treat-
ment period (1%, 5% or 10%), whom to contact in case of emergency (general practitioner or 
pulmonary ward in the hospital), number of hours of informal care (1, 3 or 5 hours per day), 
number of different nurses visiting the patient (1-2 or more than two).
The questionnaire consists of 14 choice scenarios, two of which have a ‘right answer’ and 
aimed at testing if the respondent understands the task. There are three versions of the ques-
tionnaire, which add up to a D-optimal design of 36 different scenarios. Each respondent is 
asked to complete one version of the questionnaire.
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In each scenario respondents indicate a preference for one of two home treatment 
options or the complete hospital treatment. Respondents who initially choose the hospital 
option, are subsequently asked to make a choice between the two home treatments. By us-
ing this forced choice question, we ascertain that all respondents provide information about 
their preferences for attributes of the home treatment.
Data analysis
Depending on the choice pattern of the respondents, the data will be analysed using con-
ditional logit model with alternative-specific constants, a random parameter multinomial 
logit model (i.e. a mixed logit model) or a multilevel latent class conditional logit model, all 
with and without interaction effects.
This analysis results in a regression coefficient for each level of the attributes. The 
estimated coefficients allow conclusions to be drawn about the relative importance of the 
attributes and possible trade-offs between them.
Furthermore, we will test whether the patients who were assigned to the early assisted 
discharge scheme have different preferences for various characteristics of the care delivery 
than patients who were assigned to the conventional inpatient hospital care.
Finally, we will test for differences in preferences between patients, their informal and 
formal caregivers.
3.4 Discussion
We presented the protocol of the GO AHEAD study, which assesses the effectiveness and 
cost-effectiveness of an early assisted discharge intervention for patients admitted to the 
hospital for a COPD exacerbation. It is a multi-centre RCT comparing the early assisted 
discharge intervention with usual care in the hospital.
Despite research on the effectiveness of early assisted discharge for COPD exacerba-
tions, several aspects of these hospital-at-home schemes remain unclear. This study will 
provide not only information on the effectiveness and cost-effectiveness, but also on which 
aspects of the intervention are important for patients to make a certain choice and second-
ary outcome measurements, namely effects on quality of life, effects on primary caregiver 
burden and patient and primary caregiver satisfaction.
Several critical success factors are to be mentioned. In the past two decades average 
length of hospital stay, for acute care of all conditions, has already decreased internationally 
from approximately 9 days to 6 days [51]. Average length of stay for COPD exacerbations 
follows these trends, with changes from approximately 8.5 days to 6.5 days [11,52,53]. Al-
though this trend has occurred in the Netherlands as well, average length of hospital stay 
for COPD patients is still 10.5 days [54]. With the projected increasing prevalence of COPD, 
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especially for women, in the following years, this leaves room for interventions that reduce 
length of stay.
Prolonged hospital stay is associated with the presence of comorbidities [55], continu-
ation of conservative therapy (e.g. therapies that can only be given in hospital or pulmon-
ologists wish to observe stable patients) [52] and complex discharge planning that requires 
additional home care arrangements) [52,53] among others. Moreover, comorbidities are 
more present in patients with more severe COPD [56], and most patients hospitalised have 
COPD stages III or more [53,57]. This might suggest that the Dutch hospitalised population 
is different from that in the United Kingdom. However, the national UK audit from 2008 [57] 
showed that severity of the disease of patients admitted to the hospital has not changed 
between 2003 and 2008 (median FEV
1
-% = 38% of predicted value, GOLD stage III) and 77% 
of all patients admitted to hospital have one or more comorbidities.
Early assisted discharge also anticipates for the need for social work involvement during 
hospitalisation. In the early assisted discharge scheme care at home is arranged for a certain 
number of days and patients are closely monitored at home. Because of the presence of 
nurses at home, the possible need for prolonged or extended home care is quickly identified. 
Arrangements can be made more easily because patients are already in the system of the 
home care organisation.
In the United Kingdom, early assisted discharge for COPD exacerbations is more com-
mon in hospitals that are characterised by greater number of hospital beds, higher numbers 
of hospital admissions and the presence of respiratory nurses [15]. The Dutch hospitals are 
of similar as or larger than those in the United Kingdom [51] [51]. The number of admissions 
is high (11.6 per 10.000 population in 2007 [54]) and respiratory nurses have an important 
role in patient care. The Dutch health care system also has a large network of primary care 
organisations that deliver home care that is easily accessible for the population. Therefore 
the use of generic community nurses in the early assisted discharge scheme is possible.
Despite similarities between the British and Dutch health care system, organisational 
and financial differences between these countries exist and results from studies performed 
in one country, with its own characteristics, cannot simply be translated to and implemented 
in other countries. Similarities and differences should be studied more intensively and taken 
into account before implementing early assisted discharge in the Dutch health care system. 
Possible boundaries to implementation in the Netherlands are the different reimbursement 
systems and budgets of hospital care and home care. An integrated financing structure may 
facilitate the implementation in the health care system.
In this trial supervision of the treatment at home is either performed by community based, 
generic nurses or hospital resourced specialised respiratory nurses (nurse practitioners). 
The use of hospital resourced specialised respiratory nurses is the most frequently described 
and studied form of supervision at home. Using generic community nurses, who are more 
available and less costly, could enable the development of more hospital-at-home services. 
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In this study both strategies for early assisted discharge (hospital resources or community 
based) and the different professionals involved in home care (generic nurses or specialised 
respiratory nurses) are being used. When sample sizes of both groups allow it, this study may 
provide more insight in which model for early assisted discharge is more preferable.
Compared to commonly applied measures of satisfaction, a DCE quantifies the relative 
importance of the characteristics and levels. It assesses the trade-offs that respondents make 
and provides an estimate of the overall value of early assisted discharge treatments and the 
usual inpatient hospital care option.
Because common satisfaction questionnaires do not quantify the relative importance 
of attributes and levels, it is likely that patient preferences are not represented correctly in 
organising the process of care delivery. This may lead to suboptimal decision-making and 
may impair the acceptance of early assisted discharge.
In summary, in this contribution we presented the research protocol of a multi-centre 
RCT studying the effectiveness and cost-effectiveness of an early assisted discharge scheme 
for COPD exacerbations in the Netherlands.
3.5 References
 1 World Health Organization. World Health Statistics 2008. Geneva, 2008.
 2 Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 
2007; 370: 765-773.
 3 Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention 
of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 
2007; 176: 532-555.
 4 Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 
2003; 41: 46s-53s.
 5 Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir 
Care. 2003; 48: 1204-13; discussion 1213-5.
 6 Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epidemiology. Thorax. 2006; 61: 164-168.
 7 Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients 
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157: 1418-22.
 8 Wang Q, Bourbeau J. Outcomes and health-related quality of life following hospitalization for an 
acute exacerbation of COPD. Respirology. 2005; 10: 334-340.
 9 Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, et al. Case fatality of COPD exacerba-
tions: a meta-analysis and statistical modelling approach. Eur Respir J. 2011; 37: 508-515.
 10 Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission in patients 
with chronic obstructive pulmonary disease. Respiration. 2006; 73: 311-317.
 11 Saynajakangas O, Kinnunen T, Tuuponen T, Keistinen T. Length of stay and interval to readmission 
in emergency hospital treatment of COPD. Age Ageing. 2004; 33: 567-570.
 12 Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000; 117: 5S-9S.
 13 Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. 
Chest. 2001; 119: 344-352.
62 Chapter 3
 14 Johnson MK, Flanigan U, Fuld J, et al. Hospital at home services for acute exacerbation of chronic 
obstructive pulmonary disease: a survey of British practice. Health Bull (Edinb). 2001; 59: 163-170.
 15 Quantrill SJ, Lowe D, Hosker HS, et al. Survey of early discharge schemes from the 2003 UK Na-
tional COPD Audit. Respir Med. 2007; 101: 1026-1031.
 16 Ram FS, Wedzicha JA, Wright J, Greenstone M. Hospital at home for patients with acute exacerba-
tions of chronic obstructive pulmonary disease: systematic review of evidence. BMJ. 2004; 329: 315.
 17 Shepperd S, Doll H, Broad J, et al. Early discharge hospital at home. Cochrane Database Syst Rev. 
2009; (1): CD000356.
 18 Aimonino Ricauda N, Tibaldi V, Leff B, et al. Substitutive “hospital at home” versus inpatient care 
for elderly patients with exacerbations of chronic obstructive pulmonary disease: a prospective 
randomized, controlled trial. J Am Geriatr Soc. 2008; 56: 493-500.
 19 Cotton MM, Bucknall CE, Dagg KD, et al. Early discharge for patients with exacerbations of chronic 
obstructive pulmonary disease: a randomized controlled trial. Thorax. 2000; 55: 902-906.
 20 Davies L, Wilkinson M, Bonner S, et al. “Hospital at home” versus hospital care in patients with 
exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. 
BMJ. 2000; 321: 1265-1268.
 21 Hernandez C, Casas A, Escarrabill J, et al. Home hospitalisation of exacerbated chronic obstructive 
pulmonary disease patients. Eur Respir J. 2003; 21: 58-67.
 22 Nicholson C, Bowler S, Jackson C, et al. Cost comparison of hospital- and home-based treatment 
models for acute chronic obstructive pulmonary disease. Aust Health Rev. 2001; 24: 181-187.
 23 Ojoo JC, Moon T, McGlone S, et al. Patients’ and carers’ preferences in two models of care for acute 
exacerbations of COPD: results of a randomised controlled trial. Thorax. 2002; 57: 167-169.
 24 Skwarska E, Cohen G, Skwarski KM, et al. Randomized controlled trial of supported discharge in 
patients with exacerbations of chronic obstructive pulmonary disease. Thorax. 2000; 55: 907-912.
 25 Callaghan S. ACTRITE: Acute Chest Triage Rapid Intervention Team. Accid Emerg Nurs. 1999; 7: 
42-46.
 26 Chetty M, MacKenzie M, Douglas G, Currie GP. Immediate and early discharge for patients with 
exacerbations of chronic obstructive pulmonary disease: is there a role in «real life»? Int J Chron 
Obstruct Pulmon Dis. 2006; 1: 401-407.
 27 Davison AG, Monaghan M, Brown D, et al. Hospital at home for chronic obstructive pulmonary 
disease: an integrated hospital and community based generic intermediate care service for pre-
vention and early discharge. Chron Respir Dis. 2006; 3: 181-185.
 28 Gravil JH, Al-Rawas OA, Cotton MM, et al. Home treatment of exacerbations of chronic obstructive 
pulmonary disease by an acute respiratory assessment service. Lancet. 1998; 351: 1853-1855.
 29 Murphy NM, Byrne CC, O’Neill SJ, et al. An outreach programme for patients with an exacerbation 
of chronic obstructive pulmonary disease. Ir Med J. 2003; 96: 137-140.
 30 Sala E, Alegre L, Carrera M, et al. Supported discharge shortens hospital stay in patients hospital-
ized because of an exacerbation of COPD. Eur Respir J. 2001; 17: 1138-1142.
 31 Ansari K, Shamssain M, Farrow M, Keaney NP. Hospital-at-home care for exacerbations of chronic 
obstructive pulmonary disease: an observational cohort study of patients managed in hospital or 
by nurse practitioners in the community. Chron Respir Dis. 2009; 6: 69-74.
 32 British Thoracic Society Guideline Development Group. Intermediate care--Hospital-at-Home in 
chronic obstructive pulmonary disease: British Thoracic Society guideline. Thorax. 2007; 62: 200-
210.
 33 Frick KD, Burton LC, Clark R, et al. Substitutive Hospital at Home for older persons: effects on 
costs. Am J Manag Care. 2009; 15: 49-56.
Effectiveness and cost-effectiveness of early assisted discharge for COPD exacerbations 63
3
 34 Puig-Junoy J, Casas A, Font-Planells J, et al. The impact of home hospitalization on healthcare costs 
of exacerbations in COPD patients. Eur J Health Econ. 2007; 8: 325-332.
 35 Shepperd S, Harwood D, Gray A, et al. Randomised controlled trial comparing hospital at home care 
with inpatient hospital care. II: cost minimisation analysis. BMJ. 1998; 316: 1791-1796.
 36 van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the 
Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003; 1: 13.
 37 Diaz LS, Gonzalez LF, Gomez Mendieta MA, et al. [Evaluation of a home hospitalization program in 
patients with exacerbations of chronic obstructive pulmonary disease]. Arch Bronconeumol. 2005; 
41: 5-10.
 38 Stichting Ketenkwaliteit COPD. Richtlijn Ketenzorg COPD [Guideline Transmural Care COPD] . 
Alphen aan den Rijn: Van Zuiden, 2005.
 39 Kocks JW, Tuinenga MG, Uil SM, et al. Health status measurement in COPD: the minimal clinically 
important difference of the clinical COPD questionnaire. Respir Res. 2006; 7: 62.
 40 Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37: 53-72.
 41 Robinson BC. Validation of a Caregiver Strain Index. J Gerontol. 1983; 38: 344-348.
 42 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbid-
ity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83.
 43 Schreurs PJG, van de Willige G, Brosschot JF, Tellegen B, Graus GMH. Handleiding Utrechtse 
Coping Lijst UCL (herziene versie) [Manual of the Utrecht Coping List] . Lisse: Swets & Zeitlinger, 
1993.
 44 Drummond MF, Sculpher MJ, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic 
Evaluation of Health Care Programmes (3rd ed.). Oxford: Oxford University Press, 2005.
 45 Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective 
design for national EQ-5D valuation studies. Health Econ. 2006; 15: 1121-1132.
 46 DiCiccio TJ, Efron B. Bootstrap confidence intervals. Statist Sci. 1996; 189-228.
 47 Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. 
Health Econ. 1998; 7: 723-740.
 48 van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. 
Health Econ. 1994; 3: 309-319.
 49 Hensher DA, Rose JM, Green WH. Applied choice analysis: a primer . Cambridge: Cambridge 
University Press, 2005.
 50 Louviere JL, Hensher DA, Swait JD. Stated Choice Methods: Analysis and Applications . Cambridge: 
Cambridge University Press, 2000.
 51 OECD. OECD Health Data. http:/stats.oecd.org/index.aspx?lang=en] 2010
 52 Mushlin AI, Black ER, Connolly CA, et al. The necessary length of hospital stay for chronic pulmo-
nary disease. JAMA. 1991; 266: 80-83.
 53 Wong AW, Gan WQ, Burns J, et al. Acute exacerbation of chronic obstructive pulmonary disease: 
influence of social factors in determining length of hospital stay and readmission rates. Can Respir 
J. 2008; 15: 361-364.
 54 Centraal Bureau voor de Statistiek [Statistics Netherlands]. http://statline.cbs.nl/Stat-
Web/publication/?DM=SLNL&PA=71859NED&D1=6,8&D2=0&D3=0,I&D4=106&D5=9-
26&HDR=T&STB=G1,G2,G3,G4&VW=T 2010
 55 Crockett AJ, Cranston JM, Moss JR, Alpers JH. An association between length of stay and co-
morbidity in chronic airflow limitation. Int J Qual Health Care. 2000; 12: 41-46.
 56 Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension 
and cardiovascular disease in COPD. Eur Respir J. 2008; 32: 962-969.
64 Chapter 3
 57 The Royal College of Physicians of London, British Thoracic Society, British Lung Foundation. 
Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: clinical audit of 
COPD exacerbations admitted to acute NHS units across the UK. www.rcplondon.ac.uk/clinical-
standards/ceeu/Current-work/ncrop/Documents/Report-of-The-National-COPD-Audit-2008-
clinical-audit-of COPD-exacerbations-admitted-to-acutre-NHS-units-across-the-UK.pdf
Lucas M.A. Goossens, Cecile M.A. Utens, Frank W.J.M. Smeenk, Onno C.P. van Schayck, 
Monique van Vliet, Walter van Litsenburg, Maria Braken, Maureen P.M.H. Rutten-van Mölken
Submitted for publication.
4Cost-effectiveness of early assisted discharge for COPD 
exacerbations in the Netherlands
Objectives Hospital admissions for exacerbations of chronic obstructive pulmonary 
disease (COPD) are the main cost drivers of the disease. An alternative is to treat suitable 
patients at home instead of in the hospital. This paper reports on the cost-effectiveness and 
cost-utility of early assisted discharge (EAD) in the Netherlands.
Methods In the multi-centre randomised controlled GO AHEAD trial (n=139), one group 
received 7 days of inpatient hospital treatment (HOSP), and one group was discharged after 
three days and treated at home by community nurses for four days. Healthcare resource 
use, productivity losses and informal care were recorded in cost questionnaires. Microcost-
ing was performed for inpatient day costs.
Results Seven days after admission, mean change from baseline Clinical COPD Ques-
tionnaire (CCQ) score was better for HOSP, but not statistically significantly: 0.29 (95% CI: 
–0.04; 0.61). The difference in the probability of having a clinically relevant improvement 
was significant, in favour of HOSP: 19.0%-point (0.5%; 36.3%). After three months follow-up, 
differences in effectiveness had almost disappeared. The difference in quality-adjusted life 
years (QALYs) was 0.0054 (-0.021; 0.0095). From a healthcare perspective, EAD was cost-
saving: -€ 244 (treatment phase, CI: -315; -€168) and -€168 (three months, CI: -€1253; €922). 
Societal perspective: -€65 (treatment phase, CI: -€152; €25) and +€908 (three months, CI: 
-€553; €2296). The savings per QALY lost were €31,111 from a healthcare perspective. From 
a societal perspective, HOSP was dominant.
Conclusions No clear evidence was found to conclude that either treatment was more 
effective or less costly.
66 Chapter 4
4.1 Introduction
Hospital admissions for exacerbations of chronic obstructive pulmonary disease (COPD) 
are important drivers of the high treatment costs for the disease [1-5]. These admissions put 
great pressure on scarce hospital beds of respiratory wards, especially during winter months 
[6]. From an economic and organisational point of view, it may be attractive to treat suitable 
patients at home instead of in the hospital, if this is medically possible and responsible.
Treatment schemes in which patients are treated and supervised at home, as an alter-
native to usual hospital treatment, are often called hospital-at-home. [7,8] These schemes 
may either avoid admission completely or discharge patients from the hospital early and 
continue treatment at home.
Studies on the costs and cost-effectiveness of hospital-at-home services for patients with 
a COPD exacerbation have shown varying results. Shepperd et al. concluded that a particu-
lar scheme in England led to significantly higher costs [9], while Skwarska et al. found cost 
savings in a different scheme in the same country.[10] Significant cost savings were reported 
for hospital-at-home services in Australia [3], Spain [11,12] and the United States [13]. The 
results in an Italian study were inconclusive [14].
Although these studies were performed in different countries and in different healthcare 
systems, they had some aspects in common. They all took a healthcare perspective; the costs 
or value of resources used outside of the healthcare sector were not taken into account. Sec-
ondly, the length of treatment was variable in each study. Physicians and/or nurses decided 
on the timing of discharge from the hospital or from treatment at home, depending on the 
patient’s recovery.
The current paper reports on the cost-effectiveness and cost-utility of an early discharge 
scheme that is different in the two aspects mentioned above. The study was performed in 
the Netherlands as part of the GO AHEAD trial (Assessment of GOing Home under Early 
Assisted Discharge). In this multi-centre randomised controlled trial, one group of COPD 
patients received usual inpatient hospital treatment for seven days. The other group was 
discharged after three days and was treated and supervised at home for the remaining four 
days. The Netherlands have a nation-wide infrastructure for community nursing provided 
by homecare organisations. Dutch hospitals do not deliver healthcare in the community. 
Therefore, the care at home in this trial was provided by community-based homecare 
organisations which employ mostly generically-trained nurses and few specialised nurses. 
The clinical results of this study have been presented in detail elsewhere [15].
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4.2 Methods
Study design
The GO AHEAD study was a randomised, controlled, multi-centre trial comparing two man-
agement strategies for patients admitted to the hospital for a COPD exacerbation [16]. After 
three days of usual hospital treatment patients were randomised to be either discharged 
home with homecare or to continue hospital treatment. The total duration of this initial 
treatment phase was 7 days for both groups, unless the treatment failed and patients had 
to be either re-admitted or had to prolong their hospital stay. Patients were followed for 3 
months, with outcome measurements scheduled after 7 days and 3 months.
Patients
Patients admitted to one of the participating hospitals because of an exacerbation of 
their COPD, were screened for eligibility. On the day of admission they were considered 
potentially eligible for early discharge if they met the following inclusion criteria: age ≥ 40, 
sufficiently competent to consider informed consent, and a smoking history of ≥ 10 pack 
years. In order to be randomised on day three of the admission, their physical and respira-
tory complaints (dyspnoea, wheezing and rhonchi) had to be improved compared to the day 
of admission, they should not be depending on therapies that could not be administered at 
home and they should be able to visit the toilet independently. Also, blood sugar level had to 
be normal or only moderately increased (≤ 15 mmol/L or regulated independently at home).
Exclusion criteria were: major uncontrolled comorbidity, mental disability, active 
alcohol or drug abuse, inability to understand the program, living outside the region of the 
participating homecare organisation, indication for admission to the intensive care unit or 
non-invasive ventilation and insufficient availability of informal care at home.
Intervention
During the first three days of the treatment all patients received usual hospital care. The 
pharmacological part of this treatment consisted of systemic corticosteroids (10 days), 
nebulised bronchodilators, subcutaneous thrombosis prophylaxis and stomach protection. 
If necessary, oxygen therapy and/or antibiotics were prescribed. Non-pharmacologic usual 
care consisted of physiotherapy for all patients for breathing- and coughing instructions and 
dietary advice if indicated (Body Mass Index ≤ 21 or 10% unintended weight loss in the six 
months prior to admission).
Patients randomised to early assisted discharge were discharged home on the fourth 
day of admission and further treated at home. Community nurses visited the patient once to 
three times on the day of discharge and the three following days. Main objective of the su-
pervision of the home treatment was the observation of the patient’s recovery and providing 
counselling and reassurance to the patient and the primary informal caregiver. The nurses 
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also addressed medication compliance and inhalation techniques, provided support in 
applying breathing- and coughing techniques and, if applicable, in adhering to dietary 
advices. If necessary patients, could be supported in their daily life activities (e.g. washing 
and dressing) by the home care organisation. During the four days of home treatment, the 
emphasis lies on the recovery of the exacerbation. In case COPD symptoms suddenly wors-
ened, the patients could contact the respiratory hospital ward directly and round-the-clock. 
The general practitioner was informed of the early discharge but the respiratory physician of 
the hospital kept the final responsibility.
Effects
The following outcome measures were used: 1) the incremental change from day of ran-
domisation in Clinical COPD Questionnaire (CCQ) score at day 7 and 3 months, 2) the incre-
mental proportion of patients with a clinically relevant improvement in CCQ score (i.e. ≥ 0.4 
units) [17] on day 7 and at 3 months, and 3) the gain in quality-adjusted life years (QALYs) 
after 3 months using utilities as measured by the EQ-5D questionnaire using the Dutch tariff 
for the valuation of health states.[18] The CCQ score can range from 0 (best possible score) 
to 6 (worst possible score). Based on the Dutch tariff, the EQ-5D score can range from -0.329 
(worst possible utility) to 1 (perfect health).
Costs
Costs were calculated from two perspectives, the healthcare perspective and the societal 
perspective. The former included only the direct healthcare costs within three months after 
randomisation. The latter includes direct healthcare costs, non-healthcare costs and costs 
of productivity loss for the three months follow-up period. This is in accordance with the 
Dutch recommendations that economic evaluations should be conducted from a societal 
perspective [19].
In the 7-day treatment phase, the duration of hospital admission and the amount of 
community nursing care were recorded. Patients randomised to early discharge, were asked 
to record all additional formal healthcare as well as informal care and days of absence from 
paid work of the informal caregiver in a 4-day cost diary, a specially designed questionnaire 
on the amount of resources used on each day.
During the follow-up phase, the following types of resource use were recorded on a 
weekly basis in costs questionnaires that were distributed for each month of the trial: num-
ber and length of hospital readmissions, number of visits to the emergency department, 
number of contacts with pulmonologist and other specialist physicians, general practitio-
ner, respiratory nurse, homecare, dietician, physiotherapist, and social worker, number of 
ambulance rides and medication use. Direct non-healthcare costs recorded in these ques-
tionnaires were paid and unpaid domestic help, including the time spent by the primary 
informal caregiver. In order to capture all informal care, respondents were asked to provide 
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information on help with domestic tasks, personal care and practical support. They were 
instructed only to consider time they would not have spent on these purposes if the patient 
had not experienced the exacerbation. Indirect costs were costs of productivity losses. The 
days a patient was absent from paid work were recorded in the cost questionnaires.
Costs (in 2009 euros) were calculated by multiplying the volume of resource use (such 
as hospital days, physician visits, time spent by formal and informal caregivers, production 
losses) by a cost per unit that includes total, not marginal costs. Except for inpatient hospital 
days, standard unit costs from the Dutch Manual for Costing Studies [20] were used for all 
healthcare resource use. The unit costs for production losses represented the mean of sex-
specific mean wages per day, weighted for the sex distribution in our sample.
Unit costs are presented in table 4.1. Medication prices were based on the official list 
prices of drugs obtained from retail pharmacists which were published on the internet [21], 
including value added tax and increased by a standard prescription reimbursement for the 
pharmacist. Costing for permanent medication was done based on one prescription per 
three months.
Table 4.1 Unit costs (Euros 2009) [19]
Type of resource Unit costs
GP, consultation 28
GP, home visit 43
GP, phone call 14
Specialist, consultation 64
Specialist, hour 135.50
Resident, hour 27.85
Nurse in hospital, hour 26.75
Physiotherapist, consult 36
Dietician, consult 27
Pulmonary nurse, consult 36
Social worker 36
Emergency room, visit 151
Ambulance transport 504
Community nurse, hour 65
Domestic community care, per hour 24
Informal care, hour 12.5
Production loss, hour (patient) 29.72
Inpatient hospital day, standard price 435
70 Chapter 4
Costs of inpatient hospital days
Costs for each inpatient hospital day were estimated using the microcosting methodology, 
which provides cost estimates that most accurately reflect actual costs by identifying cost 
components at the most detailed level [22,23].
We interviewed ten nurses, three pulmonologists and one laboratory staff member who 
worked in one of hospitals that participated in the trial. They were required to have been 
involved in the treatment of at least three randomised patients in order to be acquainted 
with the disease severity of these patients and of the intensity of care that they needed.
First, during interviews with healthcare professionals participating in the trial, all steps 
in the treatment and nursing process were identified. Then, at the two hospitals which 
recruited the most patients, which were the Catharina Hospital in Eindhoven and Atrium 
Medical Centre in Heerlen, pulmonologists, residents, nurses and laboratory staff who 
participated in the trial and were very familiar with the type of COPD patients enrolled, 
were asked to provide best estimates of resource utilization. Separate estimates were made 
for each inpatient hospital day, in order to detect possible changes in care intensity over 
the course of the stay. Using standardised reporting templates, the participants were asked 
how many minutes they spent on each component of care per average patient. Additionally, 
nurses were asked what proportion of their yearly working hours were ‘indirect treatment 
time’, i.e. time not spent directly caring for patients, but for instance on trainings and depart-
ment meetings. Indirect treatment time was then allocated to patients by adding a mark-up 
of 24.5% to the amount of direct treatment time they received. This mark-up was calculated 
as the proportion of time spent on indirect treatment (averaged over all nurses), divided by 
the proportion of time spent on direct treatment (averaged over all nurses) [23].
Labour time was valued using standardised costs per minute, which reflected national 
average incomes per profession (including social premiums, fees for irregular working 
hours, and the costs of replacement during illness) divided by the number of workable 
minutes per year. For consulting physicians, the standardised time-costs included a 43% 
mark-up for indirect treatment time. For residents, a mark-up of 30% was applied. The latter 
percentage was chosen to be in-between those for physicians and nurses.
For hotel and nutrition costs, the national reference costs from the Dutch Manual for 
Costing Studies was used. For the first and last day of hospital admission, only half of these 
costs were taken into account. Finally, labour and hotel costs for each hospital day were 
supplemented with a proportional mark-up for overhead and capital costs (42%), which was 
the national reference percentage [20]. In these cost calculations, the day of admission was 
considered as day one when patients were admitted before 12:00 pm. If the patient was ad-
mitted after 12 pm, the day of admission was considered day 0 and the following day as day 
one. Hence, costs of day 1 were calculated separately for patients who were admitted on day 
1, and for patients who were admitted on day 0. For inpatient day 4, separate calculations 
were performed for the patients who were discharged and those who remained in hospital.
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Statistical analysis
Effects
The change from day of randomisation in CCQ score and the EQ-5D score were analysed in 
repeated measures analyses. In these linear models with correlated errors, the covariance 
matrix was unstructured.
The final model was developed in a backward selection process, which started with the 
following covariates. In addition to time (i.e. measurement at days 7 (end of treatment) or at 
the end of follow-up) and the interaction of time and treatment, starting model contained 
the following variables were tested: baseline CCQ or EQ-5D score, treatment centre, age, 
gender, co-morbidity, smoking status, living situation, availability of informal caregiver, 
presence of home care prior to admission, course of oral corticosteroids and/or antibiotics 
prior to admission. In each step, the variable with the highest p-value was removed unless 
its exclusion led to a 10% change in the estimated treatment effect [24].
The explanatory variables in the final model were treatment, CCQ score or EQ-5D score 
at day of randomisation, time (moment of measurement), the interaction of treatment and 
time, and Charlson’s comorbidity score (1 or >1, only in the EQ-5D model) [25].
In the CCQ model the coefficient for treatment could directly be interpreted as the mar-
ginal difference in change from the day of randomisation to day 7, i.e. the difference between 
the hypothetical situations in which all patients were treated at home or all received usual 
hospital treatment. The marginal difference in change from day of randomisation at three 
months was the sum of the coefficient for treatment and the coefficient for the interaction of 
treatment and measurement.
In order to calculate the mean marginal difference in EQ-5D score per measurement, 
scores were predicted for all patients for each measurement: one score for each treatment. 
To calculate QALYs the mean utility of two subsequent measurements was multiplied with 
the number of days between these measurements, the sum of which was divided by 365.25.
The probability of experiencing improvement ≥ 0.4 units in CCQ between the day of 
randomisation and day 7 and month 3 was analysed with logistic regression analyses. 
Explanatory variables were treatment and the CCQ score on day of randomisation. The 
results of these regression analyses were used to predict the probabilities in each treat-
ment group, based on the CCQ score distribution of the full sample (two treatment groups 
combined).
Costs
In the usual care group, total costs during the 7-day treatment phase include all hospital 
costs. In the early discharge group, these costs were calculated as the sum of the hospital 
costs, the community care costs and the costs of healthcare utilization as recorded in the 
diaries for the 4-day period of homecare.
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Total costs during the follow-up phase were calculated as the sum of the predicted 
monthly treatment costs, the predicted medication costs and the costs of readmissions. 
To obtain the predicted costs, the monthly cost questionnaires were analysed in a linear 
repeated measures model with correlated error terms and unstructured covariance. The 
dependent variable was the costs in a certain month. The explanatory variables were the 
time (first, second or third month) and the interaction of treatment and time of measure-
ment. The results were used to predict the mean costs per treatment group for each month. 
Monthly medication costs were analysed in the same way. Because all explanatory variables 
were dummy variables, it was not necessary to apply a transformation to the cost variable 
in order to achieve a normal distribution. A generalized estimating equations (GEE) model, 
which could have been used for that purpose, would have led to the same results as the 
linear repeated measures model with correlated error terms. The reason for choosing the 
latter model is its more intuitive interpretation and the analogy with the effects models.
Intention to treat
Data analysis was performed according to the intention-to-treat principle. Data from pa-
tients who died, quit participation or were otherwise lost to follow-up were included in the 
analysis up to the point of drop-out.
Missing data were handled by the repeated measures models, which have the capacity to 
exploit the covariance structure of the existing data to adjust the results. This characteristic 
of the statistical models was used to achieve unbiased estimates of the treatment effect at 
each measurement and of the mean costs for each month during follow-up [26,27].
Cost-effectiveness and cost-utility
Health outcomes on day 7 were related to costs of the initial treatment phase; health out-
comes after three months were related to total costs of the initial treatment phase and the 
follow-up period combined. If one of the treatment options was more effective and also 
more costly, results were presented in incremental cost-effectiveness ratios (ICERs): the 
additional cost per additional unit of health gain or the savings per unit of health loss, which 
was calculated as the difference in mean costs divided by the difference in mean health 
outcomes.
Uncertainty around the estimates of costs and health outcomes was addressed by boot-
strapping the data [28]. All statistical analyses were performed on each of 1000 bootstrap 
replications. The mean values of incremental costs and effects from the bootstrap replica-
tions were used as the point estimates. The 95% confidence interval around the difference 
in mean total costs and health outcomes was determined by taking the 2.5th percentile and 
the 97.5th percentile of these bootstrap replications. The bootstrap replicates for the out-
comes and costs after three months were plotted in cost-effectiveness planes (CE-planes).
[29] The information from the CE-planes on incremental costs per QALY was summarised 
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in cost-effectiveness acceptability curves, which represent the likelihood that early assisted 
discharge is the most cost-effective option at different values of the maximum acceptable 
willingness to pay (WTP) for a health outcome [30].
Sensitivity analyses
Several sensitivity analyses were performed. Firstly, the costs of informal care in the follow-
up period were left out of the total costs in the societal perspective (SA1). Secondly, a differ-
ent unit cost per inpatient hospital day was used instead of the costs from the microcosting 
study (SA2). This cost was the standard unit price from the Dutch Manual for costing studies 
[20], which is based on a broad spectrum of diagnoses and is constant for all days during an 
admission.
Additionally, in order to express the uncertainty about the estimate of the costs per in-
patient hospital day, sensitivity analyses were performed using the estimates of the respon-
dent with the highest (SA3) and lowest (SA4) costs (most costly and least costly healthcare 
provider), and the highest (SA5) and lowest (SA6) estimates of all aspects of care across 
respondents (most costly and least costly scenario).
4.3 Results
Patients
From December 2007 to March 2011, 139 patients were randomised. In the usual care group, 
75% of patients completed the entire trial. In the hospital-at-home group, 90% remained in 
the trial until the end of the follow-up period. Due to early drop-out or failure to complete 
questionnaires, no effectiveness data were available for 1% of patients and no cost data for 
12%. The characteristics of all randomised patients are presented in table 4.2.
Table 4.2 Baseline characteristics
Usual hospital care (N=69) Early assisted discharge (N=70)
Age in years (SD) 67.80 (11.30) 68.31 (10.34)
Male 55.1% 68.9%
Current smoker 39.1% 32.9%
Pack years (SD) 44.52 (31.04) 46.97 (27.27)
Body Mass Index (SD) 25.57 (4.33) 24.97 (5.14)
Receiving homecare before admission 23.2% 24.3%
Charlson comorbidity score (SD) 1.68 (1.10) 1.74 (1.10)
 Proportion with score > 1 39.1% 45.7%
CCQ (SD) 2.22 (0.97) 2.63 (1.03)
EQ-5D (SD) 0.71 (0.22) 0.66 (0.26)
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Costs of inpatient hospital days
Table 4.3 shows that the first day of the hospital admission was the most costly. After that, the 
intensity of care by physicians and nurses decreased, which is reflected in lower costs per 
day. The total inpatient hospital costs during the 7-day treatment phase were €1430 for the 
usual hospital care group and €976 for the early assisted discharge group.
Table 4.3. Costs per inpatient hospital day
Day Usual hospital care Early assisted discharge Difference
0 (with admission after noon) €319 €319
1 (with admission before noon) €323 €323
1 (for patients admitted on day 0) €195 €195
2 €192 €192
3 €178 €178
4 €162 €188
5 €157 -
6 €156 -
7 €167 -
Total costs for admission* €1430 €976 €454
SA2 €3045 €1305 €1740
SA3 €1721 €1122 €599
SA4 €1228 €858 €370
SA5 €2312 €1534 €778
SA6 €952 €655 €297
* Totals are based on the assumption that 50% of patients are admitted on day 0 and 50% on day 1. This does not affect the difference between 
the treatment arms, because the same assumption is made for both groups.
Abbreviations: SA2 (sensitivity analysis 2): standard costs per inpatient hospital day instead of costs from microcosting study; SA3/4 cost 
estimates from most and least costly healthcare provider in microcosting study; SA5/6: highest and lowest estimates of care costs across 
respondents.
Effects
The mean improvement in CCQ scores between days 3 and 7 was larger in the hospital group 
than in the early assisted discharge group (-0.303 versus -0.013), but this difference was of 
only borderline significance (see table 4.4). Both groups showed an almost equal improve-
ment in CCQ score between day 3 and three months.
There was a statistically significant difference between the groups in the probability of 
having a clinically relevant improvement in CCQ score between days 3 and 7 (51.3% in the 
usual hospital care group versus 31.7% in the early discharge group). It was not significant 
between day 3 and three months (39.9% versus 35.8%, respectively).
The difference in QALYs was very small and not statistically significant.
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Resource use and costs
Resource use is presented in table 4.5. Table 4.6 shows that the costs for the first hospital 
admission were, obviously, lower in the early assisted discharge group than in the usual 
hospital care group. Hospital costs were reduced by €462 per patient. These savings were 
partly offset by the costs of community nursing care, which were €211, resulting in a net cost 
reduction of €244. During the follow-up phase, the early discharge group had somewhat 
higher costs than the usual hospital care group. In total, from a healthcare perspective, early 
assisted discharge led to mean costs savings of €168 (95% confidence interval (CI): -€1253; 
+€922) per patient.
From a societal perspective, savings in hospital costs during the 7-day treatment phase 
were not only offset by the costs of community nursing but also by the costs of informal 
care and production losses. From this perspective the initial treatment phase was only €65 
Table 4.4 Cost-effectiveness of early assisted discharge versus usual inpatient hospital care
Usual hospital care Early assisted discharge Difference
Effects
Mean change in CCQ score, day 7 -0.303 -0.013 0.290 (-0.03; 0.61)
Mean change in CCQ score, end of follow-up 0.024 0.065 0.041 (-0.41; 0.48)
Probability of improved CCQ score, day 7 51.3% 32.7% -19.41% (-36.25%; -0.50%)
Probability of improved CCQ score, end of follow-up 39.9% 35.8% -4.17% (-21.94%; 15.27%)
QALYs 0.175 0.170 -0.005 (-0.021; 0.0095)
Healthcare perspective Usual hospital care Early assisted discharge Difference
Costs of initial episode €1463 €1219 -€244 (-€315; -€168)
Costs of initial episode plus follow-up €4297 €4129 -€168 (-€1253; €922)
Incremental cost-effectiveness ratios* 
Point deterioration in mean CCQ score, day 7 €842
Point deterioration in mean CCQ score, end of follow-up €4098
Additional patient without improved CCQ score, day 7 €1257
Additional patient without improved CCQ score, end of follow-up €4000
Incremental QALY lost €31,111
Societal perspective Usual hospital care Early assisted discharge Difference
Costs of initial episode €1463 €1398 -€65 (-€152; €25)
Costs of initial episode plus follow-up €5395 €6304 €880 (-€580; €2268)
Incremental cost-effectiveness ratios*
Point deterioration in mean CCQ score, day 7 €224
Point deterioration in mean CCQ score, end of follow-up Usual hospital care is dominant
Additional patient without improved CCQ score, day 7 €335
Additional patient without improved CCQ score, end of follow-up Usual hospital care is dominant
Incremental QALY lost Usual hospital care is dominant
* Savings per unit of health lost.
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less costly in the early discharge group. Including the costs during the follow-up phase, 
which were €945 higher in the early discharge group led to a total estimated cost increase of 
€880 (-€580; +€2268) per patient in the early discharge group, from a societal perspective. 
This is primarily due to the higher costs of informal care and the greater productivity loss 
(table 4.6).
Cost-effectiveness and cost-utility
From a healthcare perspective, all point-estimates of cost and effects pointed towards lower 
costs but somewhat less effects for early assisted discharge. Therefore, the ICERs represent 
cost savings per unit of health forgone. After seven days, the savings costs per unit of deterio-
ration in CCQ were €842, at three months this ratio was €4098 (see table 4.4). The savings per 
additional patient without a clinically relevant improvement in CCQ score were €1257 after 
7 days and €4000 at three months. The savings per QALY lost were €31,111. The probability 
that early assisted discharge was cost-saving from a healthcare perspective was 61.2%.
From the societal perspective, no ICERs were calculated for the outcomes after the fol-
low-up period because the point-estimates of costs and effects pointed towards dominance 
of the usual hospital care group. The probability that early assisted discharge was cost-saving 
was 12% from this perspective.
Table 4.5. Resource use
Usual hospital care Early assisted discharge Difference
Initial treatment phase
Community nursing, hours - 3.25 3.25
Informal care, hours - 13.03 13.03
GP, home visits - 0.015 0.015
Follow-up period
GP, consultations 0.76 0.86 0.11
GP, home visits 0.45 0.81 0.36
GP, phone calls 0.44 0.82 0.38
Pulmonologist, consultations 1.34 1.69 0.35
Other specialist, consultations 1.27 1.24 -0.03
Paramedic care, consultations 3.88 8.88 5.01
Emergency room 0.35 0.32 -0.04
Ambulance rides 0.16 0.05 -0.11
Community nursing, hours 9.60 9.65 0.05
Domestic community care, hours 13.93 12.05 -1.87
Readmissions 0.39 0.39 0
Informal care, hours 78.50 118.97 40.47
Production losses, hours (patient) 2.38 15.56 13.18
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After seven days, the savings per unit of deterioration in CCQ were €224. The savings per 
patient without a clinically relevant improvement in CCQ score were €335.
There is considerable uncertainty around incremental costs and effects, as is presented 
in CE planes, for both perspectives (figure 4.1). From the healthcare perspective, there is a 
greater probability that early assisted discharge leads to net cost saving than from the soci-
etal perspective, as is shown by a greater proportion of combinations of incremental costs 
and effects below the x-axis. When adopting the healthcare perspective, the largest propor-
tion of all dots was located in the southwest quadrant, with lower costs and less optimal 
health outcomes for early assisted discharge. From the societal perspective, the majority 
Table 4.6 Treatment costs (in euros, 2009)
Usual hospital care Early assisted discharge Difference
Initial treatment phase
Inpatient days^ €1463 €1001 -€462
Community nursing - €211 €211
Other costs of home treatment (societal perspective) - €186 €186
Other costs of home treatment (healthcare perspective) - €6 €6
Total (healthcare perspective) €1463 €1219 -€244 (-315;-168)
Total (societal perspective) €1463 €1398 -€65 (-152; 25)
Follow-up period
GP €46 €71 €25
Pulmonologist €86 €107 €21
Specialist €114 €99 -€15
Paramedic care €191 €314 €123
Emergency room €52 €48 -€4
Ambulance €80 €25 -€55
Medication €346 €396 €50
Community nursing €971 €932 -€39
Readmissions €941 €941 €0
Informal care €973 €1488 €515
Production loss, patient €71 €466 €395
Total* (healthcare perspective) €2834 €2910 €76 (-€1005; €1159)
Total* (societal perspective) €3904 €4848 €945 (-€450; €2375)
Total study period (initial treatment phase plus follow up-period)
Healthcare perspective* €4297 €4129 -168 (-€1253; €922)
Societal perspective* €5366 €6246 880 (-€580; €2268)
*Totals for follow-up period are based on regression analysis; means per cost category are not.
^These costs are higher than those in table 4.3 because the costs of prolonged hospital stay beyond 7 days (usual hospital care group) and the 
costs of readmission during the initial treatment phase (usual hospital care group) were included.
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of simulated outcomes were found in the northwest quadrant, with higher costs and less 
optimal health outcomes for early assisted discharge.
The cost-effectiveness acceptability curves in figures 4.2 and 4.3 show that, from a 
healthcare perspective, early assisted discharge is likely to be cost-effective for thresholds up 
to €46,000. From a societal perspective, early assisted discharge is unlikely to be considered 
cost-effective compared to usual hospital care at any threshold of maximum costs per QALY 
gained. In the base case, this probability is close to 10% for all thresholds.
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Figure 4.1: Cost-effectiveness planes.
Healthcare perspective, incremental costs set against: a) incremental improvement in CCQ-score, month 3, b) incremental proportion of patients 
with clinically relevant improvement, month 3; c) incremental QALYs.
Societal perspective, incremental costs set against: d) incremental improvement in CCQ-score, month 3, e) incremental proportion of patients 
with clinically relevant improvement, month 3; f) incremental QALYs.
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Figure 4.2 Cost-effectiveness acceptability curves for costs per QALY gained, healthcare perspective.
SA2 (sensitivity analysis 2): standard costs per inpatient hospital day instead of costs from microcosting study. SA3/4: cost estimates from most 
and least costly healthcare provider in microcosting study. SA5/6: highest and lowest estimates of care costs across respondents.
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Figure 4.3 Cost-effectiveness acceptability curves, societal perspective.
SA2 (sensitivity analysis 2): standard costs per inpatient hospital day instead of costs from microcosting study. SA3/4: cost estimates from most 
and least costly healthcare provider in microcosting study. SA5/6: highest and lowest estimates of care costs across respondents.
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Sensitivity analyses
Table 4.7 shows the results of the sensitivity analyses. The ICERs for usual hospital care 
compared to early assisted discharge, were sensitive to changes in the assumptions. In the 
initial treatment phase, early assisted discharge was almost certain to lead to cost savings 
from a healthcare perspective, under any of the alternative assumptions about the costs of 
inpatient hospital days, similar to the base case analysis. From a societal perspective, costs 
savings were very likely to occur during the initial treatment phase, except if mean costs per 
hospital day were assumed to be much lower than in the base case analysis (SA4 and SA6).
Over the entire three-month period, cost savings were more likely to occur than cost 
increases from a healthcare perspective. This likelihood was more or less comparable across 
sensitivity analyses, except when the standard unit costs for inpatient hospital days were 
applied (SA2). In this sensitivity analysis, the likelihood that early assisted discharge led to 
cost savings was 99.8%
From a societal perspective, cost savings were unlikely to occur under all assumptions 
except when the standard unit costs for inpatient hospital days were used (SA2). This is 
the only sensitivity analysis in which early assisted discharge was not dominated by usual 
hospital care.
The cost-effectiveness acceptability curves in figures 4.2 and 4.3 make it clear that as-
sumptions on the costs of inpatients days do not have a strong impact on the probability that 
early assisted discharge is to be cost-effective.
4.4 Discussion
This study compared the costs and health effects of two treatments for patients who were 
admitted to the hospital with a COPD exacerbation. Patients stayed in the hospital for seven 
days, or went home after three days where they were supervised and treated by community 
nurses. No clear evidence was found to conclude that either treatment was more effective or 
less costly than the other.
Against the obvious savings in inpatient hospital costs, there were extra costs for com-
munity nursing, and, from a societal perspective, informal care. While costs from a societal 
perspective were higher among patients who were discharged early, this difference was not 
statistically significant. Cost savings in the healthcare perspective were not significant either. 
However, early discharge was much more likely to reduce healthcare costs than it was to 
reduce total societal costs.
At the end of the 7-day treatment phase, all outcomes measures had improved more in 
the patients in the usual hospital treatment group than in patients in the early discharge 
group. However, this difference was not statistically significant, except for the probability of 
having a clinically relevant improvement in CCQ-score on day 7. Patients who underwent 
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Table 4.7 Sensitivity analyses
Cost difference
(EAD minus HOSP)
ICER* Probability of cost-savings
for early discharge
Healthcare costs, initial episode
Base case -€244 100%
SA2 -€1522 100%
SA3 -€389 100%
SA4 -€160 100%
SA5 -€568 100%
SA6 -€86 99.0%
Societal costs, initial episode
Base case -€65 93.2%
SA1 -€65 93.2%
SA2 -€1343 100%
SA3 -€210 100%
SA4 €19 33.9%
SA5 -€389 100%
SA6 €93 2.0%
Healthcare costs, 3 months
Base case -€168 €31,111 61.2%
SA2 -€1464 €271,111 99.8%
SA3 -€313 €57,963 69.2%
SA4 -€84 €15,556 55.1%
SA5 -€492 €91,111 81.2%
SA6 -€10 €1,852 50.0%
Societal costs, 3 months
Base case €880 Dominance 11.5%
SA1 €370 Dominance 25.4%
SA2 -€416 €77,037 69.9%
SA3 €735 Dominance 15.7%
SA4 €964 Dominance 9.8%
SA5 €556 Dominance 21.6%
SA6 €1038 Dominance 8.1%
* Savings per QALY lost.
Abbreviations: EAD, early assisted discharge; HOSP, usual hospital care; ICER, incremental cost-effectiveness ratio; SA1, sensitivity analysis 1: 
informal care costs during follow-up not included in societal costs; SA2: standard costs per inpatient hospital day instead of costs from 
microcosting study; SA3/4: cost estimates from most and least costly healthcare provider in microcosting study;  SA5/6: highest and lowest 
estimates of care costs across respondents.
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usual hospital care, were more likely to experience an improvement in CCQ score of more 
than 0.4 points.  By the end of the follow-up period, at 3 months, the difference had disap-
peared. In a publication of the clinical results of this study, it was reported that there was 
no difference in readmissions and mortality, while treatment failures were somewhat more 
frequent in the usual hospital care group [12].
From a societal perspective, no incremental cost-effectiveness ratios were calculated for 
outcomes after the follow-up period because early assisted discharge led to higher mean 
costs as well as less optimal health outcomes: it was dominated by usual hospital treatment. 
This was illustrated by the large proportion of bootstrap samples in the northwest quadrant 
of the CE plane and by the low acceptability curves. The verdict of dominance is often fatal 
for the conclusion on the treatment to which it is applied. In this case, however, it might 
be given less weight, since the dominance is based on a very small difference in effects. 
Analogously, it could be argued that the position of the majority of bootstrap replications 
on the CE plane should not be described as the northwestern quadrant of the CE plane, but 
rather as the proximity of the Y-axis and the origin.
ICERs could be calculated for outcomes after seven days from a societal perspective 
and for all outcome measures from a healthcare perspective. The savings per QALY lost 
were €31,111. This is close to the threshold values below which an ICER would generally 
be considered cost-effective if the new treatment were more effective than the comparator. 
However, in this case the threshold must represent the costs savings that would be required 
to make a health loss acceptable (willingness to accept). There are indications that this 
threshold is much higher than the threshold for the amount of incremental costs that society 
would be willing to pay for health gains [31]. In this light, the interpretation of the accept-
ability curves could also shift somewhat in favour of the comparator arm [32].
This is the first study to include the costs of informal care in the costs of the early assisted 
discharge scheme. The impact of this was considerable. In the 7-day treatment phase, the 
cost savings for early assisted discharge decreased from €244 to €65 per patient. For the full 
treatment period, cost savings turned into cost increases.
The costs of informal care during the follow-up phase were much higher in the early 
assisted discharge group. We have no good explanation for this finding. Although it might 
be a true difference, it is also possible that informal caregivers in the early assisted discharge 
group were more primed to record their activities as informal care, due to the attention it 
may have got during the initial treatment phase at home. For this reason, we performed a 
sensitivity analysis in which informal care costs during the follow-up period were excluded 
from the calculations. In this analysis, total costs for the early discharge group were still 
higher, mostly because of the higher number of patient work days lost. The difference was 
smaller than in the base case, as was the probability of a cost increase.
Generally, the amount of informal care can be recorded in two ways: the diary method, 
in which resource use is recorded on a daily basis, and the recall method, in which a 
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respondent is asked to provide information on the preceding week [33]. Both methods have 
advantages and disadvantages. Most importantly for the diary method, it may not be fea-
sible to ask to complete it over a longer period of time. On the other hand, the recall method 
has been shown to have a potential to overestimate informal care time, when respondents 
do not take into account that they have combined certain activities with providing informal 
care [33]. The diary method was applied during the treatment phase in our study, while the 
follow-up period was covered by the recall method.
How to value informal care is still debated. Different estimation methods have led to 
different estimates [34]. Following Dutch guideline recommendations, we used a shadow 
price of €12.50 per hour, which was based on the standard tariff for the reimbursement of 
house cleaning costs for chronic patients. When it is applied to informal care, it reflects 
the assumption that informal caregivers cannot match the efficiency of professionals, who 
would require a higher hourly tariff. While our cost estimates are dependent on the assumed 
hourly unit costs of informal care, the unit costs we have used are in the center of the range 
of costs (€7 to €17) that were estimated by Koopmanschap et al. using different valuation 
methods [34].
Like the costs of informal care, the productivity losses in the early assisted discharge 
group were higher as well. This was mostly due to one patient, who incurred a very high 
amount of costs.
In our study, the duration of hospital or home treatment was fixed. Whenever possible, 
patients were discharged or homecare was stopped after seven days. It is conceivable that 
the threshold for adding another day of treatment may be lower for treatment at home. In 
other studies, in which no fixed treatment duration was used and physicians were fully 
free to decide on the duration of treatment, different durations were observed for each 
treatment group and the total duration of treatment in hospital-at-home was longer than 
that in usual hospital care. Such an approach may have commingled the effects of the 
treatment per se with the effects of the length of stay or even with the timing of health 
measurements. Treating patients for a longer time may lead to better health, but mea-
suring their health at a later time may also lead to seemingly better results. Our design 
made it possible to make the comparison exclusively on the basis of where and by whom 
treatment was provided. Four patients in the usual hospital care group remained in the 
hospital for a longer period of time. One patient who was discharged early needed to 
be re-admitted within the seven days of initial treatment. The additional costs of these 
patients were included in the costs of the initial treatment phase. No patient required 
homecare beyond seven days.
It is possible – although far from certain – that the early assisted discharge treatment 
would in daily practice be longer than the hospital treatment. This would clearly lead to 
higher costs than in this trial, whereas the study did not yield indications that it would or 
would not improve health outcomes.
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The patients in the trial can be considered representative for other patients who would 
be eligible and willing to participate. Almost two thirds of screened patients were too ill, did 
not have an obvious informal caregiver or did not live in the catchment area of the com-
munity nursing organization. This may reduce the potential for the early assisted discharge 
treatment, but it is still considerable, given the size of the patient population.
This study has shown the potential impact of a detailed unit cost calculation of an inpa-
tient hospital day based on treatment-intensity compared to standard tariffs or references 
prices. A sensitivity analysis using Dutch reference costs, which represent average costs of 
a hospital day based on all patients irrespective of their diseases [20], led to much larger 
savings for early assisted discharge. From the societal perspective, the cost increase due 
to early assisted discharge disappeared almost entirely. From the healthcare perspective, 
the finding that early assisted discharge led to cost savings was surrounded by almost no 
uncertainty.
However, using standard costs of a hospital day would not be opportune in this study 
because only the least-costly inpatient days were substituted by home care. Furthermore, 
hospital care for patients with COPD exacerbations that meet the in- and exclusion criteria 
of our trial are likely to be less intensive than the hospital care for the average admitted 
patient.
The calculations for the costs per inpatient day were not based on a large sample of 
patients, whose treatment was actually timed and recorded. This was not feasible in this 
study, due to the unpredictability of hospital admissions, the relatively small number of 
patients eligible for the study, and the large number of treatment aspects that would have to 
be recorded. It would have required researchers permanently present in the hospitals for a 
long period of time. Instead, we interviewed hospital care providers with much experience 
in treating this patient group. A standardised questionnaire was used, in which all aspects 
of care on a particular day were distinguished. Respondents were not asked to estimate 
the total amount of time they spent on each patient but on an average patient. Tan et al. 
concluded that this method leads to a good balance between feasibility and reliability [22]. 
A problem with this method is, however, that it does not yield measures of variability on a 
patient level. This means that the uncertainty about the costs of treatment in the hospital, 
which inevitably exists, was not represented in the uncertainty around the total costs of treat-
ment. While this may always be the case when fixed unit costs are used, inpatient hospital 
days are different. They contain a large number of separate elements – not just capital costs, 
hotel services and overhead costs, which could be fairly similar for all patients, but also time 
from several healthcare providers for many different aspects of care. It is conceivable that the 
price of a general practitioner consultation does not differ much across patients because all 
more or less take the same amount of time, whereas inpatient hospital days are much more 
different for different patients. This may not be a problem when hospital costs are merely 
one a relatively infrequent element in the total costs of care, but in the initial treatment 
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episode for COPD exacerbations the costs of inpatient hospital days are virtually the only 
cost driver. Therefore, we performed sensitivity analyses assuming different unit cost prices 
per inpatient hospital day. These gave an indication about the range of possible costs savings 
and increases.
Most of the other cost studies of hospital-at-home found larger cost savings than we 
did, also from a healthcare perspective [3,9-14]. This may be explained by the design of our 
study – early assisted discharge, not admission avoidance, which brought a reduction of four 
inpatient hospital days. In some other studies, this reduction was larger. In England, two eco-
nomic evaluations were performed. Skwarska et al. calculated savings of £876 per patient by 
eliminating five inpatient days (median) in an admission avoidance program (no statistical 
testing was done) [10]. In contrast, Shepperd et al. found significant cost increases (differ-
ence between medians £1176) for an early assisted discharge scheme, in which five inpatient 
days were substituted for care at home as well [9]. The cost increases in this study were mostly 
due to the large proportion of patients who were readmitted to the hospital after having been 
discharged early compared to usual treatment, which makes it plausible that the health ef-
fects of treatment were better in the usual hospital care group. Although differences were 
not statistically significant in their small sample, almost all health indicators were in favor of 
usual hospital care. In a Spanish study, significant savings of around €800 were reported, the 
exact amount depending on the analysis [11,12]. In this scheme an average of 3.8 inpatient 
hospital days was substituted by 1.7 home visits and 2.3 phone calls per patient. Some pa-
tients were discharged early, while others avoided admission completely. In this study, even 
some patients who were randomised to the usual hospital treatment, did not spend a night in 
the hospital. In an Australian admission avoidance study, in which community nurses were 
employed instead of hospital-based staff, the savings were AUS$1696 [3]. Aimonino Ricauda 
et al. examined an admission avoidance program in Italy [14]. The cost difference of US$215 
was not significant. However, the hospital-at-home scheme contained visits by physicians 
and a transport home by ambulance for all patients, which made the cost difference smaller. 
In a non-randomised study in the United States – all previously mentioned studies were 
randomised – Frick et al. found the largest savings, US$2314 per patient [13].
In conclusion, transferring hospital care for a COPD exacerbation to the patient’s home 
is likely to lead to modest savings in healthcare costs in the Netherlands, while there is no 
evidence that it would be medically impossible or irresponsible for selected patients.  When 
the societal costs of informal care and productivity losses are taken into account, the cost 
savings decrease considerably or even turn into cost increases. 
Since there is no compelling reason – from a medical or economic point of view – to 
recommend either the early supported discharge treatment or usual hospital care, patients’ 
preferences should play an important role in deciding where (s)he is treated. If homecare is 
preferred, this study has shown that the wide-spread network of homecare organizations in 
the Netherlands, which employs community nurses, is able to meet this preference.
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5Should I stay or should I go home?A latent class analysis of a discrete choice 
experiment on hospital-at-home
Background This study aimed (1) to quantify patient preferences for different aspects of 
hospital-at-home in the Netherlands for patients who were admitted with a COPD exacer-
bation (2) to provide an application of latent class modelling of discrete choice data. This 
technique is rarely used in health economics.
Methods In a discrete-choice experiment, respondents were asked to make multiple 
choices between hospital treatment as usual (7 days) and two combinations of hospital 
admission (3 days) followed by treatment at home. The latter was described by a set of at-
tributes: training of homecare nurses, number of different nurses involved in home visits, 
number of daily visits day, co-payments, readmission risk, whom to contact in case of 
worsening disease, and informal caregiver burden. Hospital treatment was constant across 
choice sets. Respondents were COPD patients in a randomised controlled trial investigating 
the cost-effectiveness of early assisted discharge, and their informal caregivers. The data 
were analysed in latent-class conditional logit regression, which allowed for heterogeneous 
preferences across groups.
Results 25% of respondents opted for hospital treatment regardless of the description of 
the hospital-at-home program, 46% never chose for the hospital. The best model contained 
four latent classes of respondents, defined by different preferences for the hospital and for 
the caregiver burden. Preferences for the other attributes were the same across classes. 
Attributes with the strongest influence on choices were the burden on informal caregivers 
and co-payments. Except for the number of visits, all attributes had a significant effect on 
choices in the expected direction.
Conclusion Considerable segments of respondents had fixed preferences for either 
treatment option. Applying latent class analysis was essential in quantifying preferences 
for attributes of hospital-at-home.
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5.1 Introduction
Many patients with chronic obstructive pulmonary disease (COPD) are more or less fre-
quently admitted to the hospital for an exacerbation of their disease. The average annual 
frequencies have been estimated to vary from 0.11 for patients with mild COPD (GOLD stage 
I, as defined by lung function [1]) and 0.16 for moderate disease (GOLD II), to 0.22 and 0.28 
for severe and very severe COPD (GOLD III and IV)[2]. Nevertheless, the extent to which 
patients are prone to exacerbations varies substantially within GOLD stages [3].
Hospitalisations for exacerbations are the main drivers of COPD treatment [4-9]. They 
put pressure on scarce hospital beds of respiratory wards, especially during winter months 
[10]. However, COPD patients are vulnerable to infections in a hospital environment. They 
may prefer to be in the hospital for as short a period as possible for reasons of privacy and 
comfort. It may therefore be attractive to treat suitable patients at home instead of in the 
hospital, if this is medically possible. This approach is often called hospital-at-home. It can 
either substitute the entire hospital admission for home treatment (admission avoidance) or 
the last days of the admission (early assisted discharge) [11,12].
The GO AHEAD trial, which compared early assisted discharge with a conventional 
hospital admission, did not lead to the conclusion that either treatment was clearly prefer-
able from a medical or economic point of view [13,14]. No clear and significant differences 
were found in health outcomes or costs, although early assisted was more likely to be the 
less costly alternative from the healthcare perspective. This lack of clear superiority of either 
treatment increases the importance of the preferences of patients and their informal care-
givers. Adapting a treatment program to their preferences may enhance its acceptability.
The first objective of this chapter was to quantify patients’ and informal caregivers’ 
preferences for different characteristics of an early assisted discharge scheme in the Neth-
erlands and to determine when these characteristics make the new scheme more attractive 
than usual hospital care.
A commonly used technique for eliciting preferences is the discrete choice experiment 
(DCE), in which respondents are asked to choose between alternatives, which are described 
by a number of attributes [15]. Statistical analysis is then used to quantify the weight of each 
attribute in the choices of the respondents. In health economics, one of the most widely 
applied methods to analyse data from such experiments is McFadden’s conditional logit, 
otherwise known as multinomial logit [16-18]. However, one of the asssumptions of this 
technique is homogeneity of preference across respondents [19]. When this assumption is 
violated – in other words, when some respondents have consistently different preferences 
than others – the model may lead to biased results. The most popular methods to take prefer-
ence heterogeneity into account are based on random parameters: the random effect probit 
and logit models for binary choices and the mixed logit model for choices with more than 
two alternatives [16].
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An alternative method, which is particularly suited for segmented samples of respon-
dents, is latent class analysis. Unfortunately, this technique is rarely used in health eco-
nomics. In a review of DCE methods in this field, Bekker-de Grob et al. found that latent 
class analysis, was applied only once in the period from 1990 to 2008 [16], in a study on 
appointments with general practitioners [20]. To our knowledge, the only more recent 
example of latent class analysis in health economics is a study on preventive treatment of 
latent tuberculosis [21].
Latent class analysis groups respondents in a pre-specified number of latent classes with 
distinct preferences. This allows for the estimation of class-specific preference parameters 
and of the probability of class membership. One of the developers of DCE methodology, 
Louviere, has argued for a more frequent use of latent class models [22] because they fit the 
data at least as well as random parameter models while estimation and interpretation are 
easier.
An additional objective of this chapter was therefore to provide a new example of the 
application of latent class modelling of discrete choice data by investigating whether there 
were subgroups with clearly different preferences.
5.2 Methods
Selection of attributes
A literature search led to a selection of characteristics of hospital-at-home treatments for 
COPD. These were considered potential attributes for the DCE. The attributes had to de-
scribe the process, not the outcomes of treatment. The provisional attributes were discussed 
with physicians connected to the trial and with COPD patients who were admitted to the 
hospital. They were invited to mention additional attributes and levels. Non-nominal at-
tribute levels were chosen in order to reflect a wide range of possibilities and being able to 
have an impact on choices, without becoming unrealistic or unimaginable to respondents.
The final questionnaires contained the following attributes for hospital-at-home treat-
ment: (1) specialisation of the community nurse, (2) number of home visits, (3) number of 
different nurses involved in the treatment, (4) co-payment, (5) whom to contact in case of 
worsening disease, (6) burden on informal caregivers, (7) risk of readmission to the hospital 
before the scheduled end of home treatment. Table 5.1 shows the levels of each attribute.
Design of DCE questionnaire
Choice sets consisted of three labelled alternatives: two early-assisted-discharge treatments 
and the usual hospital treatment (see figure 5.1 for an example). Since many characteristics 
of hospital-at-home are not applicable to usual hospital treatment and vice versa, only the 
hospital-at-home treatments were described by attributes. Because all respondents were 
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hospitalised they were assumed to be familiar with hospital treatment, which was constant 
over all choice sets.
In order to extract as much choice information as possible, respondents who preferred 
the hospital option in a certain choice set were subsequently asked which of the hospital-at-
home options they preferred.
No opt-out was presented, since all COPD patients who are admitted to the hospital for 
an exacerbation cannot be left untreated. Respondents were asked to assume that all treat-
ments were equally effective in medical terms, i.e. after seven days, a patient’s health state 
would be the same under all treatment options.
SAS 9.1 software was used to generate a d-efficient fractional factorial design for the 
questionnaire, which consisted of 36 choice sets divided into three versions. Each question-
naire contained 12 choice sets, to which we added two fixed choice sets with a dominant 
alternative, i.e. an alternative that is better on all attributes, in order to test the respondents’ 
comprehension of the task. Choice sets were presented in random order.
Respondents
The questionnaires were presented to all COPD patients and their informal caregivers who 
participated in the GO AHEAD trial, which was carried out in five hospitals in the Neth-
erlands from November 2007 to March 2011. In the early assisted discharge arm of this 
randomised trial, patients spent three days in the hospital, after which they were treated 
in their own homes by community nurses for four more days. Patients in the control group 
remained in the hospital for seven days. Participants had diagnosed COPD, were ≥40 years 
Table 5.1 Attributes and levels for early assisted discharge options
Treatment attribute Levels
Specialisation of community nurse Generic
Pulmonary
Number of home visits 1 per day
2 per day
3 per day
Number of nurses involved in treatment 1 or 2
More than 2
Co-payment €0
€50
€100
Contact GP
Pulmonary ward, hospital
Burden on informal caregivers 1 hour per day
3 hours per day
5 hours per day
Risk of readmission 1%
5%
10%
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old, had no major uncontrolled co-morbidities, and had no indication for admission to an 
intensive care unit or for non-invasive ventilation. After three days in the hospital, they had 
to be clinically stable in order to be randomised.
Since trial-participants were more likely to have a preference for hospital-at-home than 
the general patient population additional respondents were recruited among patients who 
were ineligible for inclusion or who did not consent.
Each respondent was asked to fill out the questionnaire during an outpatient visit to the 
hospital one month after the initial admission. If patients did not appear at the appoint-
ment, questionnaires were sent to home addresses. Ethics approval was obtained from the 
ethics board of Catharina Hospital in Eindhoven, the Netherlands.
Statistical analysis
First, we investigated how many respondents were principally willing to consider the hospi-
tal alternative as well a hospital-at-home alternative or whether they had a fixed preference, 
irrespective of the attribute levels of the hospital-at-home alternatives. This was done by 
examining the initial answers of all choice sets for each respondent.
Next, all choices – the initial answer and the possible second answer – were analysed in 
a multinomial logit model (MNL), otherwise known as conditional logit. All attribute levels 
 
Early assisted 
discharge A 
Early assisted 
discharge B 
Hospital 
Nurse specialisation 
 
Generic nurse 
 
 
Pulmonary nurse 
 
  
Number of nurse visits  3 per day 1 per day 
Co-payment 50 euros 100 euros 
Re-admission risk  1 in 10 1 in 20 
Whom to contact in case of 
worsening disease 
Hospital, 
pulmonary ward 
General practitioner 
Informal care burden 3 hours per day 1 hour per day 
Number of different nurses 1 or 2 More than 2 
  A B Hospital 
Which treatment would you 
choose? (Tick 1 box.)  □ □ □ 
  A B   
Which treatment would you 
choose if you can only opt 
for early assisted discharge? 
(Tick 1 box.)  
□ □   
 
 
 
Figure 5.1 Example of choice set from questionnaire.
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were dummy-coded. Constants were added for the hospital alternative, in order to detect 
a preference or aversion to this treatment relative to hospital-at-home, and for one of the 
hospital-at-home-options, in order to test a possible ordering effect (i.e. whether respon-
dents were more likely to choose the option that was presented first or second).
The MNL model assumes that all choices are made independently, which is not realistic 
when respondents have systematically different preferences than others. To express this 
potential preference heterogeneity, a latent class model (LC) was developed. A LC model fits 
the best possible model with a pre-determined number of classes. For each class, different 
coefficients (or discrete random effects) are estimated for one or more attributes.
The optimal number of classes was determined in an iterative procedure, by making 
comparisons of models with different numbers of classes, based on the Akaike Informa-
tion Criterion 3 (AIC) and supported by the AIC. The AIC3 is more critical towards models 
with more parameters than the AIC. It imposes a penalty of 3 instead of 2 points per model 
parameter. According to Andrews and Currim, the AIC3 is the best performing criterion in 
determining the optimal number of classes in logit models [23].
First, a preliminary number of classes was determined by comparing models with the 
hospital constant as the sole random effect. In the second step, the found number of classes 
was used in models with different random effects, in addition to the hospital constant. This 
was done by examining the p-values for the discrete random effects, which were entered 
into the model one by one. In these analyses, the random effects were expressed as devia-
tions from the mean value of the coefficient for the attribute level over all classes. In the third 
step, the selected random effects were applied in models with different numbers of classes. 
Finally, the LC model was estimated without mean coefficients for attributes with discrete 
random effects, i.e. each random effect was expressed as a deviation from zero.
The association of class membership with treatment group and COPD severity stage 
defined by GOLD [1] was explored in cross tables and tested using chi-squared tests. Re-
spondents were assumed to belong to the class with the highest predicted probability.
All analyses were performed in Stata 12.0 (Statacorp, College Station, TX), using the 
GLLAMM procedure [24,25].
5.3 Results
From the GO AHEAD trial, 107 patients and 83 informal caregivers completed the question-
naire. Additionally, 7 patients and 6 informal caregivers returned the questionnaire. The 
response rates among GO AHEAD participants were 77% for patients and 64% for informal 
caregivers.
Table 5.2 shows that a quarter of respondents chose the hospital care option in all 
14 choice sets, whereas approximately 45% always chose the hospital-at-home option. 
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The preference of the remaining 29% of respondents depended on the description of the 
hospital-at-home treatment.
Multinomial logit
Table 5.3 shows the results of the multinomial logit model. Results for patients closely re-
sembled those for informal caregivers. The ordering of the alternatives played no role, which 
Table 5.2 Patterns of chosen alternatives
Choice pattern Patients (n=113) Informal caregivers (n=89)
Always usual hospital care 28 (25%) 23 (26%)
Both 33 (29%) 26 (29%)
Always early assisted discharge 52 (46%) 40 (45%)
Table 5.3. Results of multinomial logit analyses
Patients Informal caregivers
Coefficient P-value Rank Coefficient P-value Rank
Constant early assisted discharge A Reference category Reference category
Constant early assisted discharge B 0.021 0.724 13 -0.085 0.206 12
Constant hospital -0.681 <0.0005 1 -0.638 <0.0005 1
Generic nurse Reference category Reference category
Pulmonary nurse 0.371 <0.0005 5 0.374 <0.0005 5
1 or 2 nurses Reference category Reference category
More nurses -0.351 <0.0005 7 -0.508 <0.0005 3
1 visit per day Reference category Reference category
2 visits per day 0.032 0.751 12 -0.222 0.055 8
3 visits per day -0.155 0.120 10 -0.258 0.017 7
Co-payment €0 Reference category Reference category
Co-payment €50 -0.311 <0.0005 8 -0.134 0.137 11
Co-payment €100 -0.697 <0.0005 2 -0.485 <0.0005 4
Readmission risk 1% Reference category Reference category
Readmission risk 5% -0.077 0.352 11 -0.046 0.624 13
Readmission risk 10% -0.189 0.018 9 -0.159 0.081 10
Contact: pulmonary ward Reference category Reference category
Contact: general practitioner -0.375 <0.0005 4 -0.301 <0.0005 6
Informal carer burden : 1 hour per day Reference category Reference category
Informal carer burden : 3 hours per day -0.366 <0.0005 6 -0.192 0.024 9
Informal carer burden : 5 hours per day -0.456 <0.0005 3 -0.508 <0.0005 2
AIC 3894.824 2991.409
AIC3 3907.824 3004.409
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can be concluded from the small and non-significant coefficient for alternative B. The nega-
tive coefficient for the hospital option pointed to a preference for hospital-at-home, given 
the baseline levels of the other attributes. All attributes had a significant impact on patients’ 
and informal caregivers’ choices in the expected direction, except for the number of home 
visits per day, among patients, and the readmission risk, among informal caregivers, which 
were not statistically significant.
The rankings show which attribute levels had the strongest impact on choices. For both 
groups of respondents, the hospital coefficient was the largest coefficient.
Development of latent class multinomial logit models
For patients, the model with four classes was the most appropriate of all models with one 
random effect (hospital constant), based on the AIC3. The AIC supported this conclusion. 
This is shown in table 5.4. For informal caregivers, the models with three and four classes 
appeared to be equally appropriate.
In the four class model, only random effects for hospital and the two levels of informal 
caregiver burden significantly deviated from the mean effect. When these random effects 
were applied, the AIC3 pointed to models with four classes for patients as well as caregivers. 
According to AIC, a five-class model for patients had a slightly better fit. Based on both, 
models with the three random effects were more appropriate than models with one random 
effect.
Table 5.4 Goodness of fit for latent class models
Patients Informal caregivers
AIC* AIC3* AIC* AIC3*
Models with 1 discrete random effect (hospital)
1 class 3894.824 3907.824 2991.409 3004.409
2 classes 2674.043 2689.043 2171.029 2186.029
3 classes 2574.699 2591.699 2003.239 2020.239
4 classes 2549.744 2568.744 2001.269 2020.269
5 classes 2553.744 2574.744 2005.269 2026.259
Models with 3 discrete random effects (hospital, informal carer burden 3h/5h)
2 classes 2677.899 2694.899 2168.506 2185.506
3 classes 2575.479 2596.479 1999.387 2020.387
4 classes 2536.432 2561.432 1991.352 2016.352
5 classes 2533.291 2562.291 Did not converge.
*Lower value indicates a better fit.
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Final latent class model
The final models for both patients and informal caregivers contained four classes with three 
discrete random effects: hospital, burden on informal caregivers 3 hours and 5 hours per 
day. The results from these models are shown in table 5.5.
The classes for patients have somewhat different characteristics than the classes for 
informal caregivers. For patients, class 1 consisted of respondents with a strong preference 
for the hospital and with a moderate aversion to the higher levels of burden on the informal 
caregiver. Class 2 contained respondents with a moderate aversion to the hospital and mod-
erate aversion to the highest level of burden to the informal caregiver. In class 3, respondents 
had a strong aversion to the hospital and to the higher levels of burden on the informal 
caregiver. Class 4 was formed by patients with the strongest aversion to the hospital, who 
were indifferent about the burden on the informal caregiver. The informal caregivers in class 
1 had a strong preference for the hospital and were indifferent about the burden on informal 
caregivers. Respondents in group 2 had no significant preferences for the hospital or the level 
of burden. Class 3 consisted of respondents with a moderate aversion to the hospital and to 
higher levels of burden. Class 4 was formed by respondents with the strongest aversion to 
the hospital and a moderate aversion to the highest level of informal caregiver burden.
For the other attributes, strengths of preferences were equal across the classes. For both 
groups of respondents, all attributes had a significant effect on choices, in the expected di-
Table 5.5 Results of final latent class conditional logit analyses
Patients Informal caregivers
Coefficient P-value Rank Coefficient P-value Rank
Outcomes per class
Class 1
Hospital 3.30 <0.0005 4.642 <0.0005
Informal carer burden :
1 hour per day
Reference category Reference category
Informal carer burden :
3 hours per day
-0.324 0.033 -0.047 0.790
Informal carer burden :
5 hours per day
-0.610 <0.0005 -0.216 0.264
Class 2
Hospital -0.984 <0.0005 0.902 0.083
Informal carer burden :
1 hour per day
Reference category Reference category
Informal carer burden :
3 hours per day
0.070 0.732 0.306 0.485
Informal carer burden :
5 hours per day
-0.478 <0.043 0.648 0.225
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Table 5.5 Results of final latent class conditional logit analyses (continued)
Patients Informal caregivers
Coefficient P-value Rank Coefficient P-value Rank
Class 3
Hospital -4.749 <0.0005 -1.275 <0.0005
Informal carer burden :
1 hour per day
Reference category Reference category
Informal carer burden :
3 hours per day
-1.740 <0.0005 -0.691 0.002
Informal carer burden :
5 hours per day
-3.513 <0.0005 -1.651 <0.0005
Class 4
Hospital -5.621 <0.0005 -5.448 <0.0005
Informal carer burden :
1 hour per day
Reference category Reference category
Informal carer burden :
3 hours per day
-0.089 0.466 -0.176 0.159
Informal carer burden :
5 hours per day
-0.106 0.476 -0.472 0.001
Shared outcomes for all classes
Early assisted discharge A Reference category Reference category
Early assisted discharge B -0.00028 1 10 -0.082 0.239 10
Generic nurse Reference category Reference category
Pulmonary nurse 0.516 <0.0005 3 0.485 <0.0005 4
1 or 2 nurses Reference category Reference category
More nurses -0.433 <0.0005 5 -0.536 <0.0005 2
1 visit per day Reference category Reference category
2 visits per day -0.016 0.902 9 -0.168 0.245 8
3 visits per day -0.062 0.621 8 -0.107 0.420 9
Co-payment €0 Reference category Reference category
Co-payment €50 -0.478 <0.0005 4 -0.202 0.042 7
Co-payment €100 -1.107 <0.0005 1 -0.722 <0.0005 1
Readmission risk 1% Reference category Reference category
Readmission risk 5% -0.241 0.015 7 -0.207 0.057 6
Readmission risk 10% -0.409 <0.0005 6 -0.307 0.003 5
Contact: pulmonary ward Reference category Reference category
Contact: general practitioner -0.631 <0.0005 2 -0.510 <0.0005 3
AIC 2536.432 1991.352
AIC3 2561.432 2016.352
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rection, except for the number of visits by homecare nurses per day. The highest co-payment 
had the largest coefficient for patients as well as informal caregivers. Also important was the 
question whom to contact in case of an emergency – with a preference for the pulmonary 
ward in the hospital – the pulmonary specialization of the nurses and a small number of 
different nurses who were involved in treatment at home.
Latent class membership
Predicted probabilities of the designated classes were all over 96%, which means that there 
is hardly any uncertainty with regards to the classes that respondents belonged to. The great 
majority of patients as well as informal caregivers were in the extreme classes, with the 
strongest aversion to or preference for the hospital treatment (see table 5.6). For patients, 
class membership was significantly associated with the treatment they had actually received 
in the clinical trial (chi-square, p=0.039). This association was not significant for informal 
caregivers (p=0.648). Respondents with experience with home treatment less likely to have 
a preference for the hospital. Table 5.6 also shows that informal caregivers in both treatment 
groups were somewhat more likely to be in a class with a preference for the hospital than 
patients were.
Table 5.7 presents the distribution of patients in different COPD severity stages, and their 
informal caregivers, over the classes. Patients in stage IV were relatively likely to be in class 1, 
with the strongest preference for the hospital and less likely to be in class 4. This association 
was not statistically significant (p=0.340). In contrast, informal caregivers of patients in GOLD 
stage IV were relatively more likely to have a preference for treatment at home (p=0.160).
Table 5.6 Distribution of patients and informal caregivers from each treatment group over latent classes
Class Attitude towards hospital/caregiver burden Treatment group
Hospital Early assisted discharge
Patients
1 Strong preference/moderate aversion 38.8% 19.3%
2 Moderate aversion/mild aversion 10.6% 22.8%
3 Strong aversion/strong aversion 12.8% 5.2%
4 Very strong aversion/neutral 38.8% 52.6%
Total 100% 100%
Informal caregivers
1 Strong preference/neutral 31.6% 23.4%
2 Moderate preference/neutral 5.26% 6.4%
3 Moderate aversion/moderate aversion 18.4% 12.8%
4 Very strong aversion/mild aversion 44.8% 57.5%
Total 100% 100%
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5.4 Discussion
This study used latent class conditional logit models to quantify the preferences of patients 
and informal caregivers for aspects of early assisted discharge after a hospital admission for 
a COPD exacerbation.
The results have shown that the average patient and the average informal caregiver do 
not exist. For both groups, four distinct classes were distinguished, which had different at-
titudes towards being treated at home or in the hospital. Large proportions of respondents 
had a preference for either treatment option that could not be influenced by proposing 
realistic changes in the characteristics of the early assisted discharge treatment. When 
choosing between two home options – with the hospital option removed from the choice 
set – copayments and the burden on the informal caregiver had the strongest impact on 
choices. The number of visits per day did not play a role.
Results from this study could be used in the design of hospital-at-home programs for 
this category of patients. It did not appear to be required that nurses visit patients more than 
once a day. The frequency could depend on medical need, unless a higher frequency could 
lessen the burden on the informal caregiver, which did play a role in respondents’ choices.
The most attractive hospital-at-home program would be operated by pulmonary nurses 
and have no co-payments. Patients would not be visited by more than two different nurses 
and the pulmonary ward of the hospital would be reachable 24-hours a day in case of sud-
den worsening of the disease. Patients and informal caregivers appeared to be in agreement 
on this.
The attractiveness of this combination appears to be consistent across the different 
classes of respondents. However, this sample is not representative of the population of 
patients in similar health states and their caregivers. Almost half of the respondents always 
opted for early assisted discharge. The proportion of people in the overall population is likely 
to be smaller, since most of the respondents participated in the GO AHEAD trial, in which 
early assisted discharge was compared to regular hospital treatment. It is obvious that most 
Table 5.7 Associaton of GOLD stage and DCE class
Patients Informal caregivers
GOLD 2 GOLD 3 GOLD 4 GOLD 2 GOLD 3 GOLD 4
Class 1* 36.1% 17.1% 42.1% 39.4% 16.1% 26.7%
Class 2* 11.1% 24.4% 15.8% 3.0% 9.7% 6.7%
Class 3 8.3% 12.2% 5.3% 9.1% 29.0% 6.7%
Class 4 44.4% 46.3% 36.8% 48.5% 45.2% 60.0%
Totaal 100% 100% 100% 100% 100% 100%
chi2 test patients: p=0.340. Informal caregivers: p=0.161.
* For patients, class 1 represents a preference for the hospital. For in informal caregivers, this is the case for classes 1 and 2.
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of them did not have strong reservations against being treated at home. Patients who wanted 
to be treated in the hospital, could achieve this by not participating in the trial.
Because of the selection of respondents, this study could not estimate the sizes of differ-
ent classes in the population. However, their existence was shown. Furthermore, because 
we took this preference heterogeneity into account, we also showed that there was no sub-
stantial heterogeneity across classes with regard to preferences for the other attributes. This 
makes it plausible that the estimates of the importance of these attributes can be general-
ized. There is no reason to assume that patients and informal caregiver outside of this study 
would have different preferences.
The existence of classes with different preferences for either treatment option is an 
important finding. Apparently, the choice between home and hospital of many respondents 
cannot be influenced much by adjusting the treatment at home. If this treatment were to 
become the standard, it would be against the wishes of a large proportion of patients and 
caregivers. Vice versa, many respondents value early assisted discharge and would not like 
to be confined to the hospital treatment. Although patients and caregivers who experienced 
home treatment were more likely to prefer it, the experience did not lead to enthusiasm in 
everyone. The results of this study, combined with the effectiveness and cost outcomes of 
the GO AHEAD trial, argue for giving patients a choice between treatment options.
The use of latent class conditional logit models resulted in more valid estimates and a 
better fit than the conventional multinomial logit model. Application of the AIC3 criterion 
showed that the best fitting models for patients as well as informal caregivers contained 
four different classes. Respondents in different classes had clearly different preferences for 
the hospital treatment. This preference heterogeneity could not have been identified by 
the multinomial logit model. Using the latter model, it might appear possible to construct 
early-discharge programs with a higher or lower average utility than the hospital treatment 
for the average patient. However, this would have been misleading since large proportions 
of patients preferred one of the treatment options irrespective of the description of the 
early assisted discharge program. The results of the latent class conditional logit models 
are consistent with this. The difference between results of the two models is mainly in the 
estimates for the general preference for the hospital treatment and the weight of the burden 
on informal caregivers, both of which are discrete random effects in the latent class model. 
The relative importance of the other attributes is similar, but not equal, for both models.
An alternative method for dealing with preference heterogeneity is the mixed logit 
model, which estimates a continuous distribution instead of a set of discrete points for 
the random effects. This model has gained popularity in recent years, also in the field of 
health economics [16]. Mixed logit and latent class models both have their merits. The 
latent class model has been described as a semi-parametric variant of the mixed logit. On 
the one hand, it requires the pre-specification of a number of classes. On the other hand, 
it frees the analyst from making – possibly incorrect – assumptions on the distribution of 
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parameters across respondents [26] and the results are more readily interpretable [22]. In 
our case, the advantages of the latent class model prevailed. It was intuitively obvious that 
at least three groups should be distinguished based on the choice patterns. Furthermore, 
using distinct classes was conceptually more consistent with the fixed preference of many 
patients than using a distribution. The choice of four classes was validated by comparing 
the AIC3 of each model.
In conclusion, different classes of patients and informal caregivers have different fixed 
preferences for the hospital or early assisted discharge treatment. These preferences are not 
changed by alterations in the early assisted discharge program. When choosing between two 
home options, respondents put the largest weight on copayments and the burden on the 
informal caregiver. The number of visits per day did not play a role.
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6Is the EQ-5D responsive to recovery from a moderate 
COPD exacerbation?
Background The aim of the study was to correctly estimate the cost-effectiveness of 
treatments that reduce COPD exacerbations, the utility gains from preventing exacerba-
tions need to be measured. This requires utility measurement during exacerbations. The 
aim of this study was to assess the ability of the EQ-5D to detect the recovery from moderate 
COPD exacerbations.
Methods In the US, 65 COPD and/or chronic bronchitis patients (≥40 years old smok-
ers or ex-smokers with a history of 10 pack-years) were enrolled within 48 h of symptom 
onset of the exacerbation. Patients completed the EQ-5D at enrolment and after 7, 14 
and 42 days. Symptoms and medication use were recorded in diaries. Change over time 
and loss of quality-adjusted life years (QALYs) due to the exacerbation was estimated. 
Using standardised response mean (SRM) as the metric of responsiveness, we compared 
the responsiveness of the EQ-5D to the responsiveness of morning peak expiratory flow 
rate, rescue medication use and symptom scores. SRMs were also used to assess whether 
patients with greater improvements in peak expiratory flow rate, rescue medication use, 
symptom scores, clinician global impression of change, and patient global impression of 
change had a greater improvement in EQ-5D than patients with smaller improvement.
Results Mean utility index scores (standard deviation) using the US value set were 0.683 
(0.209), 0.726 (0.216), 0.768 (0.169) and 0.760 (0.181) at days 1, 7, 14 and 42, respectively. 
The mean of each patient’s lowest index score, either at visit 1 or visit 2, was 0.651 (0.213). 
Over the course of 6 weeks there was a highly significant improvement in mean utility. 
The greatest improvement was seen between day 7 and day 14. Patients lost on average 
0.00896 QALY (0.0086) or 3.27 (3.13) quality-adjusted life days during the exacerbation. 
The EQ-5D (SRM: 0.653) was more responsive to change than peak expiratory flow (0.269), 
rescue medication use (0.343) and sputum symptom scores (0.322) and equally responsive 
as cough (0.587) and dyspnoea (0.638) symptom scores.
Conclusion The EQ-5D is responsive to the recovery from a moderate COPD exacerba-
tion.
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6.1 Introduction
Many patients with chronic obstructive pulmonary disease (COPD) experience recurrent 
exacerbations with increased breathlessness and/or wheeze, often accompanied by greater 
volume of sputum and increased cough. Exacerbations greatly contribute to a decline in 
health-related quality of life [1-4]. A main objective of treatment is to reduce the frequency 
and severity of exacerbations. To fully appreciate the effectiveness of treatments, the full 
health-related quality of life gains that result from this reduction should be included. In 
clinical studies this is often not done, because health-related quality of life is measured only 
at regularly scheduled intervals, but not during exacerbations. Specific studies that measure 
quality of life during an exacerbation are necessary.
Health-related quality of life can be estimated with disease-specific or generic instru-
ments. Disease-specific instruments were designed to detect even small changes in the 
patient’s health-related quality of life. However, health economists prefer the use of generic 
instruments, because they enable the comparison of health states as well as the benefits of 
medical interventions across diseases. To express these benefits in terms of quality-adjusted 
life years (QALYs), utility weights are assigned to health states [5]. Perfect health, by defini-
tion, has a utility of 1, while death has a utility of 0. Health states may also be considered 
worse than death and have negative utility. A year spent in perfect health equals one QALY.
Among the most widely used instruments to measure utilities is the European quality of 
life scale (EQ-5D).[6]
The EQ-5D has been validated and applied in the stable phase of COPD [7-11]. In ad-
dition, O’Reilly et al. and Menn et al. applied the instrument in patients with severe exac-
erbations, requiring hospital admission [12,13]. A paper by Paterson et al. contains limited 
information on the use of the EQ-5D at the onset and after treatment of type-1-exacerbations 
(Anthonisen classification) of chronic bronchitis [14].
However, in order to capture the full health-related quality of life loss during an exacer-
bation, the entire course of recovery must be described. In the current chapter, we evaluated 
the ability of the EQ-5D to detect the recovery from a moderate COPD exacerbation, requir-
ing antibiotic or systemic steroid therapy but no hospital admission [15] over six weeks: at 
the onset of the exacerbation, during treatment, and after recovery.
We tested the changes in the EQ-5D utility index scores over time and compared the 
effect sizes to those of several symptom scores, peak flow and the use of rescue medication. 
The change in shortness of breath symptom score as well as medication use were expected 
to be most closely related to the EQ-5D score, since they have the strongest effect on quality 
of life. We also, tentatively, estimated the health loss due to a moderate exacerbation.
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6.2 Methods
The EQ-5D data were collected alongside an exacerbation study that was primarily conduct-
ed to assess the responsiveness of a previously developed cough and sputum assessment 
questionnaire, the CASA-Q [16].
Patients and setting
After institutional review board approval and written informed consent, 65 male and female 
COPD and/or chronic bronchitis patients were enrolled at 7 study sites in the United States. 
They had to be 40 years or older and had to be current or former smokers with a history of 
at least 10 pack-years. Patients were enrolled when they visited the outpatient clinic within 
48 hours of symptom onset. An exacerbation was defined as the increase or new onset of at 
least two lower respiratory symptoms related to COPD, with at least one symptom lasting 
three or more days and requiring a change in treatment. An exacerbation was defined as 
moderate if the change in treatment included the prescription of antibiotics and/or systemic 
steroids. Exacerbations that required hospital admission were considered severe and were 
excluded from this study. Also excluded were patients with significant other diseases which 
could influence the results of the study or the subject’s ability to participate in the study. 
Other exclusion criteria were a history of asthma, cystic fibrosis, bronchiectasis, active 
pneumonia or tuberculosis.
Design
The study was designed as a prospective cohort study. The change in EQ-5D scores over a 
period of 6 weeks was observed. In addition to the visit at enrolment (visit 1), patients were 
evaluated at day 7 (visit 2), day 14 (visit 3) and day 42 (visit 4). The interval between visits 
was allowed to vary by up to 3 days. The patients were treated for their exacerbation at the 
discretion of the investigator according to the standards of care.
Measurements
At each visit participants completed the EQ-5D, in which health status is described by tick-
ing off one of three levels of functioning (“no problems”, “some problems” and “extreme 
problems”) on five dimensions: mobility, selfcare, usual activities, pain/discomfort and 
anxiety/depression. Using a set of weights (value set) for each level of functioning in each 
dimension, the descriptive information can be converted into a single utility index.
Since this study was conducted in the United States, the US value set was used to calcu-
late utilities [17]. Patients were also asked to rate their health on the EQ-5D Visual Analog 
Scale (VAS), which ranges from 0 (worst imaginable health state) to 100 (best imaginable 
health state).
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In the daily diary, patients recorded how short of breath they were, how often they 
coughed and how often they brought up sputum using a 5-point response scale ranging 
from “not at all” to “a lot”, or “never” to “always”. The diary also contained measurements 
of morning peak flow (before taking medication) and use of rescue medication. Pre- and 
post-bronchodilator spirometry was performed at visit 4. Patient’s and Clinician’s Global 
Impression of Change (PGI-C, CGI-C) were measured at visit 4: they rated the change in 
cough and sputum symptoms on a seven-point scale ranging from “very much worse” to 
“very much better”.
Statistical analysis
Changes in the proportions of patients that report either “no problems” or “some 
problems”/“extreme problems” on the EQ-5D between baseline and visit 4 were analysed 
using McNemar’s test. Baseline EQ-5D VAS and utility index was defined as the score at 
either visit 1 or 2, whichever was lower. This baseline value captured the point in time when 
the impact of the exacerbation was most severe.
Mean (standard deviation, SD) scores for EQ-5D VAS and utility index scores were calcu-
lated at all visits and displayed graphically.
Responsiveness was expressed as the Standardised Response Mean (SRM) – defined as 
the average change between EQ-5D index scores at baseline and visit 4 divided by the stan-
dard deviation of that change. SRM of the EQ-5D was compared to the corresponding SRM 
of the various symptom scores derived from the diary items. We used the interpretation of 
Cohen, where 0.2 is indicative of a small effect, 0.5 of a medium and 0.8 of a large effect [18].
Using a change in morning peak expiratory flow (between the first week and the last 
week) above the median as an external criterion to define a greater improvement, we as-
sessed whether EQ-5D scores improved more in those with a greater improvement in peak 
flow than in those with a smaller improvement in peak flow, i.e. whether the SRM of the EQ-
5D index score was greater in those with a greater improvement in peak flow. Similarly, SRM 
for EQ-5D index scores were calculated for the cohort divided into two groups by 1) patient 
global impression of change ((very) much better versus the remaining response options), 
2) clinician global impression of change ((very) much better versus the remaining response 
options), 3) symptom score (change in mean daily symptom score between the first week 
and the last week below and above the median), and 4) rescue medication use (change 
in mean daily number of puffs between the first week and the last week below and above 
median). The standardised difference between the above mentioned pairs was calculated 
as the difference between the mean change from baseline at visit 4 divided by the pooled 
standard deviation of these change scores. Differences in change from baseline in EQ-5D 
index score between the pairs were tested by t-tests.
Repeated measures analysis was performed to analyse the change from baseline to 
visit 3 and 4 in EQ-5D index scores using the SAS procedure PROC MIXED with covariance 
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modelled as “unstructured”. The model included time (visits), EQ-5D score at baseline, age, 
gender, smoking status, lung function at visit 4 (as an approximation of lung function without 
exacerbation), diagnosis (chronic bronchitis/ COPD) and co-morbidity (either the Charlson 
Comorbidity Index score [19] or the number of co-morbidities), as well as the interaction of 
baseline EQ-5D score and time.
For each patient, the QALY loss due to the exacerbation was calculated by subtracting 
the QALYs during the exacerbation from the QALYs the patient would have had if the COPD 
had remained stable during the same period. The latter was approximated by taking the 
highest score at any of the visits. The number of QALYs was calculated by summing the days 
under observation weighted by their utilities (using linear interpolation).
6.3 Results
Patients In total 59 of the 65 subjects completed the study and were included in the analysis 
(see table 6.1). Three patients (hospital admissions (n = 2) and concomitant lung cancer 
(n = 1) proved to be ineligible after being included in the study. Three others discontinued 
their cooperation after the first visit. One patient had one missing value, but his other three 
values were included in the analysis.
Table 6.1 Baseline characteristics.
N 59
Age: mean (SD) 61.1 (10.4)
Female: n (%) 40 (67.8)
Current smoker: n (%) 32 (54.2)
Pack-years: mean (SD) 60.14 (30.12)
Number of co-morbidities: mean (SD) 6.69 (3.34)
Charlson co-morbidity index score: mean (SD) 0.66 (0.921)
Diagnosis COPD: n (%) 54 (91.5)
Diagnosis chronic bronchitis only: n (%) 5 (8.5)
GOLD classification at visit 4a
 Not obstructed: n (%) 19 (33.3)
 Stage 1 (Mild): n (%) 2 (3.5)
 Stage 2 (Moderate): n (%) 14 (24.6)
 Stage 3 (Severe): n (%) 13 (22.8)
 Stage 4 (Very severe): n (%) 9 (15.8)
SD: standard deviation.
a Two patients with missing lung function measurements.
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EQ-5D dimensions
The proportion of patients with “no problems” significantly increased over time on all di-
mensions (figure 6.1). P-values for differences in proportions of patients reporting no, some 
or extreme problems between baseline and visit 4 were 0.008 for the mobility dimension, 
0.007 for self-care, 0.021 for usual activities, 0.012 for pain and 0.006 for anxiety and depres-
sion.
At any visit the majority of patients had problems performing their usual activities and 
felt pain and anxiety. A minority experienced problems when performing selfcare. No prob-
lems on any dimension were reported by 4 respondents (6.8%) at baseline, by 9 respondents 
(15.3%) at visit 3 and by 10 respondents (16.9%) at visit 4.
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Figure 6.1 Proportion of patients reporting no problems (1), some problems (2) or extreme problems (3) on each EQ-5D dimension, by visit.
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EQ-5D VAS scores
For 17% of patients, VAS scores decreased from visit 1 to visit 2. However, most of the mean 
improvement in VAS scores occurred between these measurements. Table 6.2 shows that 
the highest VAS scores were reported for visit 4. The differences between baseline and visits 
3 and 4 were highly significant.
Table 6.2 EQ-5D VAS and utility index scores per visit.
EQ-5D VAS scores
Visit Mean SD Range
Lowesta 34.75 25.244 1-85
 1 36.68 25.244 1-85
 2 48.03 32.787 3-100
 3 48.19 32.336 5-100
 4 50.25 31.840 3-100
 Highestb 55.81 34.190 5-100
EQ-5D VAS, differences in scores between visits
Difference (SD) P-value
Visit 2 - Visit 1 11.356 (20.678) <0.0005
Visit 3 - Visit 2 0.153 (14.539) 0.936
Visit 4 - Visit 3 2.068 (14.027) 0.262
Visit 3 - Lowesta 13.441 (21.477) <0.00002
Visit 4 - Lowestb 15.508 (19.754) <0.000001
EQ-5D utility index score (US tariff)
Visit Mean SD Range
Lowesta 0.651 0.213 0.165-1.00
1 0.683 0.209 0.165-1.00
2 0.726 0.216 0.165-1.00
3 0.768 0.169 0.202-1.00
4 0.760 0.181 0.202-1.00
Highestb 0.828 0.148 0.202-1.00
EQ-5D utility index score, differences in scores between visits
Difference (SD) P-value
Visit 2 - Visit 1 0.0381 (0.1560) 0.068
Visit 3 - Visit 2 0.0413 (0.1523) 0.044
Visit 4 - Visit 3 -0.0073(0.1574) 0.722
Visit 3 - Lowesta 0.1167 (0.1527) <0.0000002
Visit 4 - Lowesta 0.1094 (0.1676) <0.000001
a Lowest = value at visit 1 or 2, whichever is lower.
b Highest = highest value at any visit.
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EQ-5D index scores
There was a highly significant improvement in mean utility index scores (table 6.2). Patients 
improved most between visits 2 and 3. The utility index of 76% of patients improved between 
baseline and visit 3, while it deteriorated in 8.5%. Table 6.2 shows that the mean of each 
patient’s lowest index score was lower than the mean at visit 1, following the fact that qual-
ity of life deteriorated in 25% of patients after treatment had started. Overall, VAS scores 
showed improvement before the utility index scores started to do so. Figure 6.2 presents 
the course of moderate exacerbations over time. The repeated measures analysis showed 
that the improvement of the EQ-5D utility index score at visits 3 and 4 since baseline was 
predicted by its baseline value, the patient’s gender and smoking status (goodness of fit of 
the model: −2 res log likelihood = −135.9). Patients with a higher baseline utility index score 
showed less improvement. Women did not recover as well as men (difference: 0.07242, 
p=0.0121). Current smokers covered a larger distance between baseline and recovery than 
former non-smokers (difference 0.05170 p =0.0602). As before, no significant difference was 
found between visit 3 and 4. Age (p=0.9694), post-bronchodilator FEV
1
 (in % predicted) at 
visit 4 (p=0.268) and co-morbidity (0.6229) were dropped from the final model because they 
were not significantly associated with recovery of utility values.
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Figure 6.2 EQ-5D utility index scores over the course of a moderate exacerbation: mean over all patients, patient with the best improvement 
and patient with the worst deterioration, the most volatile patient.
Health loss
Participants lost on average 0.00896 QALY (SD 0.0086) or 3.27 (SD 3.13) quality-adjusted life 
days during the exacerbation. The largest individual loss was 0.0364 QALY or 13.29 quality-
adjusted life days. Two patients incurred no loss of QALYs compared to the situation with 
stable COPD, because they had the same score throughout the study.
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Responsiveness
A medium to large SRM for the change from baseline in utilities was observed (table 6.3). 
The SRM was comparable for the symptom scores on cough and shortness of breath but 
smaller for sputum, rescue medication use and expiratory peak flow.
Table 6.3 Standardised response mean (SRM): comparison between the EQ-5D, symptoms scores, rescue medication use and morning peak 
expiratory flow.
Mean change SD of change SRM
Utility index score EQ-5Da 0.109 0.168 0.653
Symptom scores
Sputumb 0.196 0.609 0.322
Coughb 0.395 0.673 0.587
Shortness of breathb 0.588 0.207 0.638
Rescue medication 0.708 2.068 0.343
Expiratory peak flowb 14.144 52.673 0.269
a Change between lowest score at visit 1 or 2 and score at visit 4.
b Change between first and last week of study.
The largest standardised difference in EQ-5D utility change was found in the patients 
stratified by their rescue medication use (Figure 6.3). The improvement in EQ-5D utility was 
significantly greater in patients who had a greater reduction in rescue medication use than 
in those who had a smaller reduction in rescue medication use (p=0.018). Significance was 
almost reached for the improvement in EQ-5D utility stratified by improvement of shortness 
of breath (p=0.051) and peak flow (p=0.058).
The standardised differences were negative for participants with a good or very favourable 
patient’s or clinician’s impression of change compared to the rest of the sample. However, 
the differences in change in EQ-5D index scores between these groups were not significant 
(p=0.128 and p=0.657 respectively). Neither were those between groups with improvements 
in cough and sputum scores above and below the median (p=0.144 and p=0.594).
6.4 Discussion
This study has shown that the EQ-5D index score is responsive to recovery from a moderate 
COPD exacerbation. When the exacerbation was at its worst, the average utility score was 
0.651. It increased to 0.768 on day 14, after which it remained largely stable until the final 
visit at 6 weeks. Three-quarters of patients experienced an improvement in health-related 
quality of life after the worst day of the exacerbation. The mean total improvement was 
statistically significant and can be considered medium-sized to large according to Cohen’s 
classification.
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As the EQ-5D improved, so did the VAS and symptom scores, peak flow and rescue medi-
cation use. However, the SRM for the change in EQ-5D index score was generally larger than 
for peak flow, rescue medication and phlegm symptom scores. This was probably caused by 
the index covering more aspects of health-related quality of life.
The responsiveness of the EQ-5D was also demonstrated by greater improvements in 
EQ-5D scores among the patients with a greater reduction in the use of rescue medication, a 
greater improvement in morning peak expiratory flow and a greater improvement in short-
ness of breath symptoms. In contrast, change in EQ-5D scores was not better for patients 
with better scores on the patient’s global impression of change or the clinician’s global 
impression of change.
All five dimensions of the EQ-5D contributed significantly to the mean improvement 
in the EQ-5D index score. The mobility dimension showed the largest improvement. Most 
participants had problems with usual activities and experienced pain and anxiety even at 
the last visit. This may reflect their underlying impairment due to their chronic respiratory 
disease.
The EQ-5D showed a disutility at baseline in almost all patients.
COPD exacerbations are not necessarily at their most severe at the moment when pa-
tients first consult a physician. Indeed, our results showed a considerable proportion of pa-
tients whose EQ-5D scores worsened during the first week. When studying an instruments 
ability to respond to the recovery from an exacerbation, the most informative is the path 
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PGI-C (-0.413)
CGI-C (-0.170)
Sputum (0.140)
Cough (-0.395)
Shortness of breath (0.518)
Expiratory peak flow (0.505)
Rescue medication use (0.645*)
Standardised response mean 
Patients with more improvement Patients with less improvement
Figure 6.3 Standardised response means of EQ-5D utility index scores, by subgroups of patients (with standardised differences between 
subgroups in brackets).
*Difference is statistically significant, t-test p < 0.05.
Black bar: subgroup of patients with more improvement, where more improvement is defined as patients whose global impression of change 
is “(very) much better” or who have a change in mean daily symptom score, mean daily number of puffs of rescue medication, or mean daily 
morning peak flow above the median. Gray bar: subgroup of patients with less improvement (i.e. the remaining patients). The standardised 
difference between subgroups is given between brackets.
Abbreviations: CGI-C, Clinician’s Global Impression of Change; COPD, Chronic Obstructive Pulmonary Disease; EQ-5D, European Quality of Life 
Scale (5 dimensions); PGI-C, Patient’s Global Impression of Change; SD, Standard Deviation; SRM, Standardised Response Mean; QALY, (health-
related) Quality-adjusted Life Year; VAS, (health-related) Visual Analog Scale.
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from the lowest point of the exacerbation, whenever this occurs, to its resolution weeks later. 
This is what we did in our repeated measures analysis and SRM calculations, where baseline 
was defined as the score at either visit 1 or 2, whichever was lower. However, differences 
between visit 1 and visits 3 and 4 were highly significant as well.
In a tentative calculation, it was derived that the average QALY loss during the exac-
erbation was 0.00896, or 3.27 quality-adjusted life days. This calculation is sensitive to the 
estimate of the utility value during the stable phase of the disease. Since we did not have 
actual data on quality of life during the stable phase, we chose to compare the health-related 
quality of life that each patient actually experienced, with the highest individual score dur-
ing the study e as an approximation of the quality of life during stable disease. The results of 
the calculation must be considered a preliminary estimate.
It is possible that patients had not completely recovered at the end of the study to their 
stable health-related quality of life levels, although improvement appeared to reach a pla-
teau after two weeks. Furthermore, an exacerbation may cause permanent damage to the 
patient’s health. This would mean that our estimate of quality of life loss would have been 
too low. To capture the entire loss, patients would have to fill out the EQ-5D questionnaire 
during the stable phase, at times when no exacerbation is expected. Another approach 
would be to collect values for COPD health profiles that contain a description of the severity 
of the COPD during the stable phase and a description of the exacerbation profile, as was 
recently reported by Rutten-van Mölken et al.[20] The deduction in utility value due to a 
non-severe exacerbation in this study was 0.010 (Dutch value set); compared to 0.009 (US 
value set) in the current study.
As expected, the utility scores in our study were much higher than those reported by 
O’Reilly et al. for patients experiencing a severe exacerbation in Britain. At the onset, the 
mean EQ-5D utility value for their group was negative (-0.077, according to the UK tariff) 
and nearly two-thirds of respondents indicated that they felt “worse than death”. [12] At 
discharge the mean utility had improved to 0.576 with only 5% of patients indicating a 
health-related quality of life “worse than death”. However, within the three months after 
discharge quality of life deteriorated markedly again. We did not find indications of a dete-
riorating health after an initial improvement in our study, but our observation period was 
limited to six weeks. Another study in patients with a severe exacerbation was performed 
in Germany by Menn et al., who also concluded that the EQ-5D is suitable for measuring 
health-related quality in this patient group. [13] However, they found much higher utility 
scores than O’Reilly. The authors suggested that patients in Germany might be admitted to 
the hospital relatively early, which would make average inpatient exacerbations milder than 
in the UK. Paterson et al. assessed the difference between utility scores in chronic bronchitis 
patients before and shortly after treatment for a type-1-exacerbation, [14] which could in 
this case apparently be classified as “moderate”. Unfortunately, they did not present utility 
scores during the exacerbation. They did, however, report the change between the start and 
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the end of treatment – as 0.17 according to the UK value set e which is comparable to our 
estimate if it had been based on the same value set.
Respondents completed the CASA-Q instrument [16] before the EQ-5D. Concentrating 
on respiratory symptoms in the CASA-Q might have made respondents more sensitive to 
possible changes on the EQ-5D dimensions, which would increase the responsiveness of the 
latter questionnaire [21,22]. On the other hand, examples have been shown of an effect in 
the opposite direction, by inducing respondents to exclude considerations about respiratory 
problems from their answers to the EQ-5D because the impact of symptoms had already 
been covered by the other questionnaire [22,23]. However, studies on ordering effects in 
generic and specific quality of life questionnaires did not find any significant or relevant 
effects in a number of diseases [24-28]. We did not investigate the presence and magnitude 
of the question order effect.
We had two reasons for not assembling a control group of patients without exacerba-
tions to compare to the patients with exacerbations. Randomisation into groups with and 
without exacerbation was impossible and we could not ensure that the control group would 
be sufficiently comparable. It would have been possible to enrol patients and wait until an 
exacerbation developed. However, this lengthy and costly procedure was not considered 
worthwhile since utility index score values in patients outside of exacerbations are known to 
be stable [8]. Therefore, any significant change in mean utility during the exacerbation can 
be interpreted as a consequence of (the recovery from) the exacerbation.
As a generic instrument for health-related quality of life measurement, the EQ-5D was 
developed for the comparison of quality of life and of the effects of healthcare interventions 
across diseases. We do not recommend its use in routine clinical practice. The EQ-5D was 
not designed for tracking an individual patient’s response to treatment or as a measure on 
which treatment adjustments could be based. Our study does, however, have implications 
for conducting future cost-effectiveness studies. In contrast to current practice these studies 
can and should include the utility gains resulting from a reduction in exacerbations. It has 
been argued that the EQ-5D is not responsive to small changes in health of COPD patients 
[8,9], but our study has shown that it was responsive over a moderate exacerbation.
In conclusion, the EQ-5D was found to be responsive to the recovery from a moderate 
COPD exacerbation. The greatest improvement in utility scores was reached within two 
weeks after the onset of the exacerbation. The EQ-5D was more responsive than expiratory 
peak flow, rescue medication and sputum symptom scores and equally responsive as cough 
and dyspnoea symptoms scores.
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7Collapsibility and censoringWhat’s the bias in estimating time-to-event?
Background Treatment effects in time-to-event analysis are often expressed as hazard 
ratios. Parametric survival models can also be used to estimate projected mean time-to-
event. Two problems in survival analysis are often misunderstood or ignored: non-collaps-
ibility and omitted-variable bias due to non-random censoring. Non-collapsibility exists 
when the treatment effect changes as prognostic covariates are added to the regression 
model, even when confounding is absent (e.g. in a randomised controlled trial (RCT)). 
Earlier studies have sometimes confused these phenomena and misrepresented the prob-
lems that non-collapsibility and censoring can induce. The objectives of this study were to 
disentangle their effects and assess their impact on estimates of mean time-to-event.
Methods Survival, treatment and five normally distributed prognostic covariates were 
simulated in RCT-like datasets with and without censoring. Weibull regression models 
with an increasing number of covariates were used to calculate the hazard ratios and mean 
time-to-event.
Results With uncensored data, hazard ratios decreased as additional covariates were 
included, while time-to-event remained constant. With censored data, time-to-event 
estimates increased sharply and improved as covariates were added.
Conclusion Analysis of synthesized data makes it possible to distinguish between the 
impact of non-collapsibility and censoring. While hazard ratios from Weibull models are 
non-collapsible, mean time-to-event is collapsible. Censoring threatens the validity of 
estimates when prognostic factors are omitted from the regression model.
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7.1 Introduction
In time-to-event (or survival) analyses, the treatment effect is often expressed in a hazard 
ratio, the relative probability of instantly experiencing the event of interest compared to a 
reference group. This hazard ratio is a purely statistical measure and lacks a clear and in-
tuitive interpretation about the size of the actual treatment effect. Fortunately, parametric 
time-to-event models can be used to estimate the mean time-to-event (or life expectancy) 
[1]. Nevertheless, time-to-event analysis has two challenging characteristics: non-collaps-
ibility, which complicates interpretation of hazard ratios, and bias caused by non-random 
censoring. It is important that these concepts be distinguished.
Non-collapsibility refers to a situation where the estimated treatment effect changes when 
prognostic covariates are added to the analysis, even when these covariates are not confound-
ers [2,3]. Because of non-collapsibility, several conditional hazard ratios can be estimated 
for different combinations of covariates in the regression model. As long as confounding has 
been addressed successfully, these may all be correct and yet different from each other [4,5].
Non-collapsibility is not equal to confounding and does not lead to bias. Confounding is 
traditionally defined as a source of bias arising from causes of the outcome of interest that 
are associated with treatment, but not affected by it[6]. Estimates are unconfounded if prog-
nostic variables are jointly balanced across treatment groups, which they are asymptotically 
expected to be after randomisation.
In contrast to non-collapsibility, censoring can lead to bias even when no confounding 
is present. Estimates from time-to-event analysis are only valid if the probability of being 
censored is not associated with the risk of the outcome of interest (e.g. dying) within strata 
of baseline characteristics and treatment [6]. In many medical studies, this assumption of 
independent censoring is not necessarily valid if all surviving patients are censored at the 
end of the trial’s follow-up period. For example, one could imagine patients with a good 
prognosis, e.g. in a less severe disease stage, who are less likely to die before the trial ends. 
Within disease stages, patients receiving the same treatment are equally likely to be cen-
sored, i.e. to survive the trial period. Any analysis that adjusts for disease stage will ensure 
that there is no association between prognosis and probability of censoring. Conversely, if 
this adjustment is not applied, the probability of being censored is associated with the risk of 
dying within each treatment group. In that case, the assumption of independence is violated 
and an omitted-variable bias is introduced.
Several studies in the 1980s and 1990s have shown the potential impact of the combina-
tion of non-collapsibility and censoring on hazard ratios from Cox proportional hazards 
and exponential models [7-12]. However, the distinction between the two issues was often 
somewhat obscured and misinterpreted.
Furthermore, there seems to be only limited recognition of the censoring problem in 
the literature. While important prognostic factors tend to be included in Weibull models 
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on observational data, see for instance [13-15], many examples can be found of studies us-
ing data from randomised controlled trials (RCTs) with treatment as the sole covariate, for 
instance [16-23].
Confounding, non-collapsibility and non-independent censoring may all occur at the 
same time and cause differences in estimates across models. However, this does not neces-
sarily happen in all of the products of an analysis. While it is well known that odds ratios 
are non-collapsible, it does not occur in risk ratios, risk differences and mean predicted 
probabilities, which can all be derived from the same logit model. The collapsibility of pro-
jected mean survival in Weibull models was proven by Lancaster, but he did not consider 
censoring [24].
The objectives of this chapter were to disentangle the effects of non-collapsibility and 
non-dependent censoring variable bias and to assess their impact on the prediction of sur-
vival in Weibull models. We set out to demonstrate the consequences of omitting prognostic 
variables from a model in a dataset with non-random censoring and to investigate the col-
lapsibility of the predicted mean time-to-event.
An example of non-collapsibility
The concept of non-collapsibility has been explained extensively by Greenland et al.[2]. 
This phenomenon may appear in odds ratios, hazard ratios and rate ratios, and possibly 
additional statistical outcome measures. Whether these measures are collapsible depends 
on the value of the treatment effect and sometimes on the statistical model [11].
Non-collapsibility is often shown in the context of odds ratios. An instructive example 
from an imaginary RCT is presented in table 7.1. Here we see that while sex is a prognos-
tic factor, it is not a confounder since sex is not associated with probability of treatment. 
Confounding has been actively avoided, because treatment has been successfully balanced 
across the sexes by means of randomisation. Hauck has suggested calling variables of this 
type ‘mavericks’ [25].
The treatment increases the probability (or ‘risk’) of being cured in both sexes. The risk 
difference is constant across these strata and in the full sample. While the risk ratios are 
different for men and women, the ratio for all patients is simply a weighted average of the 
two sex-specific ratios. In contrast, the odds ratio shows something counterintuitive: it is 
constant across sexes but different from the overall odds ratio. In other words, the average 
treatment effect (or marginal effect) of 2.25 seen in the study population is not the same as 
the average of the treatment effects seen in individuals in the populations (i.e., the condi-
tional effect of 2.67) [26,27].
A mathematical explanation for this is provided by Greenland [2].
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7.2 Methods
An RCT-like dataset was synthesized and analysed using several marginal and conditional 
Weibull time-to-event models. The treatment effect was expressed in hazard ratios and 
mean differences in life expectancy. The results of all models were compared both with each 
other and with the true values (i.e., conditional hazard ratio and marginal mean difference 
in life expectancy). This was repeated after applying censoring on the data at 6 months (or 
183 days).
Synthesis of a dataset
We created 100,000 patients, each with a complete set of five covariates (A, B, C, D and E), 
which were determined independently of each other and randomly chosen from normal 
distributions with mean 100 and standard deviation 10. The chance of receiving treatment 
T was determined randomly in order to isolate the collapsibility and censoring effects from 
any effects of confounding,.
The prognosis of all patients was determined using the following equations for a Weibull 
function.
S
i
(t) = exp(−eXβ * tp) (1)
Xβ = β
0
 + β
1
 * A + β
2
 * B + β
3
 * C + β
4
 * D + β
5
 * E + β
6
 * T (2)
With:
β
0
 = −1
β
1
 = β
2
 = β
3
 = −0.04
β
4
 = β
5
 = 0.04
β
6
 = −1 (corresponding with HR=0.368)
p = 1.3
Table 7.1 Risk differences, risk ratios and odds ratios
Men Women Total
Treated Untreated Treated Untreated Treated Untreated
Cured 80 60 40 20 120 80
Not cured 20 40 60 80 80 120
Total 100 100 100 100 200 200
Risk 0.8 0.6 0.4 0.2 0.6 0.4
Risk differences 0.2 0.2 0.2
Risk ratios 1.33 2 1.5
Odds ratios 2.67 2.67 2.25
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S
i
(t) denotes the individual probability of being alive at time t. Equation (2) contains the co-
variates and their parameters. Covariates A, B and C and treatment T had a positive impact 
on life expectancy, while covariates D and E had a negative impact. The auxiliary parameter 
p – the shape parameter – is larger than one, which means that the hazard increased with 
time.
A complete survival curve was constructed for each patient. The survival time actually 
applied to that patient was established by randomly drawing a value from a uniform distri-
bution (0-1) and determining the associated survival time t
i
 associated with that value.
For simplicity, all patients were assumed to have started in the trial on the same day. 
Censoring was determined to take place after half a year (or 183 days). For patients who died 
before censoring, the censored survival time was equal to the uncensored survival time. For 
others, it was set at 183 days, with a flag indicating that the event had not taken place.
Analysis
We analysed both uncensored and censored data using six different Weibull regression 
models. In each case, the number of covariates (besides treatment) was increased one at a 
time, starting with a model containing no covariates (treatment T only) and ending with a 
model containing both treatment T and all five covariates (A, B, C, D and E). Hazard ratios 
from the different models were compared to illustrate the impact of non-collapsibility. Life 
expectancy was calculated per patient using the following equation:
E(Y) = exp( −1—
p
 Xβ)Γ(1 + 1−
p
) (3)
This was repeated for the situations with and without treatment. The mean life expectancy 
per treatment was the average of the individual life expectancies under that treatment.
7.3. Results
Synthesized outcomes
The mean time-to-event in the synthesized dataset was 257 days with treatment and 118 
days without treatment. The difference in mean time-to-event time between the treatment 
groups was 138 days and the marginal hazard ratio was 0.484. In the censored dataset, 68% of 
the total sample died within the imaginary trial period of 183 days, while 44% of the treated 
and 17% of the untreated patients were censored.
Hazard ratios
The non-collapsibility of the hazard ratio is visible in figure 7.1. Here we can see that the 
ratios decreased as the number of covariates in the regression model increased. In the 
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uncensored data, the hazard ratio was 0.48 when treatment was the sole covariate. The most 
extensive model yielded a hazard ratio of 0.37, which equals the exponent of the coefficient 
(−1) that was used in the synthesizing process.
When the models were estimated using censored data, the hazard ratios were consis-
tently lower, except for the model that contained all covariates. In that model, the hazard 
ratios for censored and uncensored data were equal; the simpler models with fewer covari-
ates overestimated the treatment effect.
Predicted mean time-to-event
Figures 7.2a, 7.2b and 7.2c present the life expectancy (mean projected time-to-event) for 
treated and untreated patients as well as the treatment effect (i.e., the difference in survival 
between the treated and untreated patients). In contrast to the hazard ratios, the results are 
quite stable for the uncensored data. All models led to estimates that were very close to the 
mean uncensored values in the dataset. The estimates for the treatment effect were equal to 
the marginal effect.
The analysis of the censored data led to very different results. The estimated life expec-
tancy increased sharply for both treatment groups when more covariates were added to the 
regression model. It was underestimated when no or too few covariates were included in the 
model. The estimated increase in life expectancy from treatment was correct only when the 
most extensive model was used.
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Figure 7.1 Hazard ratios for models with increasing numbers of covariates.
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7.4 Discussion
The consequences of non-collapsibility and censoring are sometimes counterintuitive and 
often misunderstood. The analysis of the synthesized data in this chapter makes it possible 
to disentangle the impact of non-collapsibility and censoring on hazard ratios and predicted 
survival.
In the uncensored data, the hazard ratio decreased as covariates were added to the 
regression model. More importantly, the estimated hazard ratio equaled the correct ratio 
(i.e., the one used in the synthesizing process) only when all covariates were included. 
The differences in estimates from the different models can be completely ascribed to 
non-collapsibility since there was no confounding (since the baseline characteristics were 
perfectly balanced) and no censoring. In contrast to the hazard ratio results, the predicted 
mean survival and the corresponding treatment effect were stable and therefore collaps-
ible.
If the one step in this study was to illustrate the role of non-collapsibility, another was 
to examine the impact of censoring in isolation. In the censored data, the estimates of the 
mean time-to-event increased – and thereby improved – as more covariates were added to 
the model. Only the fully specified model led to a correct estimate of the marginal treatment 
effect. This cannot be attributed to non-collapsibility, which was shown in the uncensored 
data only to affect hazard ratios. Since confounding can also be ruled out because of the 
balanced baseline characteristics, the differences in predicted survival across models must 
be caused by omitted-variable bias due to censoring. This bias cannot be seen directly in 
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the hazard ratios, but it becomes apparent when they are compared to the hazard ratios 
from the uncensored data. It could also be concluded from the results for projected survival, 
which showed that the model leads to biased estimates.
Paradoxically, the censoring of data led to an overestimate and an underestimate of the 
treatment effects in the models with omitted variables. Hazard ratios for similarly param-
eterized models were lower than those based on uncensored data – thereby overestimating 
the treatment effect – whereas the difference in projected mean time-to-event survival was 
smaller. This apparent inconsistency can be explained by the multiplicative character of 
the Weibull survival model. Life expectancy was underestimated for both treatment groups 
on the uncensored data. Treatment appeared to prolong life by a larger proportion in the 
censored data – as reflected in the lower hazard ratio. However, this proportion applied to a 
shorter period of time – projected mean survival.
The objective of this chapter was to clarify the impact of non-collapsibility and censoring 
on different outcomes of time-to-event models. While these issues have been investigated 
in several studies in recent decades, some confusion remains about their dangers. In the 
1980s some authors warned readers about ‘bias’ from ‘misspecification’ in models [7,10], 
even when the only issue was non-collapsibility of the hazard ratio. As Hernán remarked in 
the context of odds ratios, they saw the difference between marginal and conditional results 
as ‘bias’ even when no bias existed, in the sense that it represents an association between 
treatment and prognostic factors that leads to incorrect estimates [28].
In stark contrast, some papers have been rather sanguine and overlooked the bias in the 
inconsistencies between estimates in the presence of censoring. According to these studies, 
the differences in results only meant that they were answers to different questions, i.e. about 
the hazard ratio given the values of prognostic factors (conditional) versus the average ratio 
over all strata combined (marginal) [11,29].
Most of these studies focused on semi-parametric Cox proportional hazards models. 
Gail et al. and Schmoor et al., who assessed the results of analysis on uncensored and 
independently censored data, separately [7,10]. Both found that the hazard ratios from 
differently specified models were inconsistent and considered this potentially problematic, 
whether the data were censored or not.
Possibly because incomplete follow-up is ubiquitous in trials with time-to-event as an 
outcome measure, three other studies only investigated the consistency of the hazard ratio 
when censoring was present [8,9,12]. Unfortunately, this made it impossible to distinguish 
between the impact of censoring and the impact of non-collapsibility.
Exponential models were studied by Gail et al., Chastang et al. and Ford et al. [7,11,30], 
who found that the hazard ratios were constant across models when the data were uncen-
sored. This observation could be interpreted to mean that non-collapsibility does not play 
a role in exponential time-to-event models. Two of the studies also found, as one might 
expect, that the ratios changed across models when censoring was applied [7,11].
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With regard to Weibull models, Lancaster demonstrated mathematically that hazard 
ratios based on non-censored data are non-collapsible and ascribed this to ‘misspecifica-
tion’ [24]. He also showed that the estimates of mean time-to-event in unconfounded data 
did not depend on the number of covariates in the model. However, censoring was not 
considered in this study.
Like earlier studies, our study is based on datasets containing no confounding. However, 
the conclusions also have a bearing on data from observational studies, where treatment 
assignment does not occur at random. The non-collapsibility of the hazard ratio makes this 
measure unfit for estimating a marginal effect in unbalanced data: only a conditional model 
can address confounding. However, marginal effects can be estimated when mean time-to 
event is used as an outcome measure. When the results of a fitted conditional model are 
used to calculate the difference in mean projected outcome between the treatments for all 
patients, this yieds a marginal treatment effect. Similarly, under the assumption that the 
hazard ratio is constant across subgroups, the conditional model results can be used to 
calculate conditional, stratum-specific treatment effects.
Another argument for including covariates was provided by Lagakos and Schoenfeld, 
who pointed out that inclusion of strongly prognostic factors leads to increased power and 
prevents possible violation of the proportional hazards assumption [31].
In conclusion, non-collapsibility does not have to be a problem in time-to-event models, 
as long as confounding is properly addressed and follow-up is complete or censoring is 
random. Although inconsistent hazard ratios have often been blamed on bias and model 
misspecification, they can also reflect the choice between different specifications of strata 
in which the ratios are applicable. Different models can be simultaneously valid. When 
mean time-to-event is used as the outcome measure, the estimates are consistent across 
models. However, researchers should beware that the use of a parsimonious model will lead 
to biased estimates of the hazard ratio and mean time-to-event when censoring is present. 
This omitted-variable bias can even occur when analyzing RCT data.
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8A propensity to get it rightA Monte Carlo simulation study comparing 
statistical methods to obtain correct cost-
effectiveness estimates in observational studies
Objective Estimates of real-world cost-effectiveness are mostly based on observational 
data with non-random treatment assignments. Several methods exist to address the result-
ing confounding-by-indication, including regression and methods based on propensity 
scores (PS). This study examined the performance of these methods in the context of cost-
effectiveness analysis. The PS-methods were: PS matching (kernel and 1-to-1), covariate 
adjustment using PS, inverse probability-of-treatment weighting (IPTW) and double 
robustness, each with several specifications.
Methods Thirty-eight adjustment approaches were compared using Monte Carlo simula-
tions. In each simulation, four differently confounded samples were drawn from a synthe-
sized population. Incremental survival time and costs were calculated using the results 
of Weibull survival and generalized linear regression. These regressions – with treatment 
as sole covariate or fully specified with all confounders – were performed directly or after 
applying a PS-method. Each approach was assessed on bias (systematic deviation from the 
true effect) and accuracy (proportion of simulated results within acceptable distance from 
the true values).
Results In estimates of the average treatment effect in the treated (ATT), kernel and 1-to-
1 PS matching had similar bias and accuracy results. Regarding average treatment effects 
for the sample as a whole (ATE), double robustness and IPTW had the least bias and the 
best accuracy. Combining PS methods with fully specified regression models was most 
likely to lead to good results. PS covariate adjustment and regression without a PS method 
scored worst.
Conclusions PS methods are preferable to conventional regression for use in observa-
tional cost-effectiveness studies. Combining a PS method with fully specified regression 
should be considered for the analysis. Since no method is always superior, it is advised that 
sensitivity analyses with different techniques be performed.
132 Chapter 8
8.1 Introduction
Randomised controlled trials (RCTs) and cost-effectiveness analyses piggy-backed onto 
RCTs have long been viewed as the gold standard for estimating clinical treatment effects 
and cost-effectiveness of healthcare interventions. However, patients enrolled in clinical 
trials may not be representative of the patients seen in daily practice, to whom the therapy 
will eventually be applied. As an alternative to RCTs, the use of observational data allows 
investigators to estimate the (cost)-effectiveness of treatment in day-to-day practice, which 
should result in evidence that is more relevant to policy makers. Yet this approach has its 
own challenges. A key concern in observational studies is that treatment is not assigned 
randomly. This is likely to lead to systematic differences between treatment groups. In 
epidemiological terms, the association of treatment assignment and prognostic factors is 
known as confounding. If this confounding is not removed, estimates of the treatment are 
biased.
Traditionally, regression methods have been used for this purpose. The estimate of the 
treatment effect is adjusted by taking the effect of additional baseline covariates into account. 
More recently, methods based on PS have become increasingly popular. The propensity 
score (PS) is defined as a patients’ probability of receiving a specific treatment assignment, 
based on certain observed characteristics of that patient. This score, which is usually derived 
from a logit or probit regression model, can be used in several ways to address confounding. 
The most popular PS method is covariate adjustment [1-3][1,3,4], in which the PS replaces 
the original baseline covariates in a regression model.
Other applications of the PS are aimed at removing the association between treatment 
and prognostic factors and to create an RCT-like design. These methods include matching, 
weighting and stratification on the PS. After the PS method has been applied successfully, an 
unbiased treatment effect can be estimated without additional adjustment.
Nevertheless, it has been argued that additional adjustment is useful and that PS meth-
ods should be used as a pre-processing stage before applying an endpoint regression model 
with the original baseline covariates [5,6]. Another approach in which PS and a fully speci-
fied regression model are combined is called double robustness [7].
All PS based methods are aimed at balancing baseline covariates across treatment 
groups. However, they may lead to conceptually different estimates of the treatment effect. 
The first of these effects focuses on the patients who were actually treated, the Average Treat-
ment effect for Treated patients (ATT). This is the difference between the realised outcomes 
and the outcomes if they had not been treated. An ATT can result from PS matching methods, 
which adjust the composition of the control group to make it similar to the treatment group.
The second treatment effect is the Average Treatment Effect (ATE), which represents the 
difference in average outcomes between the hypothetical situations in which all patients are 
treated and in which none are treated. This effect is estimated when covariate adjustment, 
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inverse probability-of-treatment weighting, double robustness or conventional regression 
methods are used.
In a successfully randomised trial, the ATT and ATE are expected to be equal, since 
there should be no baseline differences between the treated and untreated patients. In an 
observational study, in contrast, this may not be the case. The ATT is different from the ATE 
when certain characteristics associated with a better treatment effect occur more frequently 
in one of the treatment groups.
PS methods have mostly been used in epidemiology and medicine, with a focus on 
clinical treatment effects. Most of the literature on the relative performance of different 
PS methods was produced in the same context [1,8,9]. Although examples of the applica-
tion of PS methods also exist in cost-effectiveness analysis [10-18], they are still relatively 
scarce. Two methods, IPTW and double robustness, have not been used in observational 
cost-effectiveness studies. Furthermore, the properties of PS methods in this field have not 
been investigated. More knowledge about the value of these methods in cost-effectiveness 
analyses would be useful given certain important differences between health economic 
studies and effectiveness studies that have consequences for the application of PS methods.
Firstly, health economic studies need different effectiveness measures than the primary 
outcomes found in most effectiveness studies. Cost-effectiveness analysis requires natural 
units of health gain instead of purely statistical measures. If the outcome is dichotomous 
and analysed in a logistic regression model, health economists are interested in the number 
of events, not in the odds ratio, rate ratio or risk difference. In a survival model, the health 
economic outcome of interest is the increase in survival time (e.g. life-years gained) incre-
mental number of day of survival; not the hazard ratio.
Secondly, cost data have different properties than data on clinical effectiveness. They are 
typically skewed and exhibit large individual variation.
Thirdly, health economic studies examine two outcomes simultaneously, incremental 
costs and incremental effects, and combine them into incremental cost-effectiveness ratios 
(ICERs). This intrinsic link between two outcomes may have consequences for the specifica-
tion of adjustment or propensity-score models. Brookhart et al. and Austin et al. investigated 
the optimal specifications of PS models and concluded that a model should contain all 
variables that are prognostic for the outcome of interest, not merely confounders [19,20]. 
They also recommended that variables associated with treatment assignment but not with 
the outcome, should be omitted. However, the optimal model for the effect estimate is not 
necessarily equal to the optimal model for the cost estimate. Nevertheless, one model must 
be used for both outcomes; otherwise costs would be investigated in a different patient 
group than effects.
The objective of the current study was to evaluate the performance of several PS methods 
with varying specifications and conventional regression in the context of cost-effectiveness 
analysis. In order to be able to assess the difference between the estimates and the true 
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treatment effects (ATT and ATE), a source population was synthesized. Incremental ef-
fects, incremental costs and incremental cost-effectiveness ratios were calculated by using 
conventional regression, 1-to-1 PS matching, kernel PS matching, inverse probability-of-
treatment weighting and double robustness.
8.2 Methods
All methods described in this section are summarized in a flowchart (figure 8.1).
Source population with potential outcomes
We performed a simulation study on a synthesized source population of 20,000 patients. 
In order to obtain reality-like data, this source population dataset reflected the variable 
distributions and covariance structures of two Dutch empirical studies on combination 
therapy (from now on: treated) versus sequential therapy (from now on: untreated) in stage-
IV colorectal carcinoma [21].
The synthesizing process was based on the Neyman-Rubin-Holland causal model [22-
24], which assumes the existence of potential (or counterfactual) outcomes for each treat-
ment option for all patients. Only one of these potential outcomes materializes: the one for 
the treatment that is actually received. The other potential outcome remains unobserved, 
or counterfactual. All patients in the synthesized dataset had potential outcomes on health 
(survival time) and healthcare expenditure for both treatment options. Which outcomes 
were to be observable, depended on the treatment assignment.
The ‘true’ individual treatment effect was defined as the difference between the poten-
tial outcomes for each treatment. The ATE was the mean of the individual treatments effects 
in a sample. The ATT was the mean individual treatment effect across patients who were 
assigned to the new treatment.
Synthesis of survival time and healthcare expenditure
A detailed description of the synthesizing process can be found in Appendix A. In short, 
survival time was assigned based on a Weibull survival regression of the empirical trial 
data. The regression results were combined with the synthesized covariates to construct 
individual survival functions per treatment option. Random drawings from a uniform distri-
bution (0-1) determined the point on the curves for each treatment option until which the 
patient survived. Patients who responded relatively well (compared to other patients in this 
treatment group) to the new treatment, also responded relatively well to the conventional 
treatment. The treatment effect was varied across patients by performing drawings from 
a distribution around the treatment coefficient from the regression analysis. For approxi-
mately 10% of patients, the effect was negative.
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Empirical data 
Synthesized source 
population
n = 20,000 
Treatment assignment processes 
Non-random 
Sample 1
n = 2000
Random 
Sample 0
n = 2000
Non-random 
Sample 2
n = 2000
Non-random 
Sample 3
n = 2000
Non-random 
Sample 4
n = 2000
Estimates
ATT
Average effect in treated patients
ATE
Average effect in treated and untreated patients
--> incremental effects
--> incremental costs
--> incremental cost-effecitveness ratio (ICER)
Monte Carlo 
simulations 
1000 repetitions
Performance assessment
Average of 1000  simulations
Bias
Average deviation from the 'true' effect
Accuracy
Proportion of samples with  acceptable results 
Adjustment approaches
 
Statistical methods
Regression             
PSM 1-to-1       
PSM Kernel      
 
PS model
Costs model
Effects model 
 
Endpoint regression
Simple model
Full model 
--> 19 adjusted options
--> 1 unadjusted option
IPTW
Covariate  adjustment
Double robustness
 
Figure 8.1. Flowchart of the method steps .
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A generalized linear model with a power link was fit on the cost data in order to estimate 
a model with which data could be synthesized. Using the coefficients from this model, 
predicted mean costs and gamma distributions around this mean were calculated for each 
patient, from which the individual patient’s costs for each treatment were drawn.
Treatment assignment process
This source population was used to draw samples, in which treatment assignment could be 
associated with certain baseline characteristics. Treatment was assigned in four processes, 
besides randomisation. A detailed description of these processes can be found in Appen-
dix B.
The mean distribution of the baseline characteristics and treatment effects for samples 
resulting from these processes are summarized in table 8.1. The first treatment assignment 
process was based on covariates that were only in the synthesizing model for costs, not for 
effects: older and female patients were less likely to receive the new treatment. The second 
process assigned the new treatment disproportionately to patients with a relatively good 
prognosis and low projected costs. In the third process, the new treatment was assigned 
mostly to patients with an unfavourable prognosis. The fourth process was based on combi-
nation of favourable and unfavourable risk factors.
Table 8.1 Drawing of samples with non-random treatment assignment
Impact on probability
to receive treatment
Non-random treatment assignment process1
1 2 3 4
Covariates with negative impact on survival
Number of metastasis > 1 Positive ● ●
Unresected tumour Positive ● ●
Abnormal LDH2 Positive ● ●
Performance score > 0 Negative ● ●
Abnormal AF3 Negative ● ●
Higher WBC4 Negative ● ●
Covariates associated with higher costs
Higher Age Negative ● ● ●
Female sex Negative ● ●
Female sex Positive ●
1 Sample 0 is not included since this treatment assignment process was random.
2 LDH = Lactate dehydrogenase level in blood
3 AF = Alcalic phosphatase level in blood
4 White blood cell count
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Monte Carlo simulations
For each of the four treatment assignment processes as well as for randomisation, 1000 
samples were drawn from the source population. Each set contained 1000 patients who 
received the new intervention and 1000 patients who were treated according to the conven-
tional treatment.
Statistical methods
Six methods were compared.
(1) Conventional regression. A fully specified Weibull regression model was used to esti-
mate the survival gains. The covariates were the prognostic factors that were used for 
synthesizing survival time. Costs were analysed in a generalized linear model with a 
log link and Gaussian variance function, with days of survival time (linear and squared) 
and the interaction terms of survival time (linear and squared) with treatment, age and 
sex. These covariates were also used for synthesizing costs data.
(2) PSM 1-to-1: PS matching (with replacement and common support requirement). Pro-
pensity scores were calculated by fitting a probit model. The closest matching untreated 
patient was selected for each treated patient, based on the differences between their 
respective PS. Untreated patients could be matched to more than one treated patient. 
Matching only took place for treated patients with common support: those with a PS in 
the range of the scores of the untreated patients. After matching, a Weibull model was 
used to analyse survival while a GLM was used to analyse costs.
(3) PSM kernel: PS matching with kernel smoothing. Each treated patient was matched to 
all untreated patients, but the latter were weighted according to their similarity to the 
particular treated patient. The combined weights of the matches equalled 1. Weighting 
was based on the distance between the PS scores and the Epanechnikov kernel function 
[25,26]. After the matching procedure, analysis was similar to the previous method.
(4) PS covariate adjustment regression analysis. Propensity scores were used as covariates 
in the Weibull model and GLM for survival and costs.
(5) IPTW: inverse probability of treatment weighting. [27,28] Treated patients were weighted 
by the inverse of their PS (the probability of being treated), controls were weighted by 
the inverse of 1 minus the PS (or the propensity of being untreated). After weighting, 
a Weibull model was used to analyse survival while a GLM was used to analyse costs.
(6) Double robustness. This technique combines regression and weighting by the PS in 
one equation [7]. Results should be unbiased if either the regression model or the 
propensity-score model is correct.
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Model specification
All methods using PS (methods 2-6) were based on a model that contained only prognostic 
factors for survival (the effects PS model) or, additionally, covariates that predicted costs 
(the costs PS model).
Furthermore, the Weibull regression models under methods 2 through 5 were either 
fully specified (full endpoint model) or contained only a variable for treatment (simple 
endpoint model, which for PS covariate adjustment also contained the PS). The GLMs con-
tained all covariates from the synthesizing model (full model) or only survival time (linear 
and squared), treatment and their interactions (simple model).
Calculation of incremental effects and costs
The mean survival for each treatment option was calculated as follows. For each patient, the 
expected survival time was projected for each option, based on their baseline covariates, 
according to this equation:
E(Y) = exp( −1—
p
 Xβ)Γ(1 + 1−
p
)
in which p is the shape parameter from the Weibull regression and Xβ denotes the com-
bination of regression coefficients and corresponding baseline characteristics, including 
the treatment. The projected costs were the fitted values of the GLM for costs, based on the 
projected survival.
Also unadjusted results were calculated via the Weibull and GLM models, without taking 
patient characteristics into account.
To calculate ATEs, the average predicted effects and costs over all patients were calcu-
lated for each treatment option. Incremental effects, costs and cost-effectiveness ratios were 
derived from these averages. When calculating the ATT, this process was applied to treated 
patients only.
Assessment of performance
Two criteria were used to assess the performance of each methods and specification: bias 
and accuracy. The bias was defined as the average positive or negative deviation of the 
estimate from the ‘true’ effect. This true effect was calculated for each of the 1000 datasets. 
Degree of bias was expressed as a percentage of the true effect.
Accuracy was defined as the proportion of samples with an effect estimate within an 
acceptable range around the true effect. These ranges were +/− 20% for effectiveness and 
costs, and €5000 for incremental cost-effectiveness ratios.
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8.3 Results
Baseline characteristics and outcomes
Table 8.2 summarizes the distribution of the baseline characteristics and health, costs and 
cost-effectiveness outcomes in the synthesized source population and the mean results 
Table 8.2 Baseline characteristics, health, costs and cost-effectiveness outcomes
Source
population
Treatment assignment process
Random Non-random
0 1 2 3 4
Untreated (U)/ Treated (T) U=T U T U T U T U T U T
Baseline characteristics
Female 38% 38% 38% 46% 30% 31% 47% 38% 38% 41% 35%
Age, mean 61 61 61 66 56 65 55 61 61 66 56
Performance Score > 0 46% 46% 46% 46% 45% 53% 35% 40% 47% 52% 40%
Abnormal AF 63% 63% 63% 59% 67% 69% 54% 51% 66% 64% 62%
WBC, mean 89 89 89 88 91 91 87 85 90 90 89
Number of metastasis > 1 55% 55% 55% 54% 55% 54% 57% 36% 60% 47% 62%
Unresected primary tumour 37% 37% 37% 37% 37% 38% 35% 23% 40% 30% 42%
Abnormal LDH 45% 44% 45% 41% 48% 46% 43% 20% 51% 35% 52%
Health outcomes
Mean survival (days) 531 664 532 664 533 665 498 725 634 634 540 656
Unadjusted incremental effect 133 132 227 0 116
True incremental effect ATT 133 133 133 145 126 131
True incremental effect ATE 133 133 133 134 142 133
Cost outcomes (euros)
Mean total costs 23,016 34,612 23,222 36,111 22,284 36,976 21,973 38,109 25,432 35,337 22,366 36,348
Unadjusted incremental costs 12,889 14,692 16,135 9,905 13,982
True incremental costs ATT 11,596 11,560 11,071 10,186 11,429 10,743
True incremental costs ATE 11,596 11,579 11,604 11,381 11,797 11,648
Cost-effectiveness outcomes (euros)
Unadjusted mean ICER 36,547 41,993 26,119 -1,223,872 46,290
 Lowest value from iterations 22,242 26,495 19,006 -671,860,412 28,610
 Highest value from iterations 70,345 90,013 36,010 19,988,728 171,586
True mean ICER ATT 31,845 31,921 30,525 25,768 33,189 30,044
 Lowest value from iterations 24,822 24,133 19,021 25,802 22,642
 Highest value from iterations 41,583 37,564 32,794 44,496 38,614
True mean ICER ATE 31,845 31,907 31,974 30,983 30,309 32,088
 Lowest value from iterations 27,391 26,546 25,425 24,441 25,593
 Highest value from iterations 36,712 38,418 35,654 35,900 38,075
Abbreviations: AF, alcalic phosphatase level in blood; WBC, white blood cell count; LDH, lactate dehydrogenase level in blood; ATT, average 
treatment effect in the treated patients; ATE, average treatment effect; ICER, incremental cost-effectiveness ratio.
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over all iterations for the random and non-random treatment assignment processes. In the 
source population all patients were, counterfactually, treated twice. Treatment groups were 
not distinguished. This means that there was no difference between ATT and ATE and be-
tween true and unadjusted results. The incremental effect was 133 days and the incremental 
costs were €11,596, which resulted in an ICER of €31,845. As expected, the mean results over 
1000 iterations for treatment assignment process 0 were almost equal to the means in the 
source population.
For treatment assignment process 1, the mean unadjusted estimate of incremental ef-
fects was unbiased, but the costs and ICER were overestimated. For process 2, incremental 
effects and costs were overestimated, while the ICER was underestimated. In the unadjusted 
analysis of treatment assignment process 3, incremental effects nearly disappeared on aver-
age, while costs were underestimated. This led to a very large negative mean ICER, implying 
that the new treatment was dominated. For process 4, incremental effects were underesti-
mated and incremental costs were overestimated. The mean ICER was an overestimation.
Bias and accuracy
The performance of all methods in all treatment assignment processes is summarized in tables 
8.3a to 8.5b. The methods, including their specifications, are ranked for bias and accuracy based 
on their performance over the four non-random treatment assignment processes combined.
Most methods succeeded in removing most of the bias and improving the accuracy in 
effectiveness estimates compared to the unadjusted analyses (see tables 8.3a and 8.3b). 
However, for treatment assignment processes 0 and 1, many adjusted analyses introduced 
or added bias and reduced accuracy of the estimates.
With regard to costs, most adjustments improved the estimates. The same was seen 
in cost-effectiveness results, with the exception of treatment assignment process 2, where 
the unadjusted results were almost unbiased and quite accurate. However, this was due to 
simultaneous biases on the estimates of costs and effects under this treatment assignment 
process, which cancelled each other out in the cost-effectiveness ratio.
The proportion of accurate estimates varied greatly across methods and treatment as-
signment processes: from 37% to 87% for effectiveness, from 14% to 100% for costs and from 
26% to 82% for cost-effectiveness.
Endpoint regression model
Fully specified endpoint regression models generally performed somewhat better than 
simple models in producing unbiased and accurate estimates of effectiveness ATTs, with 
regards to bias as well as accuracy (table 8.3a). The differences were more pronounced in for 
costs and for both ATTs and ATEs estimates of cost-effectiveness (tables 8.4a, 8.5a and 8.5b). 
However, for ATEs of effectiveness there were no clear differences, while, simple models 
generally performed better with regard to bias on ATEs for costs (tables 8.3b and 8.4b).
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Propensity-score model
For the estimation of a difference in effects, no clear difference between both PS models 
was seen (tables 8.3a and 8.3b). For costs and cost-effectiveness, the costs model for the 
PS performed at least as well as the effects model and often better. This was especially the 
case when the application of a PS method was followed by a simple regression (with only 
treatment as a covariate). When fully specified endpoint regression models were applied, 
the specification of the propensity-score model did not play an important role. The findings 
were similar for ATT and ATE.
Statistical method
For the estimation of ATTs of effectiveness, ATT methods and ATE methods achieved similar 
results (see table 8.3a). For ATEs of effectiveness, ATE methods performed better than ATT 
methods (table 8.3b). For costs, ATT methods generally had less bias and more accuracy 
in the estimation of ATTs (table 8.4a), while ATE methods generated better results on ATEs 
(8.4b). The same distinction was seen for cost-effectiveness (tables 8.5a and 8.5b).
Conventional regression achieved the best results in the estimations of differences in 
effects. For costs and cost-effectiveness, all ATE methods performed equally well, except 
for covariate adjustment by the PS, which often led to biased and inaccurate estimates. The 
performance of both of the matching techniques, 1-to-1 and kernel matching was similar.
8.4 Discussion
Main findings
The objective of this study was to evaluate the performance of different propensity-score 
statistical methods and conventional regression in the context of an economic evaluation 
based on observational time-to-event data. Incremental health effects, incremental costs 
and incremental cost-effectiveness ratios in a synthesized dataset were estimated using 
conventional regression, 1-to-1 PS matching, kernel PS matching, inverse probability-of-
treatment weighting and double robustness. These methods were compared in their ability 
to reduce bias and maximise accuracy. Different model specifications were considered: 
costs or effects model for calculating PS, full or simple regression models for calculating 
final outcomes.
Our main findings are as follows. First, no method worked best in all circumstances. The 
optimal choice was not constant for different outcome measures and different treatment 
assignment processes.
Secondly, all methods failed to achieve accurate estimates in a substantial proportion 
of samples, even when treatment assignment was random. It was most pronounced for 
cost-effectiveness ratios. Deviations in either cost or effect estimates are amplified when 
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the incremental cost effectiveness ratio is calculated, especially when they work in different 
directions. However, when they work in the same direction, they can cancel each other out 
somewhat: that is the combination of an overestimated incremental effect with overestimate 
incremental costs may lead to an unexpectedly accurate ICER.
Third, estimates were mostly better when propensity-score methods were followed by a 
fully specified regression adjustment. This was most pronounced for estimating costs and 
cost-effectiveness.
Fourth, propensity-score models containing all covariates that predicted costs (the costs 
PS model), performed at least as good as the models that only contained prognostic factors 
for survival (the effects PS model), if not better. Several authors have argued that models to 
estimate PS should include all covariates that are associated with the outcome – not only 
confounders – while covariates that are not prognostic should be excluded [19,20].
We have seen that these rules may conflict when performing cost-effectiveness analyses. 
Some variables would need to be included in the propensity-score model for cost estimates, 
but excluded from the model for effect estimates. In our example, sex and – to a lesser ex-
tent – age had an impact on cost outcomes, but not on health effects. Our findings do not 
support the recommendation to keep covariates out of the propensity-score model that are 
unrelated to the outcome. They are, however, consistent with Stuart’s advice to `err on the 
side of including more rather than fewer’ [1].
Fifth, this study illustrates the importance of choosing a statistical method that fits with 
the research question. When an average treatment effect in the treated (ATT) is estimated, 
an ATT method should be used, while ATE methods performed best when estimating an av-
erage treatment effect for the full sample (ATE). This was most pronounced when estimating 
costs. It should be noted that when estimating ATT using ATE methods, the ATE estimates 
were applied to the treated population instead of the total population. This could explain the 
relatively small difference in ATT versus ATE as found in the effectiveness estimates.
Sixth, for estimating ATTs, kernel and 1-to-1 matching led to similar results. For ATEs, 
double robustness and IPTW had the best performance. Covariate adjustment achieved 
the lowest rankings. Regression achieved the highest rank in estimating effectiveness but 
performed much worse in estimating costs and cost-effectiveness.
Regression versus PS methods
To further explain differences in PS methods versus conventional regression we want to 
emphasize that apart from the observed differences in performance, these methods also dif-
fer on a conceptual level. Adjustment for confounding can be approached from two angles. 
Defined simply, confounding is the combination of two associations – the association of 
a variable with the outcome (making it a risk factor) and the association of this variable 
with treatment assignment [29]. The problem can be solved by addressing either of these 
associations.
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Regression focuses on modelling the effect of the prognostic factors on the outcome. 
The treatment effect that is estimated by regression is the average effect of treatment over 
all observed values of covariates. Propensity-score methods eliminate the association of 
the confounder with treatment. This leads to some advantages of PS methods compared 
to conventional regression. First, it separates the design of the study from the analysis. The 
researcher can verify whether important covariates are balanced across treatment groups; 
in other words, whether adjustment has been successful. Furthermore, by comparing the 
distributions of the PS and matching treated and untreated patients, it is possible to check 
whether there is sufficient overlap between the treatment groups. This monitoring option is 
to a lesser extent also available in weighting and covariate adjustment by the PS, but not at 
all in conventional regression.
The second advantage of PS methods is in the reduction of the dimensionality problem. 
The possible number of covariates in regression is not limitless. It is restricted by the number 
of subjects or events. A ratio of at least 10 subjects or events per independent variable has 
been mentioned [30]. PS, which provide a scalar summary of the covariate information, do 
not have this limitation. After successful propensity-score adjustment, the only required 
covariate in the final analysis model would be the treatment variable.
A third advantage, which conflicts with the previous point, is that propensity-score meth-
ods can be used for ‘pre-processing’ the data before the final analysis is performed. Rubin 
et al. have argued that the consequences of a misspecified regression model are less severe 
when the covariate structure is more balanced [5,6]. This approach, which does not equal the 
double robustness method, does require that several covariates are included in the model.
Some aspects of using PS methods have not been discussed here. The practicalities have 
been discussed extensively in other papers [1,4].
New aspects of this study
Several aspects of this study are new. Propensity-score methods have mostly been assessed 
on clinical outcomes, much less on costs [31,32] and not on cost-effectiveness. Next to this, 
to our knowledge, our clinical measure, the difference in mean survival, has never been 
the outcome of interest. Martens et al. and Austin tested propensity-score methods in Cox 
proportional hazard models [33], but only assessed the impact of different models on the 
hazard ratio.
Third, our most important criterion for the assessment of the estimates was accuracy, 
which we defined as the proportion of samples with an effect estimate within an acceptable 
range around the true value. Such criterion has never been used before. To a large extent, 
accuracy is quite similar to the mean squared error, which is equal to the sum of the variance 
of the estimator and the square of the bias. Therefore, it represents a quantification of the 
variance-bias trade-off [8]. Accuracy does the same thing. Since high accuracy is achieved 
when bias and variance are comparatively small. However, a relatively higher bias may, in 
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this measure, be compensated for by a relatively small variance. In contrast to the mean-
squared error, the acceptability depends on the arbitrary definition of the acceptable range. 
However, this barely influences the ordering of successful and less successful methods and 
accuracy has the important advantage that it can be interpreted intuitively: the probability 
of getting it right.
Limitations
This study has a number of limitations. A study based on simulation is not the same as a 
study on real data. However, without simulation the ‘real’ effect would not be known and 
bias would not have been quantified. The synthesised data was based on real data from a 
randomised controlled trial and an observational study of chemotherapy in patients with 
colorectal carcinoma. Next to this, an effort was made to prevent an artificially good fit of the 
propensity-score models by using the same model in synthesizing as well as analysing the 
data. Instead, we chose the – rarely used – complementary log–log model for treatment as-
signment in the synthesizing process, while probit models were applied to estimate the PS.
Another limitation is that we did not apply censoring in our synthesized data. Although 
many real life datasets do contain censored data, this choice helped to isolate the effects of 
the other model specifications.
We also assumed that there was no unmeasured confounding. When treatments are 
assigned to patients, something like the intuition of the treating physician may play a role. 
This cannot be explicitly expressed in a variable for which adjustment can take place. On 
the other hand, if balance is achieved on the major predictors of the outcome, this may not 
always be a problem. However, it cannot be ruled out that the physician somehow has more 
information than the data show. If this information is associated with measured covariates, 
adjustment approaches that use many adjustment variables may perform better than others.
This study compared only two matching methods, 1-to-1 matching with replacement 
and kernel matching. Although both are considered good methods [1], others also exist. 
Baser compared more matching methods for estimating cost differences and found the 
choice may have a substantial effect on the estimated treatment effect [31]. In that case, 
kernel matching performed well when it was combined with regression. Without the added 
regression, Mahalanobis matching had the best results
Lastly, the performance results of the methods and specifications examined in this study 
should be seen as a minimum estimate. When they are used on real data, it is possible to 
assess covariate balance applying a propensity-score method. If necessary, the propensity-
score model can be adjusted to achieve better balance. That was not possible in our Monte 
Carlo simulations.
In this chapter we did not examine the reliability under the different methods. In the 
next chapter, we assess this uncertainty by expressing it in confidence intervals and cost-
effectiveness confidence ellipses.
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Recommendations
Based on the current study, certain suggestions can be made regarding cost-effectiveness 
analysis using observational time-to-event data. The researcher should explicitly choose to 
estimate an ATT or an ATE. If an ATT is required, matching methods are candidates. If the 
outcome of interest is an ATE, inverse probability weighting and double robustness are most 
likely to lead to acceptable results.
It is important that the same statistical method is applied to the estimation of both cost 
and effects. This prevents the estimates from being based on different samples of patients. 
The adjustment model should contain all baseline variables with an impact on costs or ef-
fects. After the application of a PS method, the ‘pre-processed’ data is best analysed in a fully 
specified regression model, including all baseline variables.
Since no method and specification has been shown to lead to the best results in all 
circumstances, it is recommended that several methods are applied and compared in 
sensitivity analyses. If they lead to similar results, this would strengthen confidence in the 
conclusions, since they are not sensitive to the choice of the statistical method. Presenting 
inconsistent results of different methods makes this structural uncertainty transparent.
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8.6 Appendix A
Synthesis of survival time
As a first step, a Weibull survival analysis was conducted in the empirical dataset to analyse 
the effect of treatment and other covariates on survival. Next, a source population of 20,000 
patients was synthesized with covariates that preserved the covariance structure of the 
original data. The covariates were those with a statistically significant effect on survival in 
the Weibull survival model (age>70 years, performance score, elevation of levels of alkalic 
phosphatase (AF), white blood cell count (WBC) and lactate dehydrogenase (LDH), resec-
tion of the primary tumour, number of involved metastatic sites) plus two additional ones 
(gender and age).
These synthesized covariates and the Weibull regression results were then combined to 
construct individual survival functions per treatment option, in which time t is related to the 
probability of survival, S(t). Random drawings from a uniform distribution (0-1) determined 
the point on S(t) (i.e., the y-axis of the survival curve) until which the patient would survive, 
which corresponded to a time t (the point on the x-axis).
For each individual, one drawing for S(t) was performed, which was used for both 
treatment arms. Patients who responded relatively well (compared to other patients in this 
treatment group) to combination treatment C, also responded relatively well to sequential 
treatment.
Instead of a fixed treatment effect, individual variation was introduced by performing 
random draws from Gaussian distributions of the confidence interval around the estimated 
treatment effect as well as the coefficients for the other covariates. The distribution for the 
treatment effect was broadened to achieve that the treatment effect would be negative in 
approximately 10% of patients. In order to retain the mean and covariance structure of the 
original data and the regression coefficients, the random draws were combined with the 
Cholesky decomposition of the variance-covariance matrix from the Weibull model.
As a consequence, survival times under both treatments depended on two elements of 
change, drawings for S(t) and for the treatment effect, which was reflected in the coefficients 
for other covariates as well.
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Synthesizing costs
A generalized linear model was fit on the cost data in order to estimate a model with which 
data could be synthesized. The best fitting model contained a power link (power=1.29) and 
a Poisson variance function. The covariates included in the final model were survival days, 
square of survival days, plus the interactions of these two variables with treatment, age, and 
sex.
Using the coefficients from this model, predicted mean costs were estimated for each 
synthesized patient for each treatment arm, as well as a standard deviation. In order to in-
troduce individual variation in individual costs, the predicted mean and standard deviation 
were used to describe gamma distributions per patient and per treatment arm, from which 
the individual patient’s costs for each treatment were drawn.
8.7 Appendix B
Treatment assignment process
The process of drawing samples with random or non-random treatment assignment con-
sisted of three steps.
This process consisted of three steps. First, a complementary log-log model equation was 
specified in order to project patient-specific probabilities of receiving the new treatment for 
all patients in the source population, based on their baseline characteristics. In the second 
step, these probabilities were applied in Bernoulli distributions, from which the treatment 
assignment was drawn for each patient. Thirdly, 1000 patients from each treatment were 
drawn from each treatment group into the sample.
The process was repeated for five combinations of parameters. In the random treatment 
assignment process, all coefficients in the complementary log-log model were set at 0, which 
lead to a 50% of receiving new treatment for all synthesized patients. In the first non-random 
treatment assignment process (see table 8.1), older and female patients were less likely to 
receive combination treatment. The second process made treatment more likely to be as-
signed to younger, female patients with a good performance score and normal values for 
AF and WBC. Under the third process, the probability of receiving combination treatment 
was positively related to having an abnormal LDH, an unresected tumour and more than 
one metastatic site. The fourth process contained the variables from the third process plus 
gender, age, elevated AF and elevated WBC.
Lucas M.A. Goossens, Chantal W.M. van Gils, Maiwenn J. Al., 
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9A propensity to be preciseA Monte Carlo simulation study comparing 
statistical methods to obtain reliable 
cost-effectiveness estimates in observational studies
Objective Estimates of real-world cost-effectiveness are mostly based on observational 
data with non-random treatment assignments. Several methods exist to address the result-
ing confounding-by-indication, including regression and methods based on propensity 
scores (PS). This study examined the precision of the estimates from these methods in the 
context of cost-effectiveness analysis. The PS-methods were: PS matching (kernel and 1-to-
1), covariate adjustment using PS, inverse probability-of-treatment weighting (IPTW) and 
double robustness, each with several specifications.
Methods A simulated source population was used to draw ten samples (n=400 or n=2000) 
in which patients were randomly or non-randomly assigned to a new or conventional 
treatment. Mean incremental costs and effects and the incremental cost-effectiveness 
ratios were calculated using each method. A bootstrapping procedure was used to express 
the uncertainty around the estimates. The precision of each method in each sample was 
quantified by 95% confidence intervals and by the area of the confidence ellipse on the 
cost-effectiveness plane.
Results In estimates of the average treatment effect in the treated (ATT) PS kernel match-
ing led to more precise estimates than PS 1-1 matching. Regarding average treatment 
effects for the sample as a whole (ATE) conventional regression performed best, while PS 
covariate adjustment led to the least precise estimates.
Conclusions For the ATT, kernel matching is an attractive option. There appears to be no 
good reason to use PS covariate adjustment.
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9.1 Introduction
The precision of estimates is an important issue in cost-effectiveness analysis. Especially 
when the point estimate of the incremental cost-effectiveness ratio (ICER) is close to a deci-
sion maker’s willingness to pay, a large amount of uncertainty increases the risk of a wrong 
decision [1,2].
When the estimated ICER is considered acceptable, a new technology could be adopted 
when its true (unobserved) cost-effectiveness is insufficient. Alternatively, the new inter-
vention could be rejected while it would actually be cost-effective.
The precision of an estimate depends on the sample size and the variation across 
subjects, but is also affected by the statistical methods that are used in the analysis. The 
inclusion of prognostic factors in the analysis of randomised controlled trials, when these 
factors are asymptotically balances across treatment groups [3,4]. This has been shown to 
enhance the statistical power and precision of the estimates [5]. According to Senn, ignoring 
balanced prognostic factors in the analysis is ‘a grave mistake’ [6].
In observational studies, making this mistake is not even an option. Prognostic factors 
have to be included in the analysis to adjust for possible systematic differences between treat-
ment groups, which would lead to confounding bias. In addition to conventional regression 
methods, a new class of methods is gaining popularity in this context. These are based on 
estimated propensity scores (PS), which are defined as a patient’s probability of receiving a 
specific treatment assignment, given certain observed characteristics. Possible applications 
of the PS include stratification on the PS, matching on the PS, the use of PS to replace original 
baseline covariates in a regression model (PS covariate adjustment), weighting on the PS 
(IPTW) and double robustness (DR). These can be applied with different model specifications.
The ability of these methods to successfully address bias has been investigated ex-
tensively in recent years [7-10]. In the previous chapter, we evaluated the performance of 
several PS methods with varying specifications and conventional regression in the context 
of cost-effectiveness analysis.
However, those studies did not cover the precision of the estimates. Although it has been 
shown that conventional regression leads to more precise estimates propensity scores meth-
ods in general [11], no comparison between different PS methods is available. A criterion in 
many comparative studies on PS methods was the mean squared error (MSE), which was 
presented as combined measure of bias and precision [9,12]. It was calculated as the mean 
squared difference between the real treatment effect and the model estimate over a large 
number of simulations. Although MSE is a very useful measure – it could be interpreted 
as the expected squared ‘incorrectness’ of the estimates – it only captures precision within 
the sample. In contrast, the term precision is generally used to describe the relationship 
between the estimate on a sample and the treatment effect in the population from which 
the sample was taken [13]: if the estimate is more precise, there is less uncertainty about the 
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value in the population. This interpretation of the term is used in confidence intervals, and 
in cost-effectiveness analysis, cost-effectiveness planes and acceptability curves.
This current chapter builds on the findings in the previous chapter on propensity 
score methods in cost-effectiveness studies. Its objective was to examine the precision of 
cost-effectiveness estimates from different PS-based statistical methods and conventional 
regression in non-randomised data.
9.2 Methods
The methods can be divided in following steps: 1) synthesizing source population, 2) draw-
ing ten samples, 3) analyzing samples with PS-based methods and conventional regression, 
4) assess precision of estimates.
Synthesis of source population
We performed a simulation study on a synthesized source population of 20,000 patients. The 
synthesizing process has been described in detail in the previous chapter. In short, the varia-
tion in characteristics found in the source population reflected the distributions and covari-
ance structures of two Dutch empirical studies comparing a new treatment in metastatic 
colorectal cancer to the conventional one [14]. The synthesized dataset contained values 
for baseline characteristics and potential outcomes in terms of health (survival time) and 
healthcare expenditures for both treatment options.
This source population was used to draw samples in which patients were assigned to 
the new or the conventional treatment in a random or non-random fashion. Five different 
treatment assignment processes were used (0, 1, 2, 3, 4) in sample sizes of n = 400 and n = 
2000, which resulted in a total of ten samples. In process 0 the new treatment was randomly 
assigned. In contrast, the treatment assignment in processes 1-4 was associated with certain 
baseline characteristics. The first treatment assignment process assigned the new treatment 
disproportionally to patients with higher projected cost. The second process assigned the 
new treatment disproportionately to patients with a relatively good prognosis and low pro-
jected costs. In the third process, the new treatment was assigned mostly to patients with an 
unfavourable prognosis. The fourth process was based on combination of favourable and 
unfavourable risk factors.
Drawing ten samples
The sample drawing process described above was repeated ten times, resulting in a total 
of 100 preliminary samples. Ten final samples, one for each treatment assignment process 
and sample size were selected from the preliminary samples. This selection was based on 
the accuracy of the point estimates for the ICER from all methods in this particular case: the 
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sample for which the estimates were the most accurate was selected. The previous chap-
ter has shown that all methods had a risk of misestimating the treatment effect in certain 
samples. The selection was made in order to isolate the issue of precision from validity and 
to make the precision estimates from different methods more comparable. In nearly all 
cases, the point estimates of the ICER for all methods in the selected samples were within 
5000 euros of the true value.
Analysis of samples with PS-based methods and conventional regression
Six methods were compared.
(1) Conventional regression. A fully specified Weibull regression model was used to esti-
mate the survival gains. The covariates were the prognostic factors that were used for 
synthesizing survival time. Costs were analysed in a generalized linear model with a log 
link and Gaussian variance function, with days of survival time (linear and squared) and 
the interaction terms of survival time (linear and squared) with treatment, age and sex.
(2) PSM 1-to-1: PS matching (with replacement and common support requirement). 
Propensity scores were calculated by fitting a probit model. The closest matching 
untreated patient was selected for each treated patient, based on their PS. Untreated 
patients could be matched to more than one treated patient. Matching only took place 
for treated patients with common support: those with a PS in the range of the scores of 
the untreated patients. After matching, a Weibull model was used to analyse survival 
while a GLM was used to analyse costs.
(3) PSM kernel: PS matching with kernel smoothing. Treated patients with common sup-
port were matched to all untreated patients, but the latter were weighted according to 
the distance between their PS and the treated patients’ in such a way that the combined 
weights equalled 1 [15]. The Epanechnikov kernel was used as a weighting function. 
After the matching procedure, analysis was similar to the previous method [16].
(4) PS covariate adjustment regression analysis. Propensity scores were used as covariates 
in the Weibull model and GLM for survival and costs.
(5) IPTW: inverse probability of treatment weighting. [17,18] Treated patients were weighted 
by the inverse of their PS (the probability of being treated), controls were weighted by 
the inverse of 1 minus the PS (or the propensity of being untreated). After weighting, 
a Weibull model was used to analyse survival while a GLM was used to analyse costs.
(6) Double robustness. This technique combines regression and weighting by the PS in 
one equation [19]. Results should be unbiased if either the regression model or the 
propensity-score model is correct.
Model specification
Propensity scores were based on a model that contained all prognostic factors for survival 
and the covariates that predicted costs. The Weibull regression models under methods 2 
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through 5 were either fully specified (full endpoint model) or contained only a variable for 
treatment (simple endpoint model, which for PS covariate adjustment also contained the 
PS). The GLMs contained all covariates from the synthesizing model (full model) or only 
survival time (linear and squared), treatment and their interactions (simple model).
Estimation of incremental costs and effects
For each patient, the expected survival time was projected for each treatment option, based 
on their baseline covariates and the Weibull regression results. The projected costs were the 
fitted values of the GLM for costs, based on the projected survival. The ATE was the mean of 
treatment effects (the differences between the two individual potential treatment outcomes) 
in the sample. The ATT was the mean individual treatment effect across patients who were 
assigned to the new treatment.
Assessment of precision
The assessment of the precision of the estimates was based on a bootstrapping procedure 
with 5000 replications. In a bootstrapping procedure, a large number of random samples 
with replacement is taken from the original sample, with a size equal to the original size. 
[20,21]. For each bootstrap sample, incremental costs and effects were calculated. The 
pairs of incremental costs and effects for all samples can be presented graphically in a 
cost-effectiveness plane. If the results have a bivariate normal distribution, the scatter plot 
is shaped as an ellipse.
The precision of each combination of method and sample size was quantified in two 
ways. First, 95% confidence intervals for incremental costs and effects were determined 
using the percentile method: the 2.5% highest and the 2.5% lowest ICER estimated were 
excluded from the intervals. However, these intervals can only be interpreted when all boot-
strap effect estimates are positive (or all are negative); in other words, if the scatter plot does 
not straddle the y-axis. Otherwise, a negative ICER could be very favourable (when health 
benefits are combined with cost savings) or unfavourable (health losses and cost increases). 
Alternatively, a positive ICER could be the result from a treatment benefit and cost increase 
(in which case a lower ICER is preferred) or from health loss and costs savings (in which case 
a higher ICER is preferred).
The width of the confidence intervals was calculated for incremental costs and effects 
and – if the interval was interpretable – for cost-effectiveness. Larger confidence intervals 
represented less precision.
The second measure of precision was the area of the 95% confidence ellipses, which 
could only be calculated when the scatter plot was ellipse-shaped. The area of an ellipse is 
given by this equation:
Area = πab (1)
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where a= the semi-major axis, i.e. half of the longest diameter of the ellipse and b = the semi-
major axis, i.e. half of the shortest diameter. The major axis is orthogonal to the minor axis.
The ellipse parameters are given by
a xy
yxx
=
2
y
+
4
xy
x yx y
b =
2
−
4
where σ
x
2 and σ
y
2 are the variances of the bootstrap estimates of incremental costs and effects 
and σ
xy
 as the covariance of incremental costs and effects. The factor γ adjusts the ellipse to 
the desired level of confidence. It is based on the χ2-distribution with 2 degrees of freedom. 
For a 95% confidence ellipse:
γ = χ2(2, 0.05) ≈ 5.99
9.3 Results
The widths of the confidence intervals and the areas of the confidence ellipses are sum-
marized in table 9.1. They could be calculated for all samples with n=2000. Twelve out of the 
50 intervals, most of them for sample 4, were not interpretable because they included both 
negative and positive estimates of the incremental effects. One area could not be calculated 
because the scatter plot was not ellipse-shaped.
The widths and areas for the samples with 400 patients were larger than those for the cor-
responding method and samples of 2000 patients. This means that larger samples produced 
more precise estimates, which was to be expected. It is illustrated by the confidence ellipses 
for IPTW and PSM kernel, both with full endpoint models from sample 2, in figure 9.1.
The centres of the ellipses, which represent the mean of the estimates for incremental costs 
and effects, did not overlap perfectly. This is due to the fact that different methods lead to 
different estimates. Furthermore, although the samples were taken from the same source 
population, they were drawn separately. Samples with n = 400 were not nested in samples 
with n = 2000. Nevertheless, the differences in shape and size of the ellipses are apparent.
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Simple versus full endpoint models
In all cases, the confidence ellipse areas for methods with fully specified endpoint models 
were smaller than those for methods with simple endpoint models. The results for the 
widths of most all confidence intervals were consistent with this observation. An illustration 
is presented in figure 9.2 for IPTW and PSM kernel in sample 2 with n=400. The ellipses for 
the fully specified endpoint models are inside the ellipses of for the simple models.
Table 9.1 ICER confidence interval widths and ellipse areas
Interval widtha Ellipse areab
Treatment assignment process Treatment assignment process
0 1 2 3 4 0 1 2 3 4
N = 400
ATT methods
PSM 1-to-1 Simple 121 73 -c 180 -c 37 55 68 55 71
PSM 1-to-1 Full 106 33 90 48 -c 25 40 49 34 34
PSM kernel Simple 53 48 74 78 -c 21 36 47 32 41
PSM kernel Full 79 27 90 38 -c 15 27 32 23 21
ATE methods
Regression Full 85 25 36 41 108 15 19 19 26 15
Covariate adjustment Simple 118 69 -c 134 -c 34 46 47 64 47
Covariate adjustment Full 107 30 85 65 -c 26 37 43 -d 30
IPTW Simple 47 76 53 95 -c 21 33 39 38 34
IPTW Full 69 68 61 59 -c 15 29 23 27 21
Double robustness Full 49 -c 38 69 -c 13 41 31 20 27
N = 2000
ATT methods
PSM 1-to-1 Simple 43 61 24 42 35 8 12 12 9 14
PSM 1-to-1 Full 27 28 16 31 19 5 8 8 8 7
PSM kernel Simple 22 32 17 25 23 4 7 8 4 8
PSM kernel Full 18 22 13 22 15 3 5 5 4 5
ATE methods
Regression Full 19 18 15 19 17 3 5 5 4 4
Covariate adjustment Simple 41 52 23 44 34 6 10 9 10 13
Covariate adjustment Full 25 29 16 30 19 5 8 7 7 7
IPTW Simple 22 32 22 24 24 4 9 7 5 7
IPTW Full 19 30 16 19 17 3 8 5 4 5
Double robustness Full 19 23 20 18 19 3 7 4 3 5
a Widths were divided by 103 for clarity of presentation. b Areas were divided by 105 for clarity of presentation. c Interval could not be interpreted. 
d Scatter plot was not ellipse shaped.
Abbreviations:  ICER, incremental cost-effectiveness ratio; ATT, average treatment effect in the treated patients; ATE, average treatment effect;  
IPTW, inverse probability-of-treatment weighting; PSM, propensity score matching.
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ATT methods compared
The PSM kernel method consistently led to smaller ellipse areas and interval widths than the 
PSM 1-to-1 method. Figure 9.3 illustrates this by showing the ellipses for both methods with 
fully specified endpoint models in sample 2 with n=400.
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Figure 9.1 95% Confidence ellipses on the CE-plane: 400 versus 2000 (sample2).
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Figure 9.2 95% Confidence ellipses on the CE-plane: full versus simple model (sample 2, n = 400).
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ATE methods compared
The differences between the ATE methods were less clear than those for the ATT methods. 
Figure 9.4 shows the ellipses for conventional regression, double robustness covariate ad-
justment (with full model), IPTW (with full endpoint model) for sample 2 with n=400.
When only the methods with fully specified endpoint models were compared, the in-
tervals for covariate adjustment were consistently wider than for the other models in the 
samples with n=400. The intervals for conventional regression were relatively small. These 
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Figure 9.3 95% Confidence ellipses on the CE-plane: ATT methods compared (sample 2, n = 400).
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Figure 9.4 95% Confidence ellipses on the CE-plane: ATE methods compared (sample 2, n = 400).
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trends were less obvious in the larger samples. With regards to the ellipse areas, however, 
regression had the best performance in most cases, while covariate adjustment performed 
worst.
9.4 Discussion
This study examined the precision of the cost-effectiveness estimates from several propensi-
ty-score based adjustment methods and conventional regression.
The relevance of this study lies in the increasing interest in observational studies to 
assess the impact of medical treatments on health, cost and cost-effectiveness outcomes. 
While randomised controlled trials (RCTs) and economic evaluations piggy-backed onto 
RCTs have long been viewed as the gold standard for estimating these outcomes, interest 
nowadays also focuses on estimating cost-effectiveness in ‘real-world’ settings, outside 
the tightly controlled confines of an RCT. In observational studies, propensity-score-based 
methods can be useful tools for addressing confounding bias, especially when an ATT is 
required.
The following are our main findings. Firstly, in very large samples (n=2000) the differ-
ences in precision were small and did not consistently favour one method over another. In 
contrast, when the sample size was smaller (n=400), the difference between methods and 
specifications were substantial.
Secondly, in estimates of the average treatment effect in the treated (ATT), kernel 
matching led to more precision than 1-to-1 matching without replacement. This could be 
explained by the fact that, under kernel matching, each treated subject is always matched 
to a great number of controls. This reduces the impact of the presence of each individual 
control patient in the matched sample.
Thirdly, regarding average treatment effects for the sample as a whole (ATE), covariate 
adjustment with the PS had the worst precision, and conventional regression led to the most 
precise estimates. This was most pronounced in the smaller samples. The other methods, 
double robustness and IPTW had a moderate precision.
Fourthly, including covariates in the endpoint model resulted in more precision than 
simple models. This confirms earlier findings that for reasons of efficiency, it is preferable to 
model the health outcome instead of treatment assignment [11].
Some authors have advocated the pre-processing approach in order to enhance the like-
lihood of achieving an estimate that is close to the true treatment effect [22]. This means that 
in the pre-processing stage, a propensity-score matching or weighting method is applied 
in order to achieve balance in the covariates across treatment groups. Next, a full endpoint 
regression is applied to the pre-processed data. With an eye to obtaining an unbiased point 
estimate, this approach is attractive because it offers two opportunities to solve the problem 
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of confounding. If covariate balance is not fully achieved in the first step of the process, this 
can be repaired by the endpoint model. Or, from the opposite perspective, if the endpoint 
model is not completely correct, this is less of a problem when the covariates have been 
balanced to a reasonable extent.
Our study adds an argument in favour of the pre-processing approach, at least compared 
to simple endpoint models after a PS-based method. Adjusting for prognostic covariates in 
the endpoint model does not only improve validity, but also the precision of the estimates. 
It must be noted, however, that applying an outcome regression model without weighting 
or matching on the propensity score still led to more precise estimates than pre-processing.
We used two measures to evaluate the precision of estimates: the width of the 95% con-
fidence intervals for the ICER and the area of the 95%-confidence ellipse on the CE plane.
When the ICER is the sole interest of the study, the width of the confidence interval 
appears the most obvious choice. A smaller interval means that the estimate is relatively 
precise. However, this does not necessarily mean that incremental costs and effects have 
been estimated precisely. If costs and effects are strongly and positively correlated, a much 
larger amount of uncertainty surrounding these outcomes may coincide with precision on 
the ICER. Furthermore, the interval is only interpretable when the bootstrap results do not 
straddle the x-axis of the CE plane.
The area of 95% confidence, in contrast, can always be interpreted. However, the area 
can only be calculated when the bootstrap replications on the plane are shaped in an ellipse. 
The area reflects the combined uncertainty on incremental costs and effects. This does not 
automatically comprise uncertainty on the ICER. When costs and effects are strongly and 
negatively correlated, the area is small, while the uncertainty on the ICER may be large.
However, the discrepancies between the two evaluation measures of precision may only 
occur in extreme circumstances. That is why, in our study, they led to the same conclusions, 
although costs and effects were correlated positively and substantially. Both are closely 
linked to the tools that are typically used to assess the uncertainty around the ICER estimate 
in economic evaluations: CE planes and acceptability curves [23]. Nevertheless, the ellipse 
and the interval are conceptually different.
This study has a number of limitations. First, a study based on simulation is not the same 
as a study on real data. However, without simulation the ‘real’ effect would not be known 
and we would not have been able to select samples that gave a relatively unbiased ICER 
results. In addition, eliminating bias gave us the opportunity to examine precision sepa-
rately from validity. We paid great attention to ensure that the synthesised dataset reflected 
real-life uncertainty. The data were based on real data from a randomised controlled trial 
and an observational study of chemotherapy in patients with colorectal carcinoma. Next to 
this, an effort was made to avoid overestimating the performance of the propensity-score 
models that would have arisen if we had used the same model in synthesizing as well as 
analysing the data. Instead, we chose the – rarely used – complementary log–log model 
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for treatment assignment in the synthesizing process, while probit models were applied to 
estimate the PS.
Another limitation is that we did not apply censoring in our synthesized data. Although 
many real life datasets do contain censored data, this choice helped to isolate the effects of 
the other model specifications.
We also assumed that there was no unmeasured confounding. When treatments are as-
signed to patients, something like the intuition of the treating physician may play a role. This 
cannot be explicitly expressed in a variable for which adjustment can take place and could 
cause bias that no regression or PS adjustment method can adjust for, nor is this taken into 
account when estimating the uncertainty surrounding the ICER results. It is expected that 
not taking unmeasured confounding into account led to an underestimation of this uncer-
tainty, but this is not expected to alter our findings would alter since none of the adjustment 
methods can take the unobserved confounding into account.
McCandless et al. proposed to perform additional sensitivity analysis to more adequately 
reflect the uncertainty by taking potential unmeasured confounding into account [24]. It is 
advised to perform such additional uncertainty analysis when using observational data.
The conclusions of this chapter can be combined and compared with those of the earlier 
study, which focussed on the validity of the estimates of incremental cost-effectiveness from 
several adjustment methods, in order to convey several recommendations
In previous chapter, we found no difference between the performance of 1-to-1 match-
ing with replacement and kernel matching with regards to the validity of ATT estimates. 
However, kernel matching led to more precision in the current study, which makes it a more 
attractive option.
For ATE estimates, both studies concluded that PS-as-covariate adjustment was likely 
to lead to suboptimal results. The method had a relatively high risk of incorrect estimates, 
while the uncertainty was large. There appears to be no good reason to apply this approach, 
although it is the most frequently used PS method [25].
Conventional regression performed moderately with regards to validity, but left relatively 
little uncertainty. A disadvantage of this method is that it requires a correct specification of 
the regression model. Double robustness and inverse probability-of-treatment weighting 
(IPTW) led to somewhat more valid estimates, but at the cost loss of precision. For PS-based 
ATT as well as ATT methods, the pre-processing approach could considerably reduce uncer-
tainty while improving accuracy.
Nevertheless, in for ATEs a trade-off between precision and accuracy remains. The 
optimal strategy to solve this problem could be comparing the results from conventional re-
gression and pre-processing (IPTW followed by fully specified regression). If both methods 
lead to similar results, the superior precision of conventional regression would prevail. If the 
results are different, the pre-processing results are likely to be the most accurate.
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10Adjusting for COPD severity in database research
Developing and validating an algorithm
Background When comparing chronic obstructive lung disease (COPD) interventions 
in database research, it is important to adjust for severity. Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines grade severity according to lung function. 
Most databases lack data on lung function. Previous database research has approximated 
COPD severity using demographics and healthcare utilization. This study aims to derive 
an algorithm for COPD severity using baseline data from a large respiratory trial (UPLIFT).
Methods Partial proportional odds logit models were developed for probabilities of 
being in GOLD stages II, III and IV. Concordance between predicted and observed stage 
was assessed using kappa-statistics. Models were estimated in a random selection of 2/3 of 
patients and validated in the remainder. The analysis was repeated in a subsample with a 
balanced distribution across severity stages. Univariate associations of COPD severity with 
the covariates were tested as well.
Results More severe COPD was associated with being male and younger, having quit 
smoking, lower BMI, osteoporosis, hospitalizations, using certain medications, and 
oxygen. After adjusting for these variables, co-morbidities, previous healthcare resource 
use (e.g., emergency room, hospitalizations) and inhaled corticosteroids, xanthines, or 
mucolytics were no longer independently associated with COPD severity, although they 
were in univariate tests. The concordance was poor (kappa = 0.151) and only slightly better 
in the balanced sample (kappa =0.215).
Conclusion COPD severity cannot be reliably predicted from demographics and health-
care use. This limitation should be considered when interpreting findings from database 
studies, and additional research should explore other methods to account for COPD 
severity.
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10.1 Introduction
Treatment effectiveness and healthcare resource use in daily practice may be different from 
effectiveness and resource use in clinical trials. This is increasingly recognized by research-
ers, policy makers and decision makers responsible for pricing and reimbursement of 
healthcare interventions. Hence, the importance of data generated from sources that reflect 
the use and the associated outcomes in routine practice settings is growing. Suitable sources 
of such real-life data could be health records kept by physicians (e.g., their routine records or 
specifically established databases; paper-based or electronic), patient registries that enrol 
patients with specific diseases or other characteristics of interest (e.g., cancer registries), or 
administrative claims databases of healthcare insurers and provider organizations set up for 
the purpose of reimbursement of providers for their expenses.
The inherent problem of analyses conducted on such databases relates to the fact that 
the data are often collected for other purposes. When treatment is not assigned to patients 
at random, disease severity and prognosis of patients may differ systematically across treat-
ments. In order to adjust for this, data that reflect disease severity must be available. The 
currently most widely used severity classification is the spirometric classification of the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) [1], which is based on lung 
function in terms of the forced expiratory volume in one second as a percentage of the value 
predicted for sex, age and height (FEV
1
-%predicted). It is used to diagnose COPD, to monitor 
disease progression and to aid in treatment decisions. Lung function is an important indica-
tor of COPD severity because it is associated with mortality [2], exacerbations [3,4], health 
care utilization and costs [5]. There is also an association between lung function and quality 
of life6 although this relationship is not as strong [6,7]. Consequently, the same associations 
have been shown for the GOLD classification as it is based on FEV
1
 [8-12].
It is widely recognized, also by GOLD [1], that the impact of COPD does not only depend 
on lung function and furthermore that is not only a lung disease but a multi-dimensional 
disease with many systemic, extra-pulmonary effects. Therefore, composite measures of 
COPD severity have been proposed. However, almost all of these still accept the importance 
of airflow limitation and they are partly based on the FEV
1
-%predicted [13-17].
However, lung function measures obtained through spirometry are not routinely avail-
able in databases and registries. Most routine databases also lack information on the other 
parameters that constitute the more recent composite measures of COPD severity. Previous 
retrospective database research has approximated COPD severity using demographic (e.g., 
age and/or smoking status) and resource utilization data (eg, medications used and/or 
hospital admission) [18-23].
In this study, we attempted to develop a multivariable predictive algorithm to derive 
the severity of COPD as classified by GOLD, using variables that are commonly available in 
routine databases. The analysis was performed on the baseline data of the “Understanding 
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Potential Long-term Impacts on Function with Tiotropium” (UPLIFT) trial, a large, 4-year 
trial in COPD patients with rate of decline in FEV
1
 as primary endpoint [24]. This trial was es-
pecially suitable for this purpose because of its size (with almost 6000 patients randomised), 
and because among the baseline data collected are many data commonly available in rou-
tine databases (e.g., demographics, medications used in the past, hospital admissions in the 
year preceding enrolment). Moreover, FEV
1
 was collected with high quality, thus providing 
confidence in the GOLD severity assignment of trial patients.
10.2 Methods
Data source
We used baseline data from the UPLIFT trial. The UPLIFT trial was a randomised, double-
blind, placebo-controlled 4-year trial, investigating the effect of tiotropium on the yearly 
rate of decline in FEV
1
 in patients with moderate to very severe COPD according to GOLD 
(stages II to IV). Patients were permitted to use all respiratory medications except inhaled 
anticholinergics. 5993 patients were randomised. 25 Main inclusion criteria besides a diag-
nosis of COPD included age of 40 years or over, a smoking history of at least 10 pack-years, 
a post-bronchodilator FEV
1
-%predicted of 70% or less, and an FEV
1
 of 70% or less of the 
forced vital capacity. Key exclusion criteria were a history of asthma, a COPD exacerbation 
or respiratory infection within 4 weeks before screening, use of supplemental oxygen for 
more than 12 hours per day. UPLIFT collected information on patients’ demographics, co-
morbidities and co-medications as well as COPD characteristics and smoking history, along 
with contacts with health care providers in various settings in the year preceding enrolment.
In order to enhance the homogeneity of treatment patterns, the sample was limited 
to 3698 patients from Western Europe, the United States, Australia and New Zealand with 
COPD severity stage II, III or IV. The sample was randomly split into two sets: one for devel-
oping the algorithm (2/3 of patients) and the other for validation (1/3 of patients).
Selection of variables
Potential variables for inclusion in the algorithm to approximate disease severity were 
those used in previous database research and those used in diagnostic and severity clas-
sifications [13-16,25-28]. Variables were then selected if available in UPLIFT and likely to 
be available in routine databases. The final list of variables to be tested consisted of age 
(continuously in years, squared, and in categories: 40–49, 50–59, 60–69, 70–79, 80–90, 90+). 
BMI (continuously and categorized: <18.5, 18.5–21.0, 21.0–25.0, 25.0–30.0, >30.0), smoking 
status (current/former smoker), pack-years of smoking (continuously and categorized: <20, 
20–60, >60), sex, type of respiratory maintenance medications (short-acting and long-acting 
bronchodilators, inhaled corticosteroids (ICS), mucolytics, leukotriene modifiers, xan-
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thine), number of medication types (0 to 5), treatment of exacerbations (number of courses 
of antibiotics or oral steroids, categorized: 0, 1, 2, ≥3 in one year), resource use in one year 
(number of emergency room visits with/without hospital admission, categorized (0, 1, ≥2), 
number of scheduled and unscheduled general practitioner (GP) visits (categorized: 0, 1, 2, 
3–4, ≥5 and 0, 1, 2, ≥3, respectively), hospital admissions (yes/no), use of oxygen at home 
(yes/ no), statin use (yes/no), use of other cardiovascular medication (yes/no), number of 
co-morbidities (categorized: 0, 1, 2, 3–5, 6–9, ≥10), Charlson comorbidity index [29] (catego-
rized: 1, 2, 3, ≥4), presence of selected co-morbidities (arrhythmia, coronary heart disease, 
vascular disease, hypertension, disorders of nervous system, stroke, diabetes, depression, 
anaemia, and platelet disorders, osteoporosis and cataract), as well as interaction terms 
(age*gender, age*BMI, BMI*gender).
Analysis
Several partial proportional odds (PPO) ordered logit models were used to estimate the 
probabilities of being in GOLD stages II (FEV
1
%-predicted >50%), III (FEV
1
%- predicted 
30%–50%), and IV (FEV
1
%- predicted <30%), as COPD severity categories are ordered. The 
“development dataset” was used for this purpose.
The PPO resembles the standard ordered logit model, which is the best known ordered 
regression model. In our case, with 3 possible outcomes Y, it estimates the probability that 
Y>stage II and the probability that Y>stage III. Ordered regression models assume that the 
observed ordered outcome Y is a function of a continuous and unobservable variable Y*. 
Two thresholds τ
j
 are assumed to determine in which stage a patient is classified: Y > Y
j
 if Y* > 
τ
j
, where j denotes a specific outcome and t
j
 is the upper limit of Y* for this outcome. Y* is re-
lated to the explanatory variables X: Y
i
* = X
i
 β
J
 + ε
j
 , where i denotes individual patients. Since 
the latent variable Y* does not completely equal the sum of the products of coefficients and 
variable values, the outcome Y cannot be determined with certainty from the data. Assum-
ing a logit distribution for the random error term makes it possible to model the probability 
that a patient is in a certain stage or worse (Y* > τ
j
). This probability may be written as:
Pr(Y
i
 > j) =
exp(−τ
J
 + X
i
β
J
)
, j = 1, 2, …, M − 1.
1 + exp(−τ
J
 + X
i
β
J
)
M is the number of possible outcomes.
In contrast to the PPO model, however, the ordered logit model can only estimate one 
coefficient for each explanatory variable. This coefficient is assumed to be identical for all 
dichotomizations of the outcome variable (in this case, stage IV versus II/III and stage III/
IV versus II), and thus coefficient β
j
 = β. This is the proportional odds or parallel regressions 
assumption. If this assumption is violated, which often happens in practice, estimates are 
invalid and important differences in the relationships at different thresholds may go un-
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noticed. The partial proportional odds model relaxes this assumption for variables where it 
does not hold [30]. For these variables, a coefficient is estimated for each dichotomization.
The final model was developed by stepwise backward elimination from the full model, 
which contained all variables. In each step the variable with the largest P-value was elimi-
nated and the model was re-estimated. This process was repeated until all variables had at 
least a value of P ≤ 0.10.
We performed two sensitivity analyses in order to account for the fact that the proportion 
of patients with very severe COPD (GOLD IV) in the dataset was smaller than the proportion 
of patients with moderate or severe COPD. Firstly, the final model was re-estimated in a sub-
sample with a balanced distribution of patients across all three severity stages. This balance 
was achieved by using all GOLD stage IV patients and random draws from patients in stages 
II and III. Secondly, the patients in GOLD stage III and IV were combined into one group. 
The probability of being in ‘severe/very severe’ was then analysed in a binary logit model 
with the same variables as in the final PPO model.
All analyses were performed in Stata 11.1, (StataCorp LP, College Station, TX) using 
the gologit2 command for the PPO model [31]. Univariate tests were analysis of variance 
(ANOVA) for continuous variables and chi-square for categorical variables. Statistical sig-
nificance was reached when a two-sided P-value was ≤ 0.05.
Predictive performance
The regression results were used to predict the probabilities of being in each GOLD severity 
stage for each patient in the validation dataset. The predicted stage was defined as the stage 
with the highest predicted probability. The agreement between the predicted and the ob-
served stage was assessed using kappa statistics [32]. For a kappa statistic, a value of 0 indicates 
that agreement has occurred by chance, whereas a value of 1 indicates perfect agreement. 
No generally accepted interpretation of the magnitude of the kappa-statistic exists. Landis 
and Koch suggested the following labels of agreement for ranges of values, which are often 
quoted: slight (up to 0.20), fair (0.21–0.40), moderate (0.41–0.60), substantial (0.61–0.80), and 
almost perfect (0.81–1.0) [33]. We present kappa statistics unweighted and weighted. In the 
weighted kappa statistics, patients misclassified in the neighbouring category (i.e., II or IV 
instead of III, or III instead of II or IV) count as 0.5 agreement and patients misclassified in a 
non- neighbouring category (II instead of IV or vice versa) as no agreement).
In addition to the agreement per disease stage, the overall agreement was calculated. 
For the binary logit model, the c-statistic was computed as a measure of its discriminative 
performance. The c-statistic represents the area under the receiver operating characteristic 
(ROC) curve, a plot of sensitivity against specificity. Values can range from 0.5 (no predictive 
ability) to 1 (perfect discrimination).
Lastly, in an analysis of correctly and incorrectly classified patients, the average values of 
FEV
1
%-predicted were compared per severity stage.
174 Chapter 10
10.3 Results
Description of sample
Patient characteristics are summarized in table 10.1a, demonstrating that 47% were in GOLD 
stage II, 44% in stage III, and 9% in stage IV. Patients in more severe disease states were more 
likely to have a lower BMI, to have quit smoking and to suffer from osteoporosis. The mean 
age of patients in stage IV was 2–3 years lower than in the less severe categories. The disease 
stage was not significantly associated with pack-years, the number of co-morbidities, Charl-
son’s comorbidity index, and various concomitant diseases.
Tables 10.1b and 10.1c show that disease stage was associated significantly with almost 
every type of medication and resource use. Patients with more severe COPD were more 
likely to use various types of pulmonary maintenance medication, oxygen at home, exac-
erbation medication, consult their GP more often (on a scheduled and unscheduled basis), 
visit the emergency room with resulting admission more often, and were more likely to have 
Table 10.1a Patient characteristics, risk factors, and comorbidity per GOLD stage in full sample (development and validation sets combined)
Stage II III IV P-value*
n=1720 (47%) n=1640 (44%) n=338 (9%)
Age (SD) 64.9 (8.47) 65.8 (7.98) 63.0 (8.23) 0.000
Male 70.10% 72.80% 75.40% 0.066
BMI<21 9.94% 12.56% 26.63% 0.000
BMI>25 62.15% 56.58% 34.61%
Underweight (BMI<18.5) 2.44% 3.84% 10.06% 0.000
Low weight (18.5>BMI<21) 7.50% 8.72% 16.57%
Normal BMI 27.91% 30.85% 38.76%
Overweight (25<BMI<30) 36.92% 36.45% 23.37%
Obese (BMI>30) 25.23% 20.12% 11.24%
Current smoker 33.43% 28.23% 27.51% 0.002
<20 Pack years 6.63% 5.85% 7.69% 0.700
20-60 pack years 66.86% 66.95% 64.79%
>60 pack years 26.51% 27.20% 27.51%
Comorbidities: 0 12.67% 12.20% 11.54% 0.752
1 14.59% 15.30% 17.46%
2 15.52% 14.27% 12.72%
3-5 27.38% 27.80% 29.29%
6-9 18.31% 29.29% 19.82%
Charlson comorbidity index: 1 69.36% 69.51% 74.56% 0.398
2 21.28% 21.16% 15.98%
3 6.40% 5.91% 5.92%
>=4 2.97% 3.41% 3.55%
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Table 10.1a (continued)
Stage II III IV P-value*
n=1720 (47%) n=1640 (44%) n=338 (9%)
Coronary heart disease 14.13% 13.41% 12.43% 0.657
Vascular disease 45.29% 43.78% 38.46% 0.067
Hypertension 41.05% 40.00% 35.50% 0.163
Nervous system disorders 14.65% 14.45% 15.68% 0.844
Stroke 0.41% 0.39% 0.30% 0.865
Diabetes 9.24% 8.35% 5.92% 0.126
Depression 10.64% 10.24% 11.54% 0.768
Anemia 0.93% 1.10% 0.30% 0.381
Platelet disorders 0.29% 0.18% 0.00% 0.533
Osteoporosis 5.64% 8.54% 8.28% 0.004
Cataract 2.50% 2.32% 3.55% 0.419
* Two-sided p-values from analysis of variance for continuous variables and from the chi-squared test for categorical variables.
Abbreviations: BMI, body mass index; SD, standard deviation; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Table 10.1b Medication per GOLD stage in full sample (development and validation sets combined)
Stage II III IV P-value*
n=1720 (47%) n=1640 (44%) n=338 (9%)
No short-acting bronchodilators 33.78% 20.91% 13.31% 0.000
1 short-acting bronchodilator 36.10% 37.56% 26.04%
2 short-acting bronchodilators 30.12% 41.52% 60.65%
Long-acting bronchodilator 62.03% 70.55% 75.74% 0.000
Inhaled corticosteroids 62.21% 69.51% 76.33% 0.000
Other steroids 5.76% 10.00% 17.16% 0.000
Xanthine 9.94% 19.33% 20.12% 0.000
Leukotrin modifier 2.79% 5.67% 8.58% 0.000
Mucolytics 4.19% 5.85% 5.33% 0.084
Home oxygen 1.05% 3.05% 9.17% 0.000
Statins 19.13% 16.52% 13.61% 0.020
Cardiovascular medication 51.16% 54.82% 48.82% 0.020
Courses of oral steroids: 0 70.76% 59.45% 52.66% 0.000
1 17.44% 22.68% 23.08%
2 6.22% 9.02% 8.84%
>=3 5.58% 8.84% 11.54%
Courses of antibiotics: 0 53.31% 44.27% 43.20% 0.000
1 22.97% 24.94% 25.15%
2 12.91% 16.10% 16.27%
>=3 10.81% 14.70% 15.38%
* Two-sided p-values from the chi-squared test for categorical variables
Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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been admitted for any reason to the hospital in the last year. The use of statins and other 
cardiovascular medication was more frequent in patients with less severe disease. There 
was no difference between the dataset used for developing the algorithm and the validation 
dataset.
Regression results
In the final model (table 10.2), the parallel regression assumption was violated for five 
variables (age, gender, xanthine and oxygen use, and two categories of the BMI variable, 
overweight and obese). In these cases, a coefficient was estimated for each dichotomization 
(GOLD III/IV versus GOLD II and GOLD IV versus GOLD II/III). For all other variables, one 
coefficient was estimated for both dichotomizations.
In the multivariable analysis, a higher risk of more severe COPD was significantly associ-
ated with being younger, being male, having a lower BMI, having quit smoking, suffering 
from osteoporosis, using oxygen, courses of oral steroids, having been hospitalized in the 
previous year, and certain types of respiratory maintenance medication (long- and short-
acting bronchodilators, xanthines, leukotriene modifiers, oral steroids).
The thresholds were not statistically significantly different from 0 (p-values: 0.466 and 
0.338, see table 10.2). However, the first threshold was significantly lower than the second 
(−0.251 versus 0.403, p-value 0.042).
Table 10.1c Health care resource use per GOLD stage in full sample (development and validation sets combined)
Stage II III IV P-value*
n=1720 (47%) n=1640 (44%) n=338 (9%)
Scheduled GP visits: 0 20.17% 14.82% 12.43% 0.000
1 18.72% 15.85% 15.09%
2 23.43% 23.05% 17.75%
3-4 23.49% 28.78% 31.36%
>=5 14.19% 17.50% 23.37%
Unscheduled GP visits: 0 74.71% 70.12% 64.50% 0.003
1 13.14% 16.46% 18.64%
2 6.40% 6.65% 9.17%
>=3 5.76% 6.77% 7.69%
Emergency room (no admission): 0 92.40% 90.47% 89.88% 0.071
1 4.97% 6.02% 8.04%
>=2 2.63% 3.50% 2.08%
Emergency room and admission: 0 91.87% 88.19% 82.74% 0.000
1 6.26% 9.04% 11.90%
>=2 1.87% 2.77% 5.36%
Direct hospital admissions (yes/no) 3.39% 4.55% 7.14% 0.006
* Two-sided p-values from the chi-squared test for categorical variables
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Table 10.2 Regression results, final partial proportional odds ordered logit model
Parallel regression
assumption holds
Parallel regression
assumption violated
Shared by both dichotomizations Stages III/IV vs stage II Stage IV vs stages II/III
Coefficient P-value Coefficient P-value Coefficient P-value
Age2 -0.00007 0.122 -0.00055 <0.0005
Male 0.423 <0.0005 0.848 <0.0005
Underweight (BMI<18.5) Reference category
Low weight (18.5>BMI<21) -0.374 0.110
Normal BMI -0.699 0.001
Overweight (25<BMI<30) -0.951 <0.0005 -1.775 <0.0005
Obese (BMI>30) -1.187 <0.0005 -1.912 <0.0005
Current smoker -0.155 0.097
Osteoporosis 0.331 0.042
Longacting bronchodilator 0.262 0.003
No short-acting bronchodilator Reference category
1 short-acting bronchodilator 0.338 0.001
2 short-acting bronchodilators 0.854 <0.0005
Leukotrin modifier 0.661 0.001
Xanthine 0.615 <0.0005 -0.076 0.706
Oral steroids (maintenance) 0.304 0.045
No incidental courses of oral steroids Reference category
1 course of oral steroids 0.222 0.037
 2 courses of oral steroids 0.292 0.064
≥3 courses of oral steroids 0.218 0.184
Oxygen 0.759 <0.0005 1.599 <0.0005
Any hospital admissions in previous year 0.349 0.081
Threshold -0.251 0.466 0.403 0.338
N 2423
Log likelihood -2057.973
Wald test for model significance <0.00005
Abbreviation: BMI, body mass index.
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Table 10.3 Predictive performance: predicted and observed GOLD stage in validation data set
a. PPO ordered logit model estimated in full development data set
Predicted GOLD stage
II III IV Total Unweighted Weighted
Observed
GOLD
stage
Overall
agreement
53% 77%
II 368 205 7 580
63% 35% 1% 100%
Kappa 0.151 0.230
III 260 283 4 547
95% CI 0.103 - 0.198 0.196 - 0.263
46% 53% 1% 100%
IV 28 82 10 120
24% 68% 8% 100%
Total 656 570 21 1,247
b. PPO ordered logit model estimated in balanced sample (sensitivity analysis)
Predicted GOLD stage
II III IV Total Unweighted Weighted
Observed
GOLD
stage
Overall
agreement 48% 68%II 64 34 23 121
53% 28% 19% 100%
Kappa 0.215 0.290
III 42 40 38 120
95% CI 0.142 - 0.288 0.205 - 0.370
35% 33% 32% 100%
IV 20 32 68 120
17% 27% 57% 100%
Total 126 106 129 361
c. Binary logit model estimated in development data set
Predicted GOLD stage
II III/IV Total
Observed
GOLD
stage
Overall
agreement
62%
II 316 264 585
54% 46% 100%
Kappa 0.228
III/IV 212 455 667
95% CI 0.173 - 0.284
32% 68% 100%
Total 528 719 1,247 c-statistic 0.614
95% CI 0.587 - 0.640
Abbreviations: CI, confidence interval; Gold, Global Initiative for Chronic Obstructive Lung Disease.
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The following variables were not maintained in the final model: inhaled corticosteroids, 
mucolytics, cardiovascular medication, courses of antibiotics, most co-morbidities (except 
osteoporosis), and healthcare resource use (emergency room, GP consultations).
Predictive performance
Sixty three percent of patients in stage II, 53% of patients in stage III and 8% of patients in 
stage IV were correctly identified with the final model (see table 10.3a). The overall agree-
ment was 53% (unweighted) to 77% (weighted), leading to ‘slight’ to ‘fair’ kappa statistics of 
0.151 (unweighted) and 0.230 (weighted).
The observed values of FEV
1
%-predicted were slightly higher for COPD stage II patients 
who were correctly classified by the model than for patients who were incorrectly classified 
(59.4% versus 57.7%, respectively). In stage III, the opposite was observed (FEV
1
%-predicted 
was 39.4% in the correctly classified versus 41.2% in the incorrectly classified), and in stage 
IV, FEV
1
 was comparable among the correctly and incorrectly classified groups (24.9% and 
25.6%).
Sensitivity analyses
In the balanced sample (regression results not presented), agreement was lower for stages 
II and III than in the unbalanced sample, but higher for stage IV: 53%, 33% and 57% respec-
tively (table 10.3b). The overall agreement was 48% (unweighted) to 68% (weighted). The 
kappa statistics were ‘fair’ with 0.215 and 0.290, respectively.
In the binary logit model (table 10.3c), agreement for patients with moderate and severe/
very severe COPD was 54% and 68%. The kappa-statistic was ‘fair’: 0.228.
10.4 Discussion
Our study has two important findings. Firstly, the variables that were independently related 
to more severe COPD defined by lung function were a lower age, male gender, a lower BMI, 
being an ex-smoker, having osteoporosis, having been hospitalized in the previous year, us-
ing oxygen and certain types of respiratory maintenance medication (long- and short- acting 
bronchodilators, xanthines, leukotrien modifiers, oral steroids). Other variables expected to 
be associated with lung function impairment, such as other resource use variables, were not 
maintained in the final model. Secondly, the performance of the final model was such that 
the confidence in using the selected variables to adjust for COPD severity in the absence of 
lung function parameters was judged to be limited.
Of the variables in the final model, the impact of age may be partly due to a healthy 
survivor effect, whereas long acting bronchodilators, multiple short-acting bronchodilators, 
oral steroids and xanthines are clearly indicated for treating more advanced stages of COPD. 
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Patients with more severe disease are more likely to have quit smoking. A low BMI, often as-
sociated with loss of muscle mass is well known to be more frequent in severe COPD and the 
higher prevalence of osteoporosis might be a side-effect of a long history of corticosteroid use.
We used a partial proportional odds model instead of the standard ordered logit model. 
This made it possible to estimate different coefficients for the probability of being in stage 
III/IV over stage II than for the probability of being in stage IV, if this was required. The paral-
lel regression assumption, which states that the coefficients are equal for both dichotomiza-
tions, was violated in five instances.
In the final base case model, only 53% of patients were classified in the correct GOLD 
stage. Especially for patients in stage IV, the predicted stage was unlikely to be correct (8% 
correct). Results from sensitivity analyses with a more balanced sample or a binary logit 
model were only slightly better.
We chose to present both unweighted and weighted kappa statistics. In cases with more 
than two categories, it is customary to weight the kappa-statistics in order to penalize dis-
agreements in terms of their seriousness – i.e., a higher penalty for misclassifying a patient 
from stage II as a stage IV patient than as a stage III patient – whereas unweighted kappa 
treats all disagreements equally. However, in our study all disagreements were considered 
serious and the weighted overall agreement might give an overly favourable impression. In 
the end, the unweighted and the weighted kappa statistics were quite similar. Based on all 
values of the kappa statistics, the agreement between predicted and observed GOLD stages 
can be characterized as slight to fair.
Several explanations for these findings may be considered. Firstly, the cut-off points 
between GOLD stages are inevitably somewhat arbitrary and artificial, especially as the 
decline in FEV
1
 is a continuous process. A patient with a FEV
1
%-predicted of 49% (GOLD 
stage III) is probably less similar to a patient with a value of 31% (also GOLD stage III) than 
to someone with a value of 51% (GOLD stage II). If this were an important explanation for 
our prediction results, misclassified patients in stage IV should have markedly better lung 
functions – closer to stage III – than the correctly classified patients, while the opposite 
should be true for misclassified patients in stage II. However, the actual differences in lung 
function between the correctly and incorrectly classified patients in our analysis were small 
(1.74%-point for stage II and 0.66%-point for stage IV).
The second explanation concerns the source of our data, which was a clinical trial. It is 
conceivable that patients with very severe disease and many symptoms were less willing to 
participate in the trial. This could then obscure some of the associations between disease 
severity and the predictors. This problem would be expected to occur particularly when 
trying to predict GOLD stage IV. However, our models did not perform well at distinguishing 
moderate from severe patients either. In the balanced sample analysis, misclassifications 
occurred equally often in each GOLD stage. Furthermore, the proportion of very severe 
patients in the sample does not appear to be low compared to the proportion in the gen-
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eral population of COPD patients in Finland [34], The Netherlands [35], Greece [36], the 
United Kingdom [37], and a combination of European and North-American countries [38]. 
Moreover, a broad range of patients was allowed to participate. For examples, patients were 
permitted to use all respiratory medications concomitantly during the trial except inhaled 
anticholinergic drugs, thus closely resembling routine care. Altogether, this protocol makes 
the UPLIFT a suitable trial for this study.
The third explanation would be the far from perfect association of resource use, which 
is often driven by symptoms and exacerbations, with GOLD stage. Patients with a relatively 
good lung function do not necessarily experience fewer symptoms than patients with worse 
lung function. Indeed, the UPLIFT sample contains a non-negligible number of patients with 
very severe COPD who do use little or no maintenance medication, as well as patients with 
moderate disease who use four or five different types of medications. Overall, we observed 
an independent association of GOLD stage with several respiratory medications, but not 
with other types of resource use such as ER visits and physician consults in our multivari-
able model, which was not expected beforehand. In univariate analyses, patients with more 
severe COPD were more likely to have higher COPD-related resource use (almost all types 
of medication use, courses of oral steroids and antibiotics, scheduled and unscheduled GP 
visits and hospital admissions with and without visits to the emergency room), not to use 
statins and other cardiovascular medication, to be younger, male, underweight, ex-smoker, 
and suffer from osteoporosis.
Several database studies have attempted to adjust for possible differences in COPD 
severity in the absence of lung function data. In an article comparing the assessment of 
COPD patients in the UK General Practice Research Database with the clinical opinion of the 
patient’s GP, Soriano et al. [18] based their severity classification on medication use. Sin and 
Tu [19] assessed the effects of ICS use on mortality and applied medication use, ER visits and 
physician services as proxies of disease severity. Similarly, Suissa [20] adjusted only for age, 
sex and medication use. Breekveldt-Postma et al. [21] identified determinants of patient’s 
persistence with ICS therapy. They considered hospital admissions and medication use to 
be proxies for disease severity. In a study relating COPD severity with cardiovascular disease, 
Curkendall et al. [22] assumed that COPD severity could be defined as the likelihood of being 
hospitalized, given the relationship with mortality. They concluded that this probability of 
hospitalization is associated with medication and oxygen use, previous hospitalizations, 
recent exacerbations, pneumonia and lung emphysema. Griffin et al. [23] assessed the ef-
fects of tiotropium compared to combined ipratropium and salbutamol on exacerbations 
and hospitalizations. They adjusted for a combination of resource use data and risk factors. 
Based on the current analyses, we conclude that the variables used in these database studies 
cannot be relied upon to adequately adjust for COPD severity in terms of lung function.
In conclusion, data from a well-controlled trial setting indicated that COPD severity de-
fined by lung function thresholds cannot be reliably predicted from patient characteristics 
182 Chapter 10
and their previous healthcare use. This limitation should be considered when interpreting 
findings from database studies, and additional research should explore other methods al-
lowing accounting for COPD severity.
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11.1 Introduction
This thesis addressed several methodological issues in the economic evaluation of health-
care. Furthermore, it contained an evaluation of a hospital-at-home program for COPD 
patients. This chapter provides an overview of the main findings, with an emphasis on the 
methodological elements, and puts them into perspective.
11.2 Hospital-at-home after a COPD exacerbation
The objective of the first part of the thesis was to perform an economic evaluation of the GO 
AHEAD trial of early assisted discharge of COPD patients after an exacerbation, to put the 
estimate of cost savings into perspective and to investigate treatment preferences of patients 
and informal caregivers.
In the GO AHEAD trial, the costs and health effects of two treatments were compared for 
patients who were admitted to the hospital with a COPD exacerbation in the Netherlands. 
Participants stayed in the hospital for seven days, or went home after three days where they 
were supervised and treated by community nurses.
In chapter 4, we found that transferring hospital care for a COPD exacerbation to the 
patient’s home was likely to lead to modest savings in healthcare costs in the Netherlands, 
while there is no clear evidence to conclude that it would lead to a slower or worse resolution 
of the exacerbation. From a societal perspective – when the societal costs of informal care 
and productivity losses are taken into account – these cost savings decrease considerably or 
even turn into cost increases.
There were differences in mean generic and disease-specific health-related quality of 
life at the end of the initial treatment phase, but these were quite small, temporary and 
only partially significant. By the end of the three-month follow-up period they had dis-
appeared. The early-assisted discharge program was likely to lead to modest savings in 
healthcare costs.
The health outcomes that we found were consistent with those of other studies of 
hospital-at-home interventions. However, most other authors found larger cost savings than 
we did. Part of this inconsistency could be attributed to differences in the design of the early 
assisted discharge or admission avoidance programs, to different patterns of usual treatment 
and to different cost structures across countries. In addition, in chapter 2, we also concluded 
that savings in most studies were overestimated. The quality of most of the papers that we 
selected in our systematic review was not high. The large majority assumed unit costs per 
inpatient hospital day that were too high, which led to an overly optimistic estimate of cost 
savings due to the reduction of length of stay. Many studies did not take into account that 
treatment intensity decreases over the course of an admission, which makes the last days 
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less costly than the first days. Furthermore, some studies did not adapt their cost estimate to 
the particular disease or intervention that is investigated.
Ultimately, cost savings for hospital-at-home occur when the costs of homecare are less 
than the costs of the avoided hospital days. One way of achieving this is simply to provide 
less care at home than in the hospital. In the case of COPD exacerbations, that means that 
there are fewer minutes of contact between the patient and healthcare professionals. The 
other way is to deliver the same amount of care more efficiently. In the accomplishment 
of the latter, a number of factors can play a role: lower hourly costs for personnel, higher 
productivity (the proportion of working time devoted to patient care), lower overhead costs, 
less expenditure on housing or capital. In the GO AHEAD trial the amount of professional 
care, measured in days as well as in minutes, was similar for both treatment groups. That 
means that the cost savings must have come from efficiency gains. Furthermore, the total 
amount of care, professional and informal combined, was larger for patients who were 
discharged early.
The GO AHEAD trial was not an equivalence trial. We cannot be completely certain that 
the early assisted discharge intervention does not lead to worse health outcomes than usual 
hospital care. Indeed, both health measures indicated that patients in the intervention group 
had on average a somewhat worse health status on day 7 and the confidence interval of the 
CCQ score contained clinically relevant values. However, we have argued that this difference 
might be explained by differences in expectations when leaving the hospital. Furthermore, 
the difference does not mean that the intervention is unsafe.
Whereas there is no compelling reason – from a medical or economic point of view – to 
recommend either the early supported discharge treatment or usual hospital care to all 
patients, many patients and informal caregivers did show a strong preference for one or 
the other option. This was presented in chapter 5. Only for a minority of respondents this 
preference could be changed by altering the characteristics of the proposed early assisted 
discharge treatment. This does not mean that the design of the intervention did not matter 
to the majority of patients and caregivers. In a choice between two early assisted discharge 
programs, copayments and the burden on the informal caregiver had a strong impact on 
preferences.
11.3 The importance of informal care
The analysis from the societal perspective in chapter 4 made clear how crucial the inclusion 
of informal care costs can be for the conclusions on cost savings. For the initial treatment 
episode, the projected savings disappeared almost completely when the costs for informal 
care were added to the calculations. For the full three-month follow-up period, the savings 
even turned into estimated costs increases.
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However this points to one of the problems concerning the costs of informal care. 
Respondents in the early assisted discharge group reported much larger amounts of 
informal care than respondents in the usual hospital care group. In contrast, there were 
no differences in mean health outcomes over the same period. There are two possible 
explanations for the discrepancy. If the responses reflected an actual difference in care 
that was provided, this might be explained by a different attitude of the informal caregiv-
ers that was formed during the initial treatment period, in which they took over part of 
the hospital care. Unfortunately, it is also plausible that informal caregivers in the early 
assisted discharge group were more primed to record their activities as informal care, due 
to the attention it may have got during visits of the homecare nurse in the initial treatment 
phase at home.
A second matter is the valuation of the time of the informal caregivers. Following Dutch 
guideline recommendations, we used a shadow price of €12.50 per hour, which was based 
on the hourly costs of cleaning services provided by homecare organizations. This amount 
is in the lower part of a range of studies with different valuation methods in various patient 
groups [1,2]: €8 to €20, indexed to the 2010 price level. It could be argued that our price led 
to a somewhat conservative estimate of the costs of informal care and therefore, to a slightly 
optimistic estimate of the cost-effectiveness of the hospital-at-home program. At any rate, 
the decision on the price is debatable. However, even if the unit price of an hour of informal 
care has not been established, it is clear that this time is valuable. Ignoring the costs of infor-
mal care would give the incorrect impression that informal care is costless.
11.4 The multidimensionality and heterogeneity of inpatient 
hospital costs
In economic evaluations, costs are often calculated by multiplying an amount of healthcare 
resources with their unit price. Inpatient hospital days are a special type of resource use in 
that context because of their multidimensionality. In fact, an inpatient day is not a ‘unit’ of 
healthcare resources. Rather, it is a combination of many different inputs: time from physi-
cians, nurses and other staff, materials, depreciation of medical equipment, medication, 
food, heating, administrative overhead, cleaning, capital costs and more.
This combination varies per patient, as well as across diseases and interventions. It is 
therefore obvious that disease-specific unit cost prices must be used, although not all stud-
ies in our review of hospital-at-home costs did so. However, they may still be insufficiently 
tailored to the patient group that is treated. In hospital-at-home studies, for instance, the 
target population is not the average patient with a certain disease. Patients who are eligible 
for hospital-at-home are likely to need less care than this average patient. This means that 
the actual savings for hospital-at-home are likely to be overestimated when average disease-
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specific prices per inpatient hospital day are used. This stricter criterion of target-patient 
unit costs was however not applied in our systematic review in chapter 2.
Of course, the multidimensionality problem applies to other resources besides inpatient 
hospital days. As an example, the costs of a general practitioner’s consult contain more than 
the physician’s time. However, the heterogeneity among individual patients with regards to 
the contents of a consult is more limited. This means that the average costs per consult can 
be calculated by averaging the total costs of a practice or the total national costs over the 
number of consults.
The cost analysis of the GO AHEAD trial in chapter 4 showed that assumptions on the 
costs of inpatient hospital days can be crucial for the conclusions. In our base case, we took 
the microcosting approach, in which detailed cost calculations were made for inpatient 
hospital days in this specific patient population. From a societal perspective, cost savings 
were negligible for the initial treatment phase and turned into cost increases when the full 
three-month period was considered. In contrast, the use of average, non-disease-specific 
reference costs per inpatient day without adjustment for the course of the admission dra-
matically increased the estimated savings for the initial phase as well as the follow-up period.
11.5 Quantifying uncertainty
The uncertainty around estimates of incremental costs and effects can be analysed by ap-
plying the bootstrapping method for sample data and by probabilistic sensitivity analysis 
in modelling studies. The results of these analyses can be presented graphically in cost ef-
fectiveness planes and acceptability curves.
When sample data are used, the uncertainty estimates result from variation within the 
sample. If the differences in health outcomes or resource use among patients are small, so 
is the uncertainty around the estimates of the mean effects and costs. The bootstrapping 
method brings this to the surface by repeatedly taking samples with replacement from 
the original dataset. The estimates and costs and effects differ for each bootstrap sample, 
depending on the patients it contains.
However, in order to appreciate the full uncertainty around the estimates, the multidi-
mensionality of inpatient hospital days and their costs must be acknowledged.
The combination of staff time, use of equipment and overhead costs is different for each 
patient, so it is technically incorrect to apply one estimate of the mean costs to all patients 
and ignore the variation. Ideally, patient-level data on each element of healthcare resource 
use should be available for each separate inpatient hospital day. Obviously, the collection of 
these data is not feasible in most circumstances.
An alternative approach is combining univariate sensitivity analyses with bootstrapping, 
as we did for the GO AHEAD trial in chapter 4: the bootstrapping procedure was repeated 
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for various levels of the unit costs per hospital admission. The results were presented in one 
figure with cost-effectiveness acceptability curves and interpreted in combination. Taken 
separately, the results from each separate bootstrapping procedure underestimate the un-
certainty around the estimated incremental costs and the incremental cost-effectiveness 
ratio since it is based on a fixed price for the hospital admission. In the GO AHEAD study, 
this became apparent from the cost-effectiveness planes for the initial treatment episode, 
in which the costs of inpatient hospital days were one of very few cost drivers. These planes 
showed virtually no uncertainty about the incremental costs, which is unrealistic and which 
is why they were not included in this thesis. The planes for the full three-month period ap-
peared correct at first sight, but they also do not express the full extent of the uncertainty 
involved in estimating the incremental costs.
In the probabilistic sensitivity analysis in health economic models, uncertainty around the 
costs can be taken into account by applying a distribution from which the costs for hospital 
admissions are sampled. However, in the absence of patient-level data of unit costs for inpa-
tient hospital days, this distribution would have to be based on even less than expert opinion.
Of course, the underestimation of uncertainty around hospital costs is only a problem 
when the costs of hospital admissions is an important driver of total cost estimates.
11.6 Quantifying preferences and preference heterogeneity
Patients’ preferences for aspects of medical treatments can be investigated in a great many 
ways [3-5]. The simplest method may be to ask respondents how important each character-
istic is to them, and possibly express this on a scale. The great advantage of discrete choice 
experiments (DCEs) compared to simpler preference questionnaires is that they can be 
used to quantify the value of treatment characteristics. A DCE makes the trade-off between 
desirable elements explicit. The results of the analysis show which attributes are considered 
important, but also what their relative position is among the others and what their value is. It 
is consistent with notions of scarcity of resources and based on economic and utility theory 
[6]. A DCE suffers from the same weakness as other questionnaires: it is a stated preference 
approach [7]. There is no guarantee that respondents would make the same choices if they 
were offered to them in real life. On the other hand, stated preference data also have ad-
vantages compared to observing actual choices (revealed preferences). The most important 
point is that stated preferences make it possible to evaluate interventions that are not yet as 
such provided to patients. Furthermore, the characteristics of current real-life interventions 
may show little variability or be highly collinear, which makes it impossible to correctly 
analyse the importance of each of them.
The questionnaires in the DCE in chapter 5 described potential future treatments of 
COPD exacerbations. An analysis of revealed preference would not have been possible.
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The data was analysed using latent class conditional logit models. This is quite a rarity 
in health economics, where the multinomial logit (or conditional logit) and mixed logit are 
the common techniques for analyzing DCE data. Latent class analysis was applied in health 
economics only twice before our study [8].
It was shown in chapter 5 of this thesis how using the conventional conditional logit 
model would have led to false conclusions: it would have appeared as if all respondents 
could have been persuaded to choose the hospital or the early assisted discharge option, if 
the characteristics of the homecare program were adjusted to their preferences. In reality, 
the majority had a fixed preference for one of the option, regardless of the characteristics of 
the early assisted discharge program. These respondents, however, were willing to choose 
between different early assisted discharge programs.
Preference heterogeneity across respondents can be addressed in in a mixed logit model 
– and it often is – which assumes that the individual preferences for each attribute follow a 
certain distribution. However, the raw data from the experiment in GO AHEAD showed a 
clear segmentation of respondents rather than differences in strength of preferences. The 
classes that were identified by the latent class conditional logit models were to a large extent 
characterized by their a priori preference for or aversion to hospital admissions or early 
assisted discharge.
11.7 Health-related quality of life during moderate COPD 
exacerbations
The study in chapter 6 showed that the EQ-5D questionnaire for the measurement of 
health-related quality of life can be used for assessing the health of COPD patients during 
a moderate exacerbation, which was defined as a worsening of their disease leading to a 
prescription of antibiotics and/or oral steroids but not to a hospital admission. The EQ-5D 
scores were responsive to the recovery from a moderate exacerbation. Three-quarters of 
patients experienced an improvement in health-related quality of life after the worst day 
of the exacerbation. All five dimensions of the EQ-5D contributed significantly to the mean 
improvement in the EQ-5D index score. The EQ-5D results were at least as responsive as the 
symptoms scores and rescue medication use.
In a tentative calculation, it was estimated that the average QALY loss during a moderate 
exacerbation could be 0.00896, or 3.27 quality-adjusted life days. At first sight, this number 
may appear negligibly small. However, if a QALY is valued at €20,000, the maximally ac-
ceptable costs for avoiding a moderate exacerbation would be €179. It is very plausible that 
certain therapies could deliver the health gain for these costs.
The aim was not to investigate if the EQ-5D could be useful in studies, not to calculate 
a standard value of the health losses that are suffered by patients during a moderate COPD 
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exacerbation. The latter was impossible and inappropriate for several reasons. The utilities 
that result from the EQ-5D are based on country-specific value sets, so a world-wide value 
for this health loss does not exist. Nevertheless, this might have been addressed by calculat-
ing different values according to different value sets.
Still, this country-specific estimate for the average health loss would be based on the 
health states in a specific sample. That means that it is, in principle, applicable only to 
similar patients. Quality of life and and changes between measurements are likely to be as-
sociated with the characteristics of the patients in the sample, especially severity of disease 
and co-morbidities. Even within a country, there is not one value for the health loss due to a 
moderate COPD exacerbation.
A third reason for not presenting the health loss we calculated as the best available 
estimate of the QALY loss due to a moderate exacerbation is that we did not have estimates 
of respondents’ health-related quality of life during the stable phase of their disease. This 
would have been the correct value for the comparison with the scores during the exacerba-
tion. Instead, we used the measurement after the exacerbation had been resolved as a proxy.
In this version of the EQ-5D, respondents chose between three levels on each dimension 
(no/some/severe problems). The new version of the questionnaire has five levels (no/slight/
moderate/severe/extreme problems). It is conceivable that this EQ-5D 5L is even more sen-
sitive to the recovery from a moderate exacerbation than the three-level version if respon-
dents are more willing to switch from, for instance, ‘no problems’ to ‘slight problems’ than 
to ‘some problems’. In that case, the new version would be able to detect smaller changes in 
health status. However, if patients were already willing to switch in the three-level version, 
the measured changes in the five-level version would be smaller and the estimated health 
losses due to a moderate exacerbation would become smaller than in the three-level EQ-5D.
11.8 The use of propensity scores in economic evaluations
As an alternative to conventional regression analysis, propensity-score based methods have 
gained popularity in observational studies in recent decades. These techniques are primarily 
applied in epidemiological and, to a lesser extent, in medical studies. Examples of their use 
in economic evaluations are still scarce. The objective of chapters 8 and 9 was to compare 
the performance of several propensity-score adjustment methods and conventional regres-
sion in the context of an economic evaluation based on observational time-to-event data.
The propensity score is defined as the probability of receiving a certain treatment condi-
tional on a patient’s characteristics. It can be used in several ways to overcome differences 
in observed characteristics of patients across treatment groups. Covariate adjustment is the 
most popular application: the propensity score is used in a regression model instead of the 
baseline characteristics themselves. Other applications include weighting and matching.
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It is conceptually important to distinguish between methods that estimate an Aver-
age Treatment effect in the Treated patients (ATT) and methods that estimate an Average 
Treatment Effect in the population as a whole (ATE). The ATT is focused on the patients who 
actually received the treatment of study: what would have been the difference if they had 
been treated differently. The ATE is the expected gain for a randomly selected subject from 
the population. It can equivalently be defined as the difference between the hypothetical 
situations that either of the treatments had been assigned to the entire population. ATT 
and ATE are different from each other if treatment is more effective in patients with certain 
characteristics than in others, i.e. when effect modification occurs.
When the data can be described by a parametric multiplicative model, such as the 
Weibull survival models in this thesis, effect modification is always present. This is due to 
the assumption that the treatment effect is proportional to the severity of the impairment 
in health status in absence of treatment. The hazard of dying is decreased by a proportion 
of the original hazard – this is the proportional hazards assumption; life is prolonged by a 
proportion of the prognosis without treatment. Even if this proportion is constant across 
subgroups of patients – so the hazard ratio or the regression coefficient of treatment is not 
affected by effect modification – the health gains still vary in absolute terms. Patients with 
a good prognosis have more survival time to gain in absolute terms, while the proportional 
gains are the same for other subgroups.
In the context of the Dutch policy for conditional reimbursement to hospitals of the costs 
of expensive medications, the ATT is probably the relevant treatment effect: what is the effect 
in the patient group that has been given the new treatment? This requires two assumption 
or observations: the treated subjects form a good representation of the patients to which 
the new treatment should be targeted, and the control group contains comparable patients.
In different circumstances, the ATE may be more relevant. This could be the case, for 
instance, for preventive programs, when the indication for the intervention is going to be 
expanded. Another example is when the treated sample is somehow different from the 
population of interest.
It is usually not acknowledged in cost-effectiveness studies that the most widely used 
methods to adjust for baseline unbalances lead to estimates of the ATE. These are con-
ventional regression methods and covariate adjustment on the propensity score [9,10]. 
Inverse probability-of-treatment weighting and double robustness also estimate this ATE. 
Matching methods, in contrast, result in an ATT estimate. In practice, the ATE and ATT may 
not always be substantially different. Indeed, in the simulations in this thesis, some ATT 
methods appeared to perform better at estimating ATEs than some ATE methods, and vice 
versa. However, this must be ascribed to the specific circumstances of this situation. It is not 
a justification for confusing ATE and ATT methods.
Given the conceptual and potentially practical difference between ATE and ATT, it is 
important that one set of propensity scores is used in the estimation of both cost and ef-
194 Chapter 11
fects. This prevents that analyses of costs and effects are performed on different samples of 
patients.
Although no method led to the best results for ATTs and ATEs in all circumstances, some 
lessons could be drawn from the simulations that were performed. Support was found for 
the pre-processing approach, which means that a fully specified regression model (step 2) 
is applied on the data after these have been balanced by using a propensity score method, 
preferably kernel matching for an ATT and inverse probability-of-treatment weighting 
(IPTW)) for an ATE (step 1). This approach lessens the demands on the performance of each 
of the two steps. On the one hand, some residual imbalance in the data after step 1 is not a 
catastrophe since it can be adjusted in the next step. On the other hand, a misspecification 
in the regression model is less of a problem if the data has been balanced to a sufficient 
degree. The preprocessing approach performed more consistently than the double robust-
ness method, which is another technique that is aimed at mitigating the consequences of 
unsuccessful adjustment in either part of the model. It also led to better results than the 
direct regression methods: conventional regression and covariate adjustment on the pro-
pensity score.
These direct regression methods have more serious disadvantages. Since they do not 
explicitly lead to an RCT-like design of the dataset, it is not possible to determine whether 
the adjustment on observed characteristics has been successful. In contrast, after matching 
or weighting, the covariate balance across the treatment groups can be inspected. Further-
more, the un-biasedness of the results depends on the correctness of the model, in particular 
the functional form of the link between the propensity score or the other covariates and the 
health or cost outcome. In our simulations, and in most other studies, this functional form is 
linear. Of course, other forms can be used and compared, but it is not possible to determine 
if the adjustment has been sufficient.
11.9 Censoring, non-collapsibility and the analysis of 
time-to-event data
Non-collapsibility and non-independent censoring have often been lumped together as a 
source of actual or apparent bias in time-to-event analysis. The analysis in chapter 7 of this 
thesis showed that only one of them leads to biased estimates: non-independent censoring.
Censoring may occur independently from health outcomes. For instance, it can be due 
to the loss of paperwork in the mail. Many trials, however, are designed to end before all pa-
tients have experienced the event of interest. This means that patients with a better survival 
prognosis are more likely to be censored: they have not yet died at the end of the trial. When 
the event is recovery, patients with a worse prognosis are more likely to be censored, i.e. they 
have not recovered during the trial period.
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In the presence of non-independent censoring, relevant prognostic variables must be 
included in the regression model. Otherwise, projected mean survival for both treatment 
groups as well as the treatment effect will be underestimated. Furthermore, the hazard 
ratios in the model will be biased as well. Even in RCT data, in which all measured and 
unmeasured covariates are expected to be balanced, the omission of prognostic covariates 
will lead to a biased estimate of the treatment effect. The severity of this bias depends on the 
proportion of censoring and on the importance of the omitted variables.
In contrast, non-collapsibility does not lead to incorrect estimates. Non-collapsibility 
occurs when models with different numbers of covariates may lead to different estimates 
of the hazard ratio for treatment. However, as long as confounding has been addressed suc-
cessfully, these hazard ratios are all valid albeit different measures of the treatment effect. 
In other words, the hazard ratios provide answers to different questions: the effect of treat-
ment within strata of the covariates (conditional effect) versus the treatment effect averaged 
over all strata (marginal effect). A conditional effect is estimated when covariates are added 
to the marginal model, which contains only treatment. The effects are different when the 
regression function is non-linear. Marginal and conditional effects are different when the 
outcome measure is the hazard ratio, but they are equal when the outcome measure is mean 
time-to-event.
These findings have implications for the analysis of data from RCTs and observational 
studies. The first implication is that, in principle, time-to-event analysis can be used to pro-
vide estimates of the incremental treatment effect when a difference in time is the outcome 
measure. This estimate is not affected by the model specification once confounding has 
been eliminated: it is collapsible.
The second implication is that all prognostic covariates should be included in the 
analysis when the data is censored non-independently. This means that it is impossible to 
estimate a marginal – or population-averaged – hazard ratio when censoring is present, even 
in data from an RCT.
The third, and related, implication is that only endpoint models containing all important 
prognostic factor should be used when propensity-score based methods are applied on cen-
sored time-to-event data. Achieving balance of observed baseline covariates by selecting an 
extensive propensity-score model is not sufficient, since this can only solve the problem of 
confounding. This is an extra argument for the use of the preprocessing approach, in addi-
tion to the arguments in the previous section.
11.10 Adjusting for severity of COPD in database studies
A rich and well-collected dataset from a large clinical trial provided the opportunity to 
examine whether the severity of COPD, defined by the extent to which a patient suffers from 
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pulmonary obstruction, could be approached in the absence of lung function measure-
ments. These data are lacking from many registries and administrative databases. However, 
spirometrically determined disease severity is associated with many health outcomes, es-
pecially in the longer term. For this reason, several observational studies have attempted to 
adjust for possible differences in COPD severity by relying on data on healthcare resource 
use, medication, sex, age, body-mass index and smoking status.
The study in chapter 10 led to the conclusion that these variables are insufficient to 
adequately adjust for COPD severity. It is true that an association with lung function was 
found: more severe COPD was more likely to be found in male patients, with a relatively low 
age, a lower BMI, who had quit smoking, suffered from osteoporosis, had been hospitalized 
in the previous year, used oxygen therapy and certain types of respiratory maintenance 
medication. However, this association was not sufficiently strong as to enable confident 
classification of patients in categories of disease severity based on the amount of airflow 
obstruction. Many patients who exhibited the characteristics that were mostly linked to a 
certain severity stage, were actually in a different stage.
This might not be a problem if the association of COPD severity and the adjusting co-
variates were consistent across subpopulations, countries and time. In that case, achieving 
a balanced distribution of covariates across the subpopulations would lead to asymptotic 
balance on disease severity, as well. In that case, it would still be impossible to determine 
with some certainty to which individual patients belonged, but wrong categorizations for 
different stages would cancel out against each other. Unfortunately, the joint distributions 
of severity stage and other characteristics cannot be observed when spirometric data are 
unavailable.
11.11 Final remarks: underestimated uncertainties
This discussion has highlighted a number of issues that increase the uncertainty around 
estimates of incremental costs, effects and cost-effectiveness. These uncertainties are often 
not fully acknowledged in economic evaluations.
The first uncertainty is about the validness of the estimate of context-specific unit prices 
for inpatient hospital days. Since an inpatient day may consist of numerous actions and may 
involve several devices and facilities, its exact contents vary from condition to condition and, 
crucially, even across patients of different disease severity. ‘The’ inpatient hospital day does 
not exist, which makes the use of a standard price inappropriate from a societal, healthcare 
of hospital perspective when the costs of hospital admission are an important driver of costs. 
However, calculating an appropriate, context-specific price is challenging.
The second uncertainty regards the variation in inpatient hospital costs across patients. 
When a fixed price is used, this variation – and the stochastic uncertainty around the mean 
General discussion 197
11
costs that follows from it – is not noticed in statistical and sensitivity analyses. This means 
that the actual uncertainty around the estimates of incremental costs and cost-effectiveness 
ratios is greater than it appears.
The third uncertainty is a result of censored data. Estimates of a treatment effect in time-
to-event analysis are only valid in the absence of censoring or when all relevant prognostic 
covariates are included in the model. However, it is never certain that all of the covariates 
have been identified.
The fourth uncertainty involves the patient group at which an intervention is targeted. 
The incremental effects and costs of treatment are not necessarily constant across patients 
with different characteristics. In observational studies, this is reflected in the difference 
between ATT and ATE. In RCTs, it is often less obvious. If the trial population is different 
from the real-life patient population, the real-life effectiveness and cost-effectiveness will be 
different from the trial estimates. Although this is widely acknowledged in principle, cost-
effectiveness analyses are often piggy-backed on RCTs.
The fifth uncertainty concerns the adjustment approach in observational studies. In 
most or all circumstances, the analyst has to choose between several options. Some ap-
proaches are better than others, on average, but all methods occasionally lead to very incor-
rect estimates. It cannot always be concluded from the results whether this has happened. 
Nevertheless, this should not be understood as a plea against observational studies, which 
can result in valuable information.
Some of these uncertainties can be reduced, some can be explored, and some remain 
unknown. Observational studies can help in estimating real-life treatment effects when 
this is not possible in an RCT. In that respect, observational studies are not second best, 
compared to the ‘gold standard’ of RCTs. In the GO AHEAD trial, however, it was possible to 
randomise a sample of patients that resembled the patients for whom the treatment would 
be appropriate in real life. Furthermore, the intervention was designed to follow daily prac-
tice as closely as possible.
When there are substantial differences between an RCT protocol and daily practice, 
univariate sensitivity analyses can be used to explore the results of different assumptions 
on the effectiveness of the treatments under comparison. The same approach can be used 
to investigate the impact of a different unit price. Univariate sensitivity analysis is a well-
established technique, which is often overshadowed by probabilistic sensitivity analysis. 
Nevertheless, it can be very useful, especially when the uncertainty is of a structural and not 
merely a stochastic character.
Reducing the amount of censoring could reduce the uncertainty about the validity of the 
estimated treatment effect as well as the stochastic uncertainty. However, as it is the case 
when sample sizes are determined, ethical and financial considerations lead to a pressure 
to terminate a trial as early as possible in order to limit costs and the exposure of patients to 
an inferior treatment.
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The uncertainty about the validity of estimates from different methods in observational 
studies can be reduced by diligently checking the balance of covariates after applying a 
matching or weighting approach. The remaining uncertainty can be explored by using 
several approaches and comparing the results. If these results are not very dissimilar, this 
could enhance confidence in their correctness. However, they may also be quite different 
and lead to different conclusions. In that case, all that is certain is that the real treatment 
effect remains uncertain.
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Summary
Many economic evaluations are based on or conducted in combination with medical studies, 
in particular phase III randomised controlled trials, also in COPD. However, an economic 
evaluation is more than a medical study with costs as an additional outcome measure. It is 
more complicated than combining the effectiveness results from a trial with the invoices 
from physicians, hospitals and pharmacies. Economic evaluations are often characterized 
by challenges that do not occur in purely clinical trials.
Firstly, in many cases costs cannot be observed directly. From a societal or healthcare 
perspective, they do not equal payments or tariffs. Secondly, the objective of many, al-
though not all, clinical trials are to find statistical proof that one intervention’s effectiveness 
is superior to another one. In an economic evaluation the size of the treatment effect is 
essential, not merely its existence. In order to estimate this size with sufficient external va-
lidity, an observational study can be conducted on patients in real life. However, this study 
design lacks the benefit of randomization. Adjustment for possible differences between 
treatment groups is required. Thirdly, the size of the treatment effect must be estimated in 
terms of natural units of health in order to be useful in an economic evaluation. However, 
the results of medical and epidemiological studies are often expressed in hazard ratios – in 
time-to-event analyses – or odds ratios – for binary count data. These cannot be used in 
economic evaluations, in which outcome measures such as survival time and numbers 
of successes and failures are required instead. Fourthly, in order to make the results of 
economic evaluations comparable across interventions and diseases, health gains must 
be expressed in a common outcome measure, such as the QALY. These challenges were 
central to this thesis.
The first part of the thesis focused on hospital-at-home, in particular but not restricted 
to COPD. Hospital-at-home aims to avoid admission, or reduce length of stay (early assisted 
discharge schemes) by delivering formal healthcare in the patient’s home.
In chapter 2, a systematic review of costs studies for hospital-at-home was performed. 
We identified 29 studies for acute conditions that were published from 1996 through 2011. 
There is a risk that cost savings due to shortening hospital admissions are overestimated. 
Cost calculations were considered incorrect if they failed to meet four criteria. Costs per 
inpatient hospital day had to be disease-specific. The decreasing intensity of care over the 
course of an admission had to be reflected in costs of inpatient days, since the last days 
in the hospital tend to be the less costly than an average day. In studies from the societal 
perspective, informal care costs had to be included. Violating any of these three criteria 
leads to overestimation of savings. Finally, follow-up had to be at least one month in order 
to capture relevant downstream costs, such as re-admissions. Only five studies met all cri-
teria. The most frequent problems were the use of average costs per inpatient hospital day 
and too short follow-up. This leads to the conclusion that, while most studies found that 
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hospital-at-home was cost-saving, these savings were probably overestimated. Savings may 
not disappear after adjusted calculations, but they will be considerably smaller.
Chapter 3, 4 and 5 described a randomized controlled trial of early assisted discharge 
compared to usual hospital treatment for patients with a COPD exacerbation in the Nether-
lands. In this GO AHEAD trial (Assessment of GOing Home under Early Assisted Discharge), 
participants stayed in the hospital for seven days, or went home after three days where they 
were supervised and treated by community nurses. The protocol was described in chapter 3.
In chapter 4, we found that transferring hospital care for a COPD exacerbation to the pa-
tient’s home was likely to lead to modest costs savings from a healthcare perspective, while 
there was no clear evidence to conclude that it would lead to a slower or worse resolution of 
the exacerbation. From a societal perspective – when the societal costs of informal care and 
productivity losses were taken into account – these cost savings decreased considerably or 
even turned into increases.
The first day of the admission was the most costly. After that, the intensity of care by 
physicians and nurses decreased, which was reflected in lower costs per day.
The preferences of patients and informal caregivers for early assisted discharge and 
usual hospital treatment were examined in chapter 5 by means of a discrete choice experi-
ment. The results showed that the average patient and informal caregiver do not exist. For 
both groups, four distinct classes were identified, which had different attitudes towards 
being treated at home or in the hospital. Large proportions of respondents had a preference 
for either treatment option that could not be influenced by changes in the characteristics 
of the early assisted discharge treatment. The most attractive hospital-at-home program 
would be operated by pulmonary nurses and have no co-payments and a light burden on 
informal caregivers. Patients would not be visited by more than two different nurses and 
the pulmonary ward of the hospital would be reachable 24-hours a day in case of sudden 
worsening of the disease.
The second part of this thesis was devoted to three additional methodological issues: 
quality-of-life measurement, natural units of health gain, and observational studies.
Chapter 6 demonstrated that the EQ-5D questionnaire can be used to measure health-
related quality of life during the recovery from a moderate COPD exacerbation. When the 
exacerbation was at its worst, the average EQ-5D utility score was 0.651. It increased to 0.768 
on day 14, after which it remained largely stable until the final visit at 6 weeks. The greatest 
improvement in utility scores was reached within two weeks after the onset of the exacerba-
tion. The EQ-5D was more responsive than expiratory peak flow, rescue medication and 
sputum symptom scores and equally responsive as cough and dyspnoea symptoms scores. 
All five dimensions of the EQ-5D contributed significantly to the mean improvement in the 
EQ-5D score.
In chapter 7, the concepts of censoring and non-collapsibility in time-to-event analysis 
were disentangled and clarified by analyzing synthesized data. Earlier studies have some-
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times confused these phenomena and misrepresented the problems that non-collapsibility 
and censoring can induce. Non-collapsibility exists when the estimated treatment effect 
changes as prognostic covariates are added to the regression model, even when confound-
ing is absent. All estimates may be valid. In contrast, censoring threatens the validity of 
estimates when prognostic factors are omitted from the regression model. Hazard ratios are 
non-collapsible, but estimated time-to-event is collapsible.
Chapters 8 and 9 investigated the validity, accuracy and precision of conventional and 
propensity-score-based adjustment methods in observational cost-effectiveness analysis. 
The PS-methods were: PS matching (kernel and one-to-one), covariate adjustment using 
PS, inverse probability-of-treatment weighting (IPTW) and double robustness, each with 
several specifications. The propensity score is the conditional probability of receiving the 
treatment under study, given a patients characteristics.
In chapter 8, conventional regression was less likely to lead to accurate and unbiased 
estimates than propensity-score methods. On the other hand, in chapter 9, it performed well 
with regards to precision. The pre-processing approach, in which a fully specified regression 
model is applied after a matching or weighting on the propensity score, combined accuracy 
with relative precision. Covariate adjustment using the propensity score performed badly 
on both counts.
In chapter 10 it was shown that it is not possible to reliably adjust for the severity of 
COPD in observational studies in the absence of data on lung function. Almost all classifica-
tions of COPD severity are at least partly based on lung function, but this information is 
not available in administrative and clinical databases and registries. Previous retrospective 
database research has approximated COPD severity using demographic and healthcare 
resource utilization data. However, our partial proportional odds model analysis made clear 
that lung function cannot be reliably predicted from these.
The final chapter highlighted six uncertainties that are generally underestimated in the 
economic evaluation of healthcare. The first uncertainty is about the validity of the estimate 
of context-specific unit prices for inpatient hospital days. Since an inpatient day may con-
sist of numerous actions and may involve several devices and facilities, its exact contents 
vary from condition to condition and even across patients of different disease severity. The 
second uncertainty regards the variation in inpatient hospital costs across patients. When 
a fixed price is used, this variation – and the stochastic uncertainty around the mean costs 
that follows from it – is not noticed in statistical and probabilistic sensitivity analyses. The 
third uncertainty is a result of censored data. Estimates of a treatment effect in time-to-event 
analysis are only valid in the absence of censoring or when all relevant prognostic covariates 
are included in the model. The fourth uncertainty involves the patient group at which an 
intervention is targeted. Real-life effectiveness and cost-effectiveness may be different from 
the trial estimates. The fifth uncertainty concerns the adjustment approach in observational 
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studies. Some approaches are better than others, on average, but all methods occasionally 
lead to very incorrect estimates.
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Veel economische evaluaties zijn gebaseerd op of worden uitgevoerd in combinatie met 
klinische studies, in het bijzonder gerandomiseerde onderzoeken met een controlegroep. 
Toch is een economische evaluatie is meer dan de combinatie van een klinische studie 
met de rekeningen van artsen, ziekenhuizen en apotheken. Het onderzoek wordt dikwijls 
gekenmerkt door problemen die niet optreden in puur medische studies.
Ten eerste kunnen kosten vaak niet direct worden waargenomen. Vanuit het maatschap-
pelijk of gezondheidszorgperspectief komen kosten niet per se overeen met betalingen of 
tarieven. Ten tweede is het doel van de veel klinische studies het statistisch aantonen dat 
een interventie beter werkt dan een andere. In een economische evaluatie is de omvang van 
dit behandeleffect essentieel, niet alleen het bestaan ervan. Een extern valide schatting van 
deze omvang kan worden gemaakt met een observationele studie. Deze studieopzet heeft 
echt niet het voordeel van randomisatie. Correcties voor mogelijke verschillen tussen de 
behandelgroepen zijn daardoor noodzakelijk. Ten derde kan de schatting van het behande-
leffect alleen worden toegepast in een economische evaluatie als het ze wordt uitgedrukt in 
eenheden van gezondheidswinst. De resultaten van klinische en epidemiologische studies 
worden echter vaak uitgedrukt in hazard ratios – in duurmodellen – of odds ratios – voor 
dichotome uitkomsten. In plaats daarvan vereist economische evaluatie uitkomstmaten als 
levensverwachting of aantallen geslaagde behandelingen. Ten vierde moet gezondheids-
winst kunnen worden uitgedrukt in een uitkomstmaat die de resultaten van verschillende 
interventies en voor verschillende aandoeningen vergelijkbaar maakt, zoals de QALY. Deze 
kwesties stonden centraal in dit proefschrift.
Het eerste deel van het proefschrift ging over ziekenhuisverplaatste zorg, in het bijzon-
der voor patiënten met een COPD-exacerbatie. Het doel van ziekenhuisverplaatste zorg is 
het voorkomen van ziekenhuisopnames of het verkorten van de opnameduur (vervroegd en 
begeleid ontslag) door formele zorg te leveren bij de patiënt thuis.
In hoofdstuk 2 werd een systematisch literatuuronderzoek van kostenstudies over zie-
kenhuisverplaatste zorg uitgevoerd. Er is een risico dat kostenbesparingen door dit concept 
worden overschat. We vonden 29 studies die werden gepubliceerd van 1996 tot 2011. De 
berekeningen werden als incorrect beschouwd als ze niet voldeden aan een van de volgende 
vier criteria. De kostprijzen van verpleegdagen moesten zijn toegespitst op de specifieke 
ziekte van de studie.
De afnemende intensiteit van de zorg gedurende de opname moest tot uiting komen in 
de kostprijzen, aangezien de laatste dagen van een verblijf in het ziekenhuis vaak minder 
duur zijn dan de gemiddelde dag. In studies met een maatschappelijk perspectief moesten 
de kosten van mantelzorg worden meegerekend. Het schenden van een van deze drie criteria 
leidt tot een overschatting van de kostenbesparingen. Ten vierde moesten de kosten, bijvoor-
beeld die van heropnames, zijn geregistreerd tot ten minste een maand na de behandeling.
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Slechts vijf studies voldeden aan alle criteria. De meest voorkomende problemen waren 
het gebruik van gemiddelde kosten per verpleegdag en een te korte periode van follow-up. 
Dit leidde tot de conclusie dat de besparingen die in de meeste studies worden waargeno-
men, waarschijnlijk zijn overschat. De besparingen zouden in een juiste berekening niet 
noodzakelijkerwijs verdwijnen, maar wel aanzienlijk kleiner worden.
De hoofdstukken 3, 4 en 5 gingen over een gerandomiseerde studie met controlegroep, 
waarin vervroegd en begeleid ontslag werd vergeleken met de reguliere ziekenhuisopname 
voor patiënten met een COPD-exacerbatie. In deze GO AHEAD-studie (Assessment of 
GOing Home under Early Assisted Discharge) verbleven patiënten ofwel zeven dagen in 
het ziekenhuis of gingen ze na drie dagen naar huis, waar ze verder warden behandeld en 
gecontroleerd door thuiszorgverpleegkundigen. Het studieprotocol staat in hoofdstuk 3.
In hoofdstuk 4 werd vastgesteld dat het vervangen van een deel van de ziekenhuisop-
name door zorg bij de patiënt thuis waarschijnlijk leidt tot bescheiden kostenbesparing bin-
nen de gezondheidszorg. Er waren geen duidelijke aanwijzingen dat het zou leiden tot een 
langzamer of minder goed herstel van de exacerbatie. Vanuit maatschappelijk perspectief 
– wanneer ook de kosten van mantelzorg en productiviteitsverliezen in aanmerking worden 
genomen – waren de besparingen aanzienlijk kleiner of veranderden ze in meerkosten.
De eerste dag van de ziekenhuisopname was de meest kostbare. Daarna werd de in-
tensiteit van de zorg door artsen en verpleegkundigen minder, wat neersloeg in een lagere 
kostprijs per dag.
De voorkeuren van patiënten en mantelzorgers voor vervroegd en begeleid ontslag en 
voor de reguliere ziekenhuisopname werden onderzocht in een discrete-keuze-experiment 
in hoofdstuk 5. Uit de resultaten bleek dat de gemiddelde patiënt en mantelzorger niet be-
staan. Beide groepen konden worden verdeeld in vier klassen, elk met een andere houding 
tegenover behandelingen thuis en in het ziekenhuis. Een groot deel van de respondenten 
had een onwrikbare voorkeur voor een van beide mogelijkheden. Veranderingen in de 
aangeboden behandeling met vervroegd en begeleid ontslag hadden daarop geen invloed. 
De meest aantrekkelijke thuisbehandeling zou worden uitgevoerd door gespecialiseerde 
longverpleegkundigen, zou geen eigen bijdrage vergen en zou geen zware last voor de man-
telzorgers opleveren. Een patiënt zou door ten hoogste twee verschillende verpleegkundi-
gen worden bezocht en de longafdeling van het ziekenhuis zou 24 uur per dag bereikbaar 
moeten zijn voor overleg over een eventuele onvoorziene verslechtering van de toestand 
van de patiënt.
Het tweede gedeelte van het proefschrift is gewijd aan drie andere methodologische 
onderwerpen: de meting van kwaliteit van leven, eenheden van gezondheidswinst en de 
analyse van gegevens uit observationele studies.
In hoofdstuk 6 werd aangetoond dat de EQ-5D-vragenlijst kan worden gebruikt om 
de kwaliteit van leven van een patiënt te meten tijdens het herstel van een matige COPD-
exacerbatie. Op het dieptepunt van de exacerbatie, was de gemiddelde EQ-5D-nutsscore 
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0,651. Op dag 14 was de het nut opgelopen tot gemiddeld 0,786, waarna het stabiel de 
volgende zes werken in grote mate stabiel bleef. De belangrijkste verbetering in nut werd 
bereikt binnen twee weken na het begin van de exacerbatie. De EQ-5D reageerde sterker op 
het herstel van de exacerbatie dan metingen van de peak expiratory flow, opgehoest slijm 
en het gebruik van noodmedicatie. De symptomen hoesten en ademnood reageerden even 
sterk als de EQ-5D. Alle dimensies van de EQ-5D droegen significant bij aan de verbetering 
van de gemiddelde EQ-5D score.
In hoofdstuk 7 zijn de concepten censoring en non-collapsibility in overlevingsmodellen 
van elkaar onderscheiden en verduidelijkt aan de hand van een analyse van gesyntheti-
seerde gegevens. Eerder studies hebben deze fenomenen soms verward. Dat leidde tot een 
verkeerde voorstelling van de problemen waartoe censoring en non-collapsibility kunnen 
leiden. Non-collapsibility treedt op wanneer een schatting van het behandeleffect verandert 
met de toevoeging van prognostische covariaten aan het regressie model, ook wanneer er 
geen confounding is. Al deze schattingen kunnen valide zijn. Censoring vormt daarentegen 
wel degelijk een bedreiging voor de validiteit van effectschattingen wanneer belangrijke 
prognostische factoren worden weggelaten uit het regressiemodel. Hazard ratios zijn non-
collapsible, maar de gemiddelde voorspelde overlevingsduur is wel collapsible.
In de hoofdstukken 8 en 9 werden de validiteit, accuratesse en precisie van verscheidene 
statistische analysemethoden onderzocht in observationeel kosteneffectiviteitsonderzoek: 
conventionele methoden en van technieken die zijn gebaseerd op propensity scores. Deze 
laatste technieken waren: propensity score matching (met kernel en 1-op-1), regressie met 
de propensity score als covariaat, inverse probability-of- treatment weighting (IPTW) en 
double robustness, elk met verschillende specificaties. De propensity score van een patiënt 
is de berekende kans dat iemand met dezelfde kenmerken als deze patiënt de onderzochte 
behandeling krijgt.
In hoofdstuk 8 bleek dat conventionele regressiemethoden minder vaak tot een accu-
rate en niet-vertekende schatting leidden dan de methoden gebaseerd op propensity scores. 
Daartegenover staat dat conventionele regressie in hoofdstuk 9 wel goed presteerde op het 
gebied van precisie. De voorbehandelingsbenadering, waarbij een volledig regressiemodel 
wordt toegepast nadat eerst matching of weging heeft plaatsgevonden, combineerde ac-
curatesse met relatieve precisie. Regressie met de propensity score als covariaat presteerde 
slecht op beide criteria.
In hoofdstuk 10 werd aangetoond dat het in observationele studies niet mogelijk is cor-
recties uit te voeren voor verschillen in ernst van COPD wanneer er geen gegevens over 
longfunctie beschikbaar zijn. Vrijwel alle classificatiesystemen voor de ernst van deze ziekte 
zijn ten minste gedeeltelijk gebaseerd op longfunctiemetingen, maar deze informatie is 
vaak niet terug te vinden opgenomen in administratieve en klinische bestanden en registers. 
In eerdere onderzoeken van bestaande bestanden is geprobeerd de ernst te benaderen met 
behulp van demografische gegevens en informatie over het zorggebruik van de patiënt. De 
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analyse van ons partial proportional odds model maakte echter duidelijk dat longfunctie 
daarmee niet betrouwbaar kan worden voorspeld.
In het slothoofdstuk werden zes onzekerheden gemarkeerd, die over het algemeen 
onderschat worden in economische evaluaties in de gezondheidszorg.
De eerste onzekerheid gaat over de validiteit van schattingen van de context-specifieke 
prijzen voor verpleegdagen in het ziekenhuis. Een verpleegdag kan bestaan uit talloze activi-
teiten en kan het gebruik van verschillende apparaten en faciliteiten met zich mee brengen. 
De exacte inhoud van zo’n dag verschilt dan ook van aandoening tot aandoening en zelfs 
tussen patiënten met een ernstiger of minder ernstige variant van dezelfde aandoening. De 
tweede onzekerheid heft betrekking op de variatie in verpleegdagkosten tussen patiënten. 
Wanneer een vast prijs wordt gebruikt, wordt deze variatie niet opgemerkt in statistische 
analyses en probabilistische gevoeligheidsanalyses. Hetzelfde geldt voor de stochastische 
onzekerheid over de gemiddelde totale kosten die het gevolg is van deze variatie. De derde 
onzekerheid is een resultaat van censoring van de gegevens. Schattingen van een behan-
deleffect in overlevingsanalyses zijn alleen valide wanneer er geen censoring optreedt of 
wanneer alle relevante prognostische covariaten zijn opgenomen in het model. De vierde 
onzekerheid gaat om de groep patiënten waarop een interventie wordt gericht. Effectiviteit 
en kosteneffectiviteit kunnen in de praktijk anders zijn dan in klinische studies. De vijfde 
onzekerheid betreft de correctiemethode in observationele studies. Sommige methoden 
zijn beter dan andere, maar alle methoden leiden in sommige gevallen tot zeer incorrecte 
schattingen.
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De voorbereidingen voor dit proefschrift begonnen in mei 2003, al wist ik dat toen nog niet. 
Ik was bij een voorlichtingsavond over de nieuwe masterstudie Health Economics, Policy 
and Law aan de Erasmus Universiteit. Eigenlijk had ik op dat moment geen enkele goede 
reden om die opleiding te gaan volgen – ik had al een beroep en een baan – maar het aanste-
kelijke verhaal van Wynand van de Ven als opleidingscoördinator trok me over de streep. Ik 
heb er geen spijt van dat ik me na die avond heb ingeschreven voor de studie.
René van Vliet en Johan Polder, tijdens het schrijven van mijn masterscriptie onder jullie 
begeleiding kreeg ik voor het eerst idee dat dit werk mijn beroep zou kunnen worden. Wer-
ner Brouwer, bedankt dat je me eind 2005 belde met de vraag of ik misschien geïnteresseerd 
zou zijn in een eventuele functie als junior onderzoeker bij het iMTA. Daarover hoefde ik 
maar een paar seconden over na te denken.
De leden van de kleine en grote promotiecommissie dank ik hartelijk voor het beoorde-
len van mijn proefschrift en de oppositie tijdens de verdediging ervan. De coauteurs van de 
artikelen waarin ik meewerkte, binnen en buiten dit proefschrift, hebben een belangrijke 
bijdrage geleverd.
Brigitta Monz, I really enjoyed working with you on studies commissioned by Boehringer 
Ingelheim, two of which were included in this thesis.
Cecile, jarenlang hebben we samengewerkt in de GO AHEAD-studie. Dankjewel voor al 
het werk dat je hebt verzet bij het voorbereiden en coördineren van de studie en het verza-
melen van alle gegevens bij de deelnemende ziekenhuizen en thuiszorgorganisaties. Onze 
discussies over statistische analyses, formuleringen en conclusies in onze artikelen waren 
soms heftig, meestal leuk, en altijd interessant. Ook de artsen en verpleegkundigen die bij 
de studie betrokken waren, ben ik veel dank verschuldigd, met name Walter van Litsenburg, 
Frank Smeenk, Wiel Seezink en Monique van Vliet. En natuurlijk aan de deelnemende 
patiënten en hun mantelzorgers.
Maureen, ik denk niet dat er een betere promotor bestaat dan jij. Je hebt een opgewekt 
soort discipline, eist veel van jezelf en bent als vanzelfsprekend vastbesloten ook uit anderen 
het beste te halen. Dat is uitdagend en inspirerend. Het duurde een hele tijd tot ik je eindelijk 
eens iets kon vertellen wat je zelf niet allang veel beter wist. Bedankt voor het delen van je 
kennis en kunde, je warme belangstelling en je vertrouwen.
Onno, weinig wetenschappers zijn zo druk bezet als jij. Het lijkt wel of heel de wereld je 
weet te vinden. Ik ben dan ook erg blij dat je tijd vrijmaakte om mijn tweede promotor te 
zijn. De manier waarop je commentaar gaf op mijn teksten was bijzonder motiverend.
Ken, toen ik je vroeg mijn co-promotor te zijn, antwoordde je meteen: “Dat zou ik een 
grote eer vinden.” Die reactie is typisch voor jou, maar het is natuurlijk precies andersom. 
Bedankt voor alles. En voortaan denk ik bij elk artikel dat ik schrijf: “What’s the take-home 
message?”
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Apostolos, Steef en Maiwenn, ik heb jullie vaak lastiggevallen als ik iets schijnbaar 
onmogelijks wilde doen, of juist als ik op zoek was naar iets uit de cursus statistiek voor 
beginners. Ik kwam nooit voor niets, zelfs als jullie dachten dat we geen stap verder waren 
gekomen. Iets voorleggen aan iemand die verstandige dingen terugzegt, dat helpt echt.
Marieke, mijn kamergenote aan de zonnige kant van het J-gebouw. We tonen elke dag 
wetenschappelijk aan dat het mogelijk is: onophoudelijk praten en ondertussen gewoon 
doorwerken. Je begon een maand eerder dan ik bij de universiteit en je proefschrift was ook 
een maand eerder af, zodat we ons lekker konden bemoeien met elkaars lettertypes, kaft en 
dankwoord. Het is een plezier om met jou een kamer te delen.
Chantal en Pepijn, het lag voor de hand dat ik jullie als mijn paranimfen zou vragen.
Pepijn, wat was het leuk om samen met jou door ondoorgrondelijke rekenmodellen 
heen te worstelen, op internet nieuwe huizen te bekijken in de buurt van Groningen, te 
stappen in Praag en te zwemmen in Madrid. Het is jammer dat je naar de andere kant van 
het land bent verhuisd.
Chantal, zonder jou zouden drie van de hoofdstukken in dit proefschrift niet zijn ge-
schreven. Vier jaar geleden bedachten we dat we samen ‘iets’ wilden doen, met propensity 
scores of zo. We wisten een onderzoekssubsidie voor het project in de wacht te slepen en 
hebben er avonden en avonden aan doorgewerkt, samen aan één toetsenbord of via de 
telefoon. Ik ben nog steeds uitermate boos over je vertrek bij de universiteit...
Alle andere vrienden en collega’s bij de sectie GE-iMTA, jullie maken het werk nog 
leuker dan het anders al zou zijn, en niet alleen op vrijdag.
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Training
Repeated measurements in clinical studies (Emmanuel Lesaffre, Erasmus Medical Centre), Netherlands 
Institute for Health Sciences, 2011
Missing values in clinical research (Geert Molenberghs, Catholic University of Leuven), Netherlands 
Institute for Health Sciences, 2010
Causal inference, (Miguel Hernàn, Harvard University), Erasmus Summer Programme, Netherlands 
Institute for Health Sciences, Rotterdam, 2008
Discrete choice analysis and choice experiment design (John Rose & Michiel Bliemer, University of 
Sydney), Executive course, Erasmus University Rotterdam, 2007
iBMG didactic courses, Erasmus University Rotterdam, 2012
Probleemgestuurd onderwijs [Problem-oriented teaching], Erasmus University, 2009
Basiscursus didactiek [Basic didactics], Erasmus University Rotterdam, 2008
Academic writing in English, Erasmus University Rotterdam, 2008
Teaching
Kwantitatief gezondheidszorgonderzoek (Methoden en technieken van onderzoek 4) [Quantitative 
research in healthcare (Research methodology 4)], bachelor program Health Sciences, Policy and 
Management: lecture on causal structures and model selection; supervision of student research 
projects, 2006-present
Supervision and co-supervision of several theses, bachelor program Health Sciences, Policy and Man-
agement and master Health Economics, Policy and Law, 2008-present
Health technology assessment, master program Health Economics, Policy and Law: supervision of 
modelling practicums, 2007-present
Advanced economic evaluation, master program Health Economics, Policy and Law: supervision of 
modelling practicums, 2007-present
Presentations
Cost-effectiveness of early assisted discharge for COPD exacerbations in the Netherlands, Longdagen 
Utrecht, 2012 
Cost-effectiveness of early assisted discharge for COPD exacerbations in the Netherlands, GE-iMTA 
lunch lecture, Rotterdam, 2012 
Collapsibility and censoring: what’s the bias in estimating survival time? GE-iMTA lunch lecture, 2012 
Measuring health by prediction, memory or experience? An experience sampling study, Low Lands 
Health Economist Study Group, Almen, 2012
A propensity to get it right. A comparison of different adjustment methods for obtaining correct cost-
effectiveness estimates in observational studies: a simulation study, Low Lands Health Economist 
Study Group, Almen, 2012
Research posters
A propensity to get it right. Comparing statistical methods for observational cost-effectiveness studies. 
ISPOR 15th annual European Congress, Berlin, 2012 (Poster award finalist)
Non-collapsibility and censoring: What’s the bias in estimated survival time? ISPOR 15th annual Euro-
pean Congress, Berlin, 2012 (Poster award finalist) 
Hospital-at-home: cost savings are overestimated. ISPOR 15th annual European Congress, Berlin, 2012
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Latent class analysis of discrete choice data: an application on hospital-at-home for COPD patients. 
ISPOR 14th annual European Congress, Madrid, 2011 
Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? ISPOR 11th annual European 
Congress, Athens, 2008 
No substitute for spirometry: adjusting for COPD severity in database research. ISPOR 13th annual 
European Congress, Prague, 2010 (Poster award finalist)
Publications in English
Rutten-van Mölken MPMH, Goossens LMA. Cost effectiveness of pharmacological maintenance treat-
ment for chronic obstructive pulmonary disease: a review of the evidence and methodological 
issues. Pharmacoeconomics. 2012; 30(4):271-302.
Utens CMA, Goossens LMA, Smeenk FW, Rutten-van Mölken MPMH, van Vliet M, Braken MW, van 
Eijsden LM, van Schayck OC. Early assisted discharge with generic community nursing for chronic 
obstructive pulmonary disease exacerbations: results of a randomised controlled trial. BMJ Open. 
2012 Oct 16;2(5). doi:pii: e001684. 
Goossens LMA, Baker CL, Monz BU, Zou KH, Rutten-van Mölken MPMH. Adjusting for COPD severity 
in database research: developing and validating an algorithm. Int J Chron Obstruct Pulmon Dis. 
2011; 6:669-78.
Goossens LMA, Nivens MC, Sachs P, Monz BU, Rutten-van Mölken MPMH. Is the EQ-5D responsive to 
recovery from a moderate COPD exacerbation? Respir Med. 2011;105(8):1195-202.
Utens CM, Goossens LM, Smeenk FW, van Schayck OC, van Litsenburg W, Janssen A, van Vliet M, Seez-
ink W, Demunck DR, van de Pas B, de Bruijn PJ, van der Pouw A, Retera JM, de Laat-Bierings P, van 
Eijsden L, Braken M, Eijsermans R, Rutten-van Mölken MP. Effectiveness and cost-effectiveness of 
early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a 
randomised controlled trial. BMC Public Health. 2010;10:618.
Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. Conclusion on cost-effectiveness of rotavirus 
vaccination highly dependent on assumptions. Vaccine. 2009 Apr 28; 27(19):2531-2.
Goossens LMA, Riemersma RA, Postma DS, van der Molen T, Rutten-van Mölken MPMH. An economic 
evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general 
practice. Adv Ther. 2009; 26(9):872-85.
Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with 
Rotarix (RIX4414) in the Netherlands. Vaccine. 2008; 26(8):1118-27.
Publications in Dutch
Hakkaart-Van Roijen L, Tan SS, Goossens LMA, Schawo S, Brouwer WBF, Rutten-van Mölken MPMH, 
Rutten FFH. Doelmatigheid in praktijkrichtlijnen voor medicijnen: resultaten van een ‘quickscan’ 
[Efficiency in practice guidelines for medication: results of a quickscan]. TSG, Tijdschrift voor 
Gezondheidswetenschappen 2010; 88(4): 172-181 (in Dutch)
Goossens LMA, Knoester P, Rutten-van Mölken MPMH Mölken.  Avastin (bevacizumab), Macugen 
(pegaptanib) en Lucentis (ranibizumab): vergelijking van medicatiekosten [Avastin (bevaci-
zumab), Macugen (pegaptanib) en Lucentis (ranibizumab): a comparison of medication costs]. 
Pharmaceutisch Weekblad Wetenschappelijk Platform. 2008: 2(4):75-79. (in Dutch)
Goossens LMA, Niessen LW. Rosuvastatine, atorvastatine en de richtlijn: kosteneffectiviteit in de secun-
daire preventie [Rosuvastatin, atorvastatin and Dutch guidelines: cost-effectiveness in secondary 
prevention]. Pharmaceutisch Weekblad Wetenschappelijk Platform.  2008; 2(3):56-61. (in Dutch)
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Curriculum vitae
Lucas Goossens was born in Oss on the 18th of November, 1973. He grew up in Uden, where 
he graduated from VWO at Kruisheren Kollege in 1991.
He studied history at Radboud University Nijmegen (MA in 1995), where he specialised 
in economic and social history, American history and the economics of public finance. 
His master thesis described the rise of the supermarket in the Netherlands and its political 
fall-out. In 1996, he was admitted to the Post-doctorale Opleiding Journalistiek (PDOJ) of 
Erasmus University.
This led to a career in newspaper journalism at the national daily Algemeen Dagblad. 
From 1997 to 2003, he reported on national politics from The Hague. After this, he selected 
and edited news stories and composed headlines as an editor of domestic news at the cen-
tral desk in Rotterdam for three years.
Meanwhile, he studied Health Economics, Policy and Law at Erasmus University (MSc 
cum laude in 2005), from which he graduated with a thesis on the consequences of popula-
tion ageing and falling mortality for health care expenditure.
Since 2006, he has worked at the Erasmus University Institute for Medical Technology 
Assessment/Institute of Health Policy and Management (iMTA/iBMG). His research in-
terests include the cost-effectiveness of treatment for pulmonary diseases, statistical and 
epidemiological methods and observational studies.
